‹ĆŃˆę——

2020”N‹ĆŃ
y‰˘•śŒ´’˜z
Naito N, Kawano H, Yamashita Y, Kondo M, Haji S, Miyamoto R, Toyoda Y, Kanematsu Y, Izumi Y, Bando Y, Nishioka Y. Neuropsychiatric systemic lupus erythematosus wihcerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy. Mod Rheumatol Case Rep, in press.

Sakamoto S, Kataoka K, Kondo Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S, and the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized trial. Eur Respir J. in press.

Homma S, Ebina M, Kuwano K, Goto H, Sakai F, Sakamoto S, Johkoh T, Sugino K, Tachibana T, Terasaki Y, Nishioka Y, Hagiwara K, Hashimoto N, Hasegawa Y, Hebisawa A; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Intractable Diffuse Pulmonary Diseases: Manual for Diagnosis and Treatment. Respir Investig. in press.

Kondo M, Tezuka T, Ogawa H, Koyama K, Bando H, Azuma M, Nishioka Y. Lysophosphatidic acid regulates the differentiation of Th2 cells and its antagonist suppresses allergic airway inflammation. Int Arch Allergy Immunol, in press.

Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer:a single-institution retrospective study. K Sci Rep 10(1):13773, 2020.

Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, Inoue Y, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res 6(2):00184-2019, 2020.

Otsuka K, Mitsuhashi A, Goto H, Hanibuchi M, Koyama K, Ogawa H, Ogino H, Saijo A, Kozai H, Yoneda H, Tobiume M, Kishuku M, Ishizawa K, Nishioka Y. Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer 146:86-96, 2020.

Morizumi S, Sato S, Koyama K, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Moll Biol 63(3):317-326, 2020.

Imakura T, Toyoda Y, Sato S, Koyama K, Nishimura H, Kagawa K, Takahashi N, Naito N, Murakami K, Kawano H, Azuma M, Shinohara T, Nishioka Y. Distinct improvement of pulmonary function, ground-1 glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment: a case report with a review of the literature. J Med Invest 67(3,4):358-361, 2020.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trialinvestigators(Nishioka Y). Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med: S2213-2600(20)30036-9, 2020.

Abe S, Sato S, Aono Y, Azuma M, Kishi M, Koyama K, Takahashi N, Kagawa K, Kawano H, Nishioka Y. Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects. J Med Invest 67:102-112, 2020.
y˜a•ś’˜‘z
˛“Ął‘ĺ, ź‰ŞˆŔ•F. nintedanib‚ĚŽg‚˘•ű‚Ć•›ě—p‘΍ô. ŠÔŽżŤ”xŽžŠłf—Ăƒ}ƒjƒ…ƒAƒ‹ ‰ü’ů‘ć3”Ĺ, ‹v•Űœ¨Žk ŠÄC, “Ą“cŽŸ˜Y ŠěŽÉę’Š—Y •ŇW, pp202-208, 2020.“ě]“°.

–L“c—DŽq, ź‰ŞˆŔ•F. ƒXƒeƒƒCƒh. äPŒ´•a‚É”ş‚¤ŠÔŽżŤ”xŽžŠł f’fEŽĄ—ĂŽwj2020 •ŇW “ú–{ŒÄ‹zŠíŠw‰ď “ú–{ƒŠƒEƒ}ƒ`Šw‰ď‡“Ż äPŒ´•a‚É”ş‚¤ŠÔŽżŤ”xŽžŠłf’fEŽĄ—ĂŽwjěŹˆĎˆő‰ď(ź‰ŞˆŔ•F,–L“c—DŽq ‘ź), pp176-178, 2020. ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ.

˛“Ął‘ĺ, ź‰ŞˆŔ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒX. V—Տ°“ŕ‰ČŠw ‘ć10”Ĺ ŠÄC –îúą‹`—Y, pp1800-1801, 2020. ˆăŠw‘‰@.

ź‰ŞˆŔ•F. ”x–E”÷ÎÇ. Ą“ú‚̐f’fŽwj ‘ć8”Ĺ ‘•ŇW ‰iˆä—ÇŽO, pp995-996, 2020. ˆăŠw‘‰@.
y˜a•ś‘ŕz
ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰ŠFf’f‚ĆŽĄ—Ă‚ĚĹ‘Oü. “ú–{“ŕ‰ČŠw‰ďŽGŽ 109(9):1899-1905, 2020.

ŽO‹´“ŐŽu, ź‰ŞˆŔ•F. ŒŒŠÇVś‘jŠQÜ‚ɑ΂ˇ‚é‘ϐŤŠl“žƒƒJƒjƒYƒ€DŽŔŒąˆăŠw 38(15)(‘):157-162, 2020.

˛“Ął‘ĺ, ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚ĚŒŒ´Šw“IŠŒŠD–ň‹Ç 71(3):26-31, 2020.

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Ě•Ď‘JD–ň‹Ç 71(3):16-20, 2020.

˛“Ął‘ĺ, ź‰ŞˆŔ•F, Martin Kolb. üˆŰ‰ť”x‘gD‚Ě×–EŠOŠîŽż‚ސüˆŰ×–E‚ĚmiR-21”­Œť‚É‹y‚Ú‚ˇ‰e‹ż‚ĚŒŸ“˘. •ŞŽqŒÄ‹zŠí•a 24(1):76-79, 2020.
y˜a•śŒ´’˜z
•Ÿ‰Ć–ƒ”ü, ‰Ź–ěL˜a, ’Řˆä–˘Šó, ‹ß“Ą^‘ă, ěk‘˘, ű•Łš‹B, ŽRúą”Ž‹P, ‹{–{—ş‰î, –L“c—DŽq, ź‰ŞˆŔ•FDƒGƒ^ƒ“ƒuƒg[ƒ‹‚É‚ć‚é’E‘Ť––˝_ŒoáŠQ‚É‚ć‚č‹}‘ŹisŤ‚Ě•ŕsáŠQ‚đ’ć‚ľ‚˝Œ‹ŠjŤ‹š–Œ‰Š‚Ě1—áDŒ‹Šj95(2):73-77, 2020.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Seidai Sato, Takushi Yamamoto, Kana Waki , Yuki Morimoto, Takeshi Imakura, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama, Yasuhiko Nishioka. Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú`12ŒŽ30“ú.

Atsushi Mitsuhashi, Tania Afroj, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú`12ŒŽ30“ú.

Naoki Takahashi, Seidai Sato, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka. The novel oligonucleotide therapeutics PK-7010 for TGF-ƒŔ1 ameliorates bleomycin-induced pulmonary fibrosis in micen. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú`12ŒŽ30“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Isei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. The Relationship Between Single-Nucleotide Polymorphisms Within Tollip and the Efficacy of Inhaled N-Acetylcysteine Therapy in Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú`11ŒŽ10“ú.

Moises Selman, R Gisli Jenkins, Eric S White, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Antje Prasse, Jin Woo Song, Benjamin Strobel, German Leparc, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Toby M Maher on behalf of the INMARK trial investigators. Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK Trial. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú`11ŒŽ10“ú.

Naoki Arai, Takefumi Saito, Takashi Ogura, Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa, Sakae Homma, Yasuhiko Nishioka, Arata Azuma. Final Results of the Primary Endpoint and Other Supportive Analysis: TAS-115 Phase 2 Study in Patients with Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú`11ŒŽ10“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•F, ˛“Ął‘ĺ. isŤüˆŰ‰ťŤƒtƒFƒmƒ^ƒCƒv‚Ě•ŞŽq•a‘Ô. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N09ŒŽ21“ú.

ź‰ŞˆŔ•F, ŹŽRˆë–ç, ŽO‹´“ŐŽu, Tania Afroji, ‰Í–ěO. ”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éscRNA-Seq‚đ—p‚˘‚˝üˆŰ×–E‚̉đÍ. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N09ŒŽ20“ú.

ź‰ŞˆŔ•FDŠÔŽżŤ”x‰ŠFf’f‚ĆŽĄ—Ă‚ĚĹ‘OüD‘ć117‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ď(‹łˆçu‰‰). WEBD2020”N8ŒŽ7“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
˛“Ął‘ĺ, X–{—FŽ÷, ŽR–{‘ěŽu, ŠŰ”ö•ü–ç, ˜e‰ŘŘ, ź‰ŞˆŔ•F. ƒCƒ[ƒWƒ“ƒOŽż—ĘŒ°”÷‹ž‚É‚ć‚éƒjƒ“ƒeƒ_ƒjƒu‚̐üˆŰŤ”x‘gD“ŕ‹ÇÝ•Ş•z‚ĚŒŸ“˘. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. WEB. 2020”N09ŒŽ20-27“ú.

ěk‘˘, ŹŽRˆë–ç, ˛“Ął‘ĺ, űü‹´’źŠó, ź‘şt‰Ŕ, ‰Í–ěO, –L“c—DŽq, ŽÂŒ´•×, ź‰ŞˆŔ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚Ż‚éLck‘jŠQ‚̍RüˆŰ‰ťŒř‰Ę. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. WEB. 2020”N09ŒŽ20-27“ú.

űü‹´’źŠó, ˛“Ął‘ĺ, ŹŽRˆë–ç, ěk‘˘, “ŕ“ĄLm, Ą‘qŒ’, –L“c—DŽq, ‰Í–ěO, ’JěŒ´–œŒ°, ’šŠC˜i, ź‰ŞˆŔ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆŰÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚éŠjŽ_ˆă–ňPK-7010‚̍RüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. WEB. 2020”N09ŒŽ20-27“ú.

–L“c—DŽq, ˛“Ął‘ĺ, ŹŽRˆë–ç, ěk‘˘, ăb„, ]“Ş—ćŽq, Ž›č‘׍O, ŽÖŕVť, ”‹Œ´Oˆę, ˆîŁ’ź•F, ź‰ŞˆŔ•F. “Á”­Ť”xœ‰ťÇ‘S‘’˛¸i’†ŠÔ•ńj. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. WEB. 2020”N09ŒŽ20-27“ú.

’J–]–˘, ‹g‘ş˛h, ŽR“c’‰–ž, ‘ĺŒF—T‰î, –k‘ä—Żˆß, ’|“c—˛”V, Œ“ź‹M‘Ľ, Œă“Œ‹vŽk, •Ä“c_l, ź‰ŞˆŔ•F, Œ´“c‘ĺŽi, ŽR“c’‰›, ˆÉ’Bh“ń, ‰–’ÐL‰î, ‰i“cˆę—m, çŒ´—C‰î, “ŕ–ě‡ŽĄ, űüŽR_ˆę. ŠůŽĄ—Ă”ńŹ×–E”x‚Ş‚ń‚đ‘ÎŰ‚Ć‚ľ‚˝ƒhƒZƒ^ƒLƒZƒ‹{ƒ‰ƒ€ƒVƒ‹ƒ}ƒu•š—p‚ÉŠÖ‚ˇ‚é‘˝Ž{Ý‹¤“ŻŒă•űŽ‹“IŒŸ“˘. ‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. WEB. 2020”N09ŒŽ20-27“ú.

Hirohisa Ogawa, Masahiko Azuma, Aya Umeno, Mayuko Shimizu, Takaaki Tsunematsu, Mayo Kondo, Kazutoshi Murotomi, Koichi Tsuneyama, Yasuhiko Nishioka. Nerve growth factor exacerbates airway hyperresponsiveness via epithelial damage by neutrophils-derived singlet oxygen in a mouse model of asthma with mixed inflammation. ‘ć69‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ďiJSA/WAO Joint Congress 2020j. WEB. 2020”N9ŒŽ17“ú|10ŒŽ20“ú.

‰Í–ěO, “ŕ“ĄLm, ˆŔ‘”Ž, Ą‘qŒ’, ŽR‰ş—Y–ç, ‚‹´’źŠó, ‹ß“Ą^‘ă, ˛“Ął‘ĺ, –L“c—DŽq, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éisŤüˆŰ‰ť‚𔺂¤äPŒ´•aŠÖ˜AŠÔŽżŤ”xŽžŠł‚ĚŒŸ“˘. ‘ć64‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď. WEB. 2020”N8ŒŽ17“ú-9ŒŽ15“ú.

˛“Ął‘ĺ, ‘şăsl, –L“c—DŽq, ŹŽRˆë–ç, ź‘şt‰Ŕ, ěk‘˘, űü‹´’źŠó, ‰Í–ěO, ŒáČ‰ë•F, ź‰ŞˆŔ•F. 2Ü‚̍RüˆŰ‰ť–ň‚đŽg—p‚ľ‚˝“Á”­Ť”xüˆŰÇÇ—á‚ĚŒŸ“˘. ‘ć117‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ď. ŽăD2020”N8ŒŽ7-9“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
Âˆä—DCěk‘˘C“ŕ“ĄLmC˛“Ął‘ĺC‰Í–ěOCŽODlłCź‰Y•ü”üC”Œ´G–çC‹gěK‘˘C–L“c—DŽqCâ“Œ—Ç”üCŒŹŒ´_C‚ŽR“NŽĄC“‡“cŒőśCź‰ŞˆŔ•FDDŽ_‹…Ť‘˝”­ŒŒŠÇ‰ŠŤ“÷‰čŽîÇ‚ĚŽĄ—Ă’†‚ɉń’°oŒŒ‚đ‚Ť‚˝‚ľAŒŒŠÇ‰Š‚Ć‚ĚŠÓ•Ę‚Ş˘“ď‚Ĺ‚ ‚Á‚˝CMV’°‰Š‚Ě1—áD‘ć260‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡D2020”N2ŒŽ2“úD
2019”N‹ĆŃ
y‰˘•śŒ´’˜z
Takezaki A, Tsukumo SI, Setoguchi Y, Ledford JG, Goto H, Hosomichi K, Uehara H, Nishioka Y, Yasutomo K. A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis. J Exp Med 216 (12):2724-2735, 2019.

Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res 8(4):450-460, 2019.

Yanagihara T, Sato S, Upagupta C, Kolb M. What have we learned from basic science studies on idiopathic pulmonary fibrosis? Eur Respir Rev 28(153):190029, 2019.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig 57(6):512-533, 2019.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG: on behalf of the INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib(INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 7(9):771-779, 2019.

Okazaki H, Sato S, Koyama K, Morizumi S, Abe S, Azuma M, Chen Y, Goto H, Aono Y, Ogawa H, Kagawa K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Kouji H,e Nishioka Y. The novel inhibitor PRI-724 for Wnt/ƒŔ-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res 45(7):188-199, 2019.

Toyoda Y, Koyama K, Kawano H, Nishimura H, Kagawa K, Morizumi S, Naito N, Sato S, Yamashita Y, Takahashi N, Goto H, Azuma M, Nishioka Y. Clinical features of interstitial pneumonia associated with systemic lupus erythematosus. Respir Investig 57(5):435-443, 2019.

Hanibuchi M, Kanoh A, Kuramoto T, Saito T, Tobiume M, Saijo A, Kozai H, Kondo M, Morizumi S, Yoneda H, Kagawa K, Ogino H, Sato S, Kawano H, Otsuka K, Toyoda Y, Nokihara H, Goto H, Nishioka Y. Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA. Oncotarget:10(38):3654-3666, 2019.

Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Sato S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y. Novel multiple tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 60(4):478-487, 2019.

Saijo A, Hanibuchi M, Ogino H, Otsuka K, Goto H, Nokihara H, Nishioka Y. Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. Mol Clin Oncol 10(5):541-546, 2019.

Ueda S, Murakami T, Ogino H, Matsuura M, Tamaki M, Kishi S, Hann M, Toyoda Y, Nagai K, Bando Y, Abe H, Nishioka Y, Doi T. Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions. Intern Med 58(5):679-684, 2019.

Ogino H, Hanibuchi M, Sakaguchi S, Toyoda Y, Tezuka T, Kawano H, Kakiuchi S, Otsuka K, Saijo A, Azuma M, Nokihara H, Goto H, Nishioka Y. The clinical features of older patients with lung cancer in comparison with their younger counterparts. Respir Investig 57(1):40-48, 2019.

Sato S, Yanagihara T, Kolb MR. Therapeutic targets and early stage clinical trials for pulmonary fibrosis. Expert Opin Investig Drugs: 28(1):19-28, 2019.
y˜a•ś’˜‘z
źžŠ“Ö˜Y, ŒŹŒ´_. ALK-TKI‚É‚ć‚éˆęŽŸŽĄ—Ă‚É‚Š‚Š‚í‚é”äŠrŽŽŒą. ƒIƒ“ƒRƒƒW[ƒNƒŠƒjƒJƒ‹ƒKƒCƒh ”xŠŕ‰ťŠw—Ă–@ ‰ü’ů2”Ĺ ŒˇŠÔş•FE—˘“ŕ”ü–íŽq•ŇW pp215-217, 2019. “ěŽR“°.

ŒŹŒ´_. CBDCA+PEM(}BEV)(PEM’PÜ). ”x‚Ş‚ń‰ťŠw—Ă–@•›ě—pƒ}ƒlƒWƒƒ“ƒg ƒvƒ‚ĚƒRƒc@‘q“c•ó•ŰE‹g‰ŞO’ÁE‹ŕ“cr•F•ŇW pp55-58, 2019. ƒƒWƒJƒ‹ƒrƒ…[ŽĐ.

ŒŹŒ´_. CDDP+PEM(}BEV)(PEM’PÜ). ”x‚Ş‚ń‰ťŠw—Ă–@•›ě—pƒ}ƒlƒWƒƒ“ƒg ƒvƒ‚ĚƒRƒc@‘q“c•ó•ŰE‹g‰ŞO’ÁE‹ŕ“cr•F•ŇW pp51-54, 2019. ƒƒWƒJƒ‹ƒrƒ…[ŽĐ.

˛“Ął‘ĺ, ź‰ŞˆŔ•FD“Á”­ŤŠÔŽżŤ”x‰Ši‚ť‚Ě‘ź‚Ě”ń“ÁˆŮŤŠÔŽżŤ”x‰ŠCŠíŽż‰ť”x‰ŠjDŽ„‚ĚŽĄ—Ă 2019-20”N“x”Ĺ ‰Ž“c‹’jE–k‘ş‘yˆę˜Y ŠÄC “dŽqƒRƒ“ƒeƒ“ƒcC2019D“ú–{ˆăŽ–V•ńŽĐD

˛“Ął‘ĺ, ź‰ŞˆŔ•FDŠÔŽżŤ”x‰ŠE‰ß•qŤ”x‰ŠD–ƉuE‰ŠÇ•a‘ԁ~ŽĄ—Á@Update, ŒFƒm‹˝~ •ŇW pp77-87, 2019. “ěŽR“°D

Œă“Œ‹vŽkDŽîᇁDŠPšuEš\ႂ̐f—ĂƒKƒCƒhƒ‰ƒCƒ“2019C“ú–{ŒÄ‹zŠíŠw‰ďŠPšuEš\ႂ̐f—ĂƒKƒCƒhƒ‰ƒCƒ“2019ěŹˆĎˆő‰ďiź‰ŞˆŔ•F ‘źj•ŇW pp88-89, 2019Dˆę”ĘŽĐ’c–@l“ú–{ŒÄ‹zŠíŠw‰ďD

–L“c—DŽqDŠÔŽżŤ”x‰ŠiIPjDŠPšuEš\ႂ̐f—ĂƒKƒCƒhƒ‰ƒCƒ“2019C“ú–{ŒÄ‹zŠíŠw‰ďŠPšuEš\ႂ̐f—ĂƒKƒCƒhƒ‰ƒCƒ“2019ěŹˆĎˆő‰ďiź‰ŞˆŔ•F ‘źj•ŇW pp85-87, 2019Dˆę”ĘŽĐ’c–@l“ú–{ŒÄ‹zŠíŠw‰ďD

‰Í–ěO, ź‰ŞˆŔ•FDäPŒ´•a‚Ě”x•a•ĎDŒÄ‹zŠíŽžŠł ĹV‚ĚŽĄ—Ă2019-2020, –ĺ“c~ˆęEŒˇŠÔş•FEź‰ŞˆŔ•F •ŇW pp384-387, 2019D“ě]“°D

Œă“Œ‹vŽk, ź‰ŞˆŔ•FDŒŒŠÇVś‘jŠQ–ň‘ϐŤ‹@\DŒÄ‹zŠíŽžŠł ĹV‚ĚŽĄ—Ă2019-2020, –ĺ“c~ˆęEŒˇŠÔş•FEź‰ŞˆŔ•F •ŇW pp54-57, 2019. “ě]“°D

ź‰ŞˆŔ•FDDŽ_‹…Ť”x‰ŠDĄ“ú‚ĚŽĄ—ĂŽwj2019”N”Ĺ, •ŸˆäŽŸ–î, ‚–ؐ˝, ŹŽşˆęŹ ‘•ŇW, pp320-321, 2019.ˆăŠw‘‰@D
y˜a•ś‘ŕz
–L“c—DŽq, ˛“Ął‘ĺ, ‰Í–ěO, ź‰ŞˆŔ•F. ŠÖßƒŠƒEƒ}ƒ`ŽĄ—Ă–ň‚Ć”x•a•Ď. ŒÄ‹zŠí“ŕ‰Č 36(6):618-626, 2019.

Œă“Œ‹vŽkCŒáČ‰ë•FC’†ŁŸ‘ĽC–Lúąă•C‰F“s‹{ł“oCź‰ŞˆŔ•FDCOPDE”x‚Ş‚ń‚É‚Č‚ç‚Č‚˘‚˝‚߂ɁDŽl‘ˆăŠwŽGŽ 75(1,2):23-30, 2019.

ź‰ŞˆŔ•FDĹVçΛ{‚Ě•ŇWˆĎˆő‚đ’S“–‚ľ‚āDĹVçΛ{ 74(6):125, 2019.

ź‰ŞˆŔ•FD”x‚Ş‚ńŽîᇊ‹Ť‚É‚¨‚Ż‚éfibrocyte-like cell‚Ě•a“IˆÓ‹`D‰ŠÇ‚ƖƉu 27(3):31-35, 2019.

ŽO‹´“ŐŽuCŒŹŒ´_D–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚ĚŒř‰Ę‚đ‘‹­‚ˇ‚é•š—p—Ă–@D•ŞŽqŒÄ‹zŠí•a 23(1):49-53, 2019.

‰Í–ěO, ź‰ŞˆŔ•FDŠÔŽżŤ”x‰ŠE–Ť•ÂÇŤ”xŽžŠłD–ň‹Ç 70(5):85-90, 2019.

ź‰ŞˆŔ•FD”x‰Š‚ĆŠ´ő‘΍ôDŠé‹Ć‚Ć‘ĺŠw 5:57, 2019.
yŠw‰ď”­•\-‘ŰŠw‰ďz

Yasuhiko Nishioka. Update immunotherapy therapy for mesothelioma. Hanoi,Vietnam. APSR 2019(Symposium). 2019”N11ŒŽ16“úD

Yasuhiko Nishioka. Biomarkers of Disease Progression in Asian Subjects with Idiopathic Pulmonary Fibrosis Treated with Nintedanib: Subgroup Analysis of the INMARK Trial. Hanoi,Vietnam. APSR 2019. 2019”N11ŒŽ15“úD

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Naoki Takahashi, Haruka Nishimura, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda, Yasuhiko Nishioka. Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice. ERS International Congress 2019. Madrid, Spain. 2019”N10ŒŽ2“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Issei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

R Gisli Jenkins, Toby M Maher, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S White, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Moises Selman on behalf of the INMARK trial investigators. Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

Takashi Ogura, Yasuhiko Nishioka, Takefumi Saito, Keisuke Tomii, Koichiro Kamio, Hiromi Tomioka, Shu Hisata, Susumu Sakamoto, Tomohiro Handa, Yasunari Miyazaki, Sakae Homma, Arata Azuma. Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ29“ú.

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ Kolb, Yasuhiko Nishioka. Expression of pro-fibrotic microRNA of fibrocytes in bronchoalveolar lavage fluid. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ21“úD

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Klaus B Rohr, Daniel Wachtlin, Carina Ittrich, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ20“úD

Kazyua Koyama, Nobuhito Naitoh, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma, Yasuhiko Nishioka. Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ19“úD

yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•FD‚Ş‚ń–ƉuƒTƒCƒNƒ‹‚Š‚çl‚Ś‚é”xŠŕ‚ɑ΂ˇ‚é•Ą‡–Ɖu—Ă–@D‘ć57‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰ŞD2019”N10ŒŽ25“úD

ŒŹŒ´_C‰Ş–{—EC—t´—˛C›Œ´rˆęC–x”V“ŕGmC“ŒŒöˆęC•Ä“ˆNbC‘şă°‘ׁC‘ʉꐰŽqC×ŒŠKśCˆŔ‘îM“ńC”öč’q”ŽC–x’r“āC“Ą“cŒ‹‰ÔC‰Ş–{_–žCˆŔ“Ąš•FC–ě‘şŽŒáCŽR–{M”VC‘ĺ]—TˆęC’†ě˜a•F. Phase III study of CBDCA/PEM followed by PEM versus DOC in elderly pts withadvanced non-sq NSCLC iJCOG1210/WJOG7813Lj. ‘ć17‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď(Presidential Symposium). ‹ž“sD2019”N7ŒŽ18“úD

ź‰ŞˆŔ•FD‚Ş‚ń–ƉuƒTƒCƒNƒ‹‚đl—ś‚ľ‚˝•Ą‡‚Ş‚ń–Ɖu—Ă–@D2019”Nˆę”ĘŽĐ’c–@l “ú–{E‘˝‘ŠÔ—Տ°ŽŽŒą‹@\ƒ[ƒNƒVƒ‡ƒbƒv(‹łˆçu‰‰)D–źŒĂ‰ŽD2019”N6ŒŽ29“úD

ź‰ŞˆŔ•F, ‰Ź–ěL˜a, ŽO‹´“ŐŽu. ŒŒŠÇVś‘jŠQ–ň‘ϐŤ‚Ć‚ť‚̍Ž•ž. ‘ć23‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ‘ĺă. 2019”N6ŒŽ13“úD

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇUpdate -RüˆŰ‰ť—Ă–@‚đŠî‘b‚Ć—Ő°‚Š‚çl‚Ś‚é-D‘ć234‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠÖ“Œ’n•ű‰ď@‹łˆçƒZƒ~ƒi[D“Œ‹žD2019”N5ŒŽ25“úD

–L“c—DŽq. Ŕ’k‰ďu—Ťˆă‹Ç’ˇ‚É•ˇ‚­IvD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒ~ƒjƒg[ƒNƒZƒbƒVƒ‡ƒ“)D“Œ‹žD2019”N4ŒŽ13“úD

˛“Ął‘ĺDƒnƒ~ƒ‹ƒgƒ“Œ¤‹†•ú˜Q‹LD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•ĘŠé‰ć)D“Œ‹žD2019”N4ŒŽ12“úD

ź‰ŞˆŔ•FD“ú–{ŒÄ‹zŠíŠw‰ď‚ĚŠCŠO—ŻŠwŽx‰‡‚ĆŠCŠO—ŻŠw•Ź‹ŕ§“xD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•ĘŠé‰ć)D“Œ‹žD2019”N4ŒŽ12“úD

ź‰ŞˆŔ•FD”x‚Ş‚ńŽîᇊ‹Ť‚É‚¨‚Ż‚éfibrocyte-like cell‚Ě•a“IˆÓ‹`D‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2019”N4ŒŽ12“úD

ŒáČ‰ë•FD‹CŠÇŽxšb‘§‚ɂ‚˘‚ÄŠw‚Ú‚¤`ŒÄ‹zŠí“ŕ‰Čˆă‚Ě—§ę‚Š‚ç`DŒ§–ŻŒöŠJuŔ@“ż“‡ƒAƒŒƒ‹ƒM[ƒtƒH[ƒ‰ƒ€2019D“ż“‡D2019”N2ŒŽ24“úD

Œă“Œ‹vŽkDCOPDE”x‚Ş‚ń‚É‚Č‚ç‚Č‚˘‚˝‚߂ɁD‘ć258‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďŽs–ŻŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“ż“‡D2019”N2ŒŽ3“úD
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
ŽO‹´“ŐŽu, ‰Ź–ěL˜a, –؏hšr, ‘ĺ’ËŒ›Ži, ŒŹŒ´_, ź‰ŞˆŔ•FD–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚¨‚ć‚ŃŒŒŠÇVś‘jŠQ–ň‚É‚ć‚é•Ą‡‚Ş‚ń–Ɖu—Ă–@‚É‚¨‚Ż‚éŽîᇓŕfibrocytelike cell‚Ě‹@”\‰đÍD‘ć32‰ń“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ďŠwpW‰ď‘‰ďD‰ŞŽRD2019”N11ŒŽ28“úD

‘ĺ’ËŒ›Ži, •Ä“c_l, ŽO‹´“ŐŽu, ‰Ź–ěL˜a, ź”Ž”V, ”ň”~—ş, ŒŹŒ´_, ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Š‡•š”ńŹ×–E”xŠŕ‚É‚¨‚Ż‚é2ŽŸ‰ťŠw—Ă–@‚ĚˆŔ‘SŤ‚Ć—LŒřŤ‚ĚŒŸ“˘. ‘ć57‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď. •Ÿ‰ŞD2019”N10ŒŽ24“úD

‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkCű•Łš‹BC‰Ź–ěL˜aCźžŠ“Ö˜YCź”Ž”VC•Ä“c_lC”ň”~—şCź‰ŞˆŔ•FD‰ťŠw—Ă–@‚ÍŽîᇓŕ‚̍œ‘—R—ˆ—}§×–E‚đŒ¸­‚ł‚š‚é‚ą‚Ć‚É‚ć‚čRPD-1R‘Ě‚ĚRŽîᇌř‰Ę‚đ‘‹­‚ˇ‚é. ‘ć28‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ďCŽ­Ž™“‡D2019”N7ŒŽ26“úD

ź‘şt‰Ŕ, •Ä“c_l, ěk‘˘, ŹŽRˆë–ç, ”ň”~—ş, ‰Ź–ěL˜a, źžŠ“Ö˜Y, ‹{–{Œ›Ć, Œ´“cŽŃŠó, â“Œ‹IŽq, –L“c—DŽq, ź‰ŞˆŔ•F. ŠŕŤƒŠƒ“ƒpŠÇÇ‚̐f’f‚ÉBAL ‚Ş—L—p‚Ĺ‚ ‚Á‚˝‘˝”­‚ˇ‚čƒKƒ‰ƒX‰A‰e‚đ’ć‚ľ‚˝”x‘BŠŕ‚Ě1 —á. ‘ć42‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2019”N7ŒŽ5“úD

•Ä“c_l, ź‘şt‰Ŕ, ěk‘˘, ”ň”~—ş, ‰Ź–ěL˜a, ŹŽRˆë–ç, źžŠ“Ö˜Y, –L“c—DŽq, ź‰ŞˆŔ•F. ‹CŠÇŽx‹žŒŸ¸‚ɂĐf’f‚ľ“ž‚˝ƒŠƒ“ƒp–ŹŠÇ‹ŘŽîÇ‚Ě1 —á. ‘ć42‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2019”N7ŒŽ5“úD

Źě”Ž‹v, ŒáČ‰ë•F, ”~–ěĘ, Žş•x˜ar, ‹ß“Ą^‘ă, â“ŒOŠî, íŽRKˆę, ź‰ŞˆŔ•F. ‹CŠÇŽxšb‘§‚É‚¨‚Ż‚éˆęd€Ž_‘fŽ_‰ťƒXƒgƒŒƒX‚Í‹C“š‰ß•qŤ‚đ˜´i‚ł‚š‚é. ‘ć68‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ď. “Œ‹žD2019”N6ŒŽ15“úD

źžŠ“Ö˜Y, Œă“Œ‹vŽk, ź”Ž”V, ‰Ź–ěL˜a, ‘ĺ’ËŒ›Ži, ź‰ŞˆŔ•F. ”ńŹ×–E”x‚Ş‚ń‚ɍ‡•š‚ľ‚˝ˆŤŤ‹š…‚ɑ΂ˇ‚ébevacizumab‚Ě—LŒřŤ‚ƑϐŤ‰ť‹@˜‚̉đÍ. ‘ć23‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‘ĺă. 2019”N6ŒŽ13“úD

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, ‰Ź–ěL˜a, ‘ĺ’ËŒ›Ži, ™–{ł“š, Ş“Œ, ź‰ŞˆŔ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚¨‚ć‚ŃŒŒŠÇVś‘jŠQ–ň•š—p—Ă–@‚É‚¨‚Ż‚éŽîᇓŕfibrocyte-like cell‚Ě‹@”\‰đÍ. ‘ć23‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‘ĺă. 2019”N6ŒŽ13“úD

˜aňrq, ˆ˘•”^ŽĄ, Œă‰Í“ŕ”üŽŃ, źˆä•ü, Œă“Œ‹vŽk, ‰Á“ĄKŹ, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚é‚Ş‚ń“ÁˆŮ“IRpodoplaninR‘ĚchLpMab-2‚Ěin vitro‚É‚¨‚Ż‚éRŽîᇌř‰Ę‚ĚŒŸ“˘. ‘ć23‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‘ĺă. 2019”N6ŒŽ13“úD

˛“Ął‘ĺCź‰ŞˆŔ•FCMartin Kolb. üˆŰ‰ť”x‘gD‚Ě×–EŠOŠîŽż‚ސüˆŰ×–E‚ĚmiR-21”­Œť‚É‹y‚Ú‚ˇ‰e‹ż‚ĚŒŸ“˘. ‘ć18‰ń”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg•ŞŽq•a‘ÔŒ¤‹†‰ď. ŽD–yD2019”N6ŒŽ1“úD

ŒáČ‰ë•FC’†ŁŸ‘ĽC–Lč“ZC‰F“s‹{ł“oCź‰ŞˆŔ•FD“ż“‡ŽsCOPDŒ[”­„iŽ–‹Ć‚Ě5”NŠÔ‚̐Ź‰ĘD‘ć116‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ďD–źŒĂ‰ŽD2019”N4ŒŽ26“úD

“ŕ“ĄLm, ‰Í–ěO, ‹ß“Ą^‘ă, ‰Ź–ěL˜a, ˛“Ął‘ĺ, –L“c—DŽq, Œă“Œ‹vŽk, ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‡•šŠÖßƒŠƒEƒ}ƒ`‚ɑ΂ˇ‚éJAK‘jŠQ–ň‚ĚŽg—pŒoŒąD‘ć63‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ďD‹ž“sD2019”N4ŒŽ16“úD

Tania Afroj, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Masatoshi Kisyuku, Atsuro Saijo, Atsushi Mitsuhashi, Kazuya Koyama, Hisatsugu Goto, Yasuhiko NishiokaDAnalyses of immuno-modulatory function of fibrocytes in tumor immunityD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ14“úD

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ. Kolb, Yasuhiko Nishioka. Fibrotic extracellular matrix upregulates pro-fibrotic miRNA expression of fibrocytesD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ14“úD

‰|–{‹I”V, –{ŠÔ‰h, ˆîŁ’ź•F, ‘ęŕVŽn, ˆäă‹`ˆę, ÎˆäŠ°, “cŒű‘P•v, ňM—L, ŽR–ě‘וF, ’J–ěŒ÷“T, ź‰ŞˆŔ•F, –L“ˆŠ˛ś, ‰Ą‘şŒőŽi, –…ěŽj˜N, Ź´…’źŽ÷, {“c—˛•śDäPŒ´•a“I”wŒi‚đ—L‚ˇ‚é“Á”­ŤŠÔŽżŤ”x‰Š‚Ě—\Œă‚ÉŠÖ‚ˇ‚錟“˘F‘˝Ž{Ý‹¤“ŻC‘OŒü‚ŤƒRƒz[ƒgŒ¤‹†D‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ14“úD

‰ŞúąO‘×, ˛“Ął‘ĺ, XZr, ŹŽRˆë–ç, Źě”Ž‹v, ěk‘˘, ź‘şt‰Ŕ, Yajuan Chen, Â–ěƒ“T, ˆ˘•”Gˆę, “Œ“‘ă, Œă“Œ‹vŽk, ‰Í–ěO, –L“c—DŽq, ăŒ´‹v“T, Ź˜HOs, ź‰ŞˆŔ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚Ż‚éWnt/B-ƒJƒeƒjƒ“/CBPƒVƒOƒiƒ‹‘jŠQ–ňPRI-724‚É‚ć‚éRüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘D‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ14“úD

Hiroshi Nokihara, Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Yasuhiko NishiokaDA multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced NSCLC patients with interstitial lung diseaseD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ13“úD

ŹŽRˆë–ç, “ŕ“ĄLm, ěk‘˘, ź‘şt‰Ŕ, ˛“Ął‘ĺ, ‰Í–ěO, –L“c—DŽq, Œă“Œ‹vŽk, ŒáČ‰ë•F, ź‰ŞˆŔ•FDŠÖßƒŠƒEƒ}ƒ`‡•šŠÔŽżŤ”x‰ŠŠłŽŇ‚Ě‹}ŤŒÄ‹z•s‘S‚Ě—Ő°“IŒŸ“˘D‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ13“úD

ź‰ŞˆŔ•F, Toby Maher, Gisli JenkinsDINMARKŽŽŒąFIPFŠłŽŇ‚Ĺ‚ĚECM ƒ^[ƒ“ƒI[ƒo[\ƒoƒCƒIƒ}[ƒJ[‚ĆŽžŠłis‚ĚŠÖ˜A‹y‚Ńƒjƒ“ƒeƒ_ƒjƒu‚ĚŒř‰Ę‚đ•]‰ż‚ˇ‚鎎ŒąD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2019”N4ŒŽ13“úD
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
ˆŔ‘”ŽC‰Í–ěOCĄ‘qŒ’C“ŕ“ĄLmC‹ß“Ą^‘ăC˛“Ął‘ĺC–L“c—DŽqCź‰ŞˆŔ•FD’`”’ŕhoŤˆÝ’°ÇAƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‚𔺂Á‚˝MCTD‚Ě1—á. ‘ć30‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD‰ŞŽRD2019”N12ŒŽ7“ú.

“ŕ“ĄLmC‰Í–ěOCĄ‘qŒ’C‹ß“Ą^‘ăC˛“Ął‘ĺC–L“c—DŽqCź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚éANCA—zŤŠÔŽżŤ”x‰ŠÇ—á‚ĚŒŸ“˘. ‘ć30‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD‰ŞŽRD2019”N12ŒŽ7“ú.

‰Ş–{—I—˘, ěk‘˘, ‘ĺ’ËŒ›Ži, ‹{–{’ź‹P, ‹g“cŒő‹P, •Ä“c_l, –L“c—DŽq, ŒáČ‰ë•F, ź‰ŞˆŔ•FD‹šo“ŕ‚É‘˝”­‚ľ‚˝ÎŠD‰ťüˆŰŤŽîᇂĚ1—áD‘ć121‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚źD2019”N12ŒŽ1“úD

Î“c‘ě–ç, ěk‘˘, •Ä“c_l, ź‘şŒŤ“ń, ŽR–{—y•˝, ˛“Ął‘ĺ, ‰Í–ěO, ŒŹŒ´_, ź‰ŞˆŔ•F. Œ°”÷‹ž“I‘˝”­ŒŒŠÇ‰Š‚ĚŽĄ—Ă’†‚ɏdÇ‹Ř–ł—͏ǃNƒŠ[ƒ[‚đ”­Ç‚ľ‚˝1—á. ‘ć121‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚źD2019”N12ŒŽ1“úD

˛ŒĂ‰ëG, ěk‘˘, ”ň”~—ş, űü‹´’źŠó, Ą‘qŒ’, “ŕ“ĄLm, ź”Ž”V, ˛“Ął‘ĺ, –L“c—DŽq, ŒŹŒ´_, ŒáČ‰ë•F, ź‰ŞˆŔ•FDMycobacterium malmoense‚É‚ć‚é”xŠ´őÇ‚Ě2—áD‘ć70‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ď. ŽRŒűD2019”N11ŒŽ23“úD

ˆé‘ş—S‘ž, ěk‘˘, •Ä“c_l, ŒŹŒ´_, ‘ĺ’ËŒ›Ži, ˛“Ął‘ĺ, ”ň”~—ş, ź”Ž”V, âŒű‹Ĺ, ŒáČ‰ë•F, ź‰ŞˆŔ•F. “–‰Č‚É‚¨‚Ż‚éˆŤŤ‹š–Œ’†”çŽî‚Ě2ŽŸŽĄ—Ă‚ĚŒŸ“˘. ‘ć62‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ŽRŒűD2019”N11ŒŽ23“úD

‘şăsl, ěk‘˘, ŹŽRˆë–ç, ŒáČ‰ë•F, ź–{‘厑, ’ŘˆäŒőO, ěăsšő, ‹ß“Ą˜a–ç, ˛“Ął‘ĺ, ‘ĺ’ËŒ›Ži, ŒŹŒ´_, ź‰ŞˆŔ•F. ‘ĺ—Ę‹š…‚¨‚ć‚Ń‹š–ŒŽîᎂđŒ_‹@‚ɐf’f‚ł‚ę‚˝bó‘Bŕh–EŠŕ‚Ěˆę—á D‘ć28‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ďDŽRŒűD2019”N11ŒŽ23“úD

Î“c‘ě–çCěk‘˘C•Ä“c_lCâ“Œ‹IŽqC“ŕ“ĄLmC‰Ź–ěL˜aC˛“Ął‘ĺC‰Í–ěOCź‘şŒŤ“ńCŽR–{—y•˝C–L“c—DŽqCŒŹŒ´_Cź‰ŞˆŔ•FDŒ°”÷‹ž“I‘˝”­ŒŒŠÇ‰Š‚ĚŽĄ—Ă’†‚ɏdÇ‹Ř–ł—͏ǃNƒŠ[ƒ[‚đ”­Ç‚ľ‚˝1—áD‘ć259‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2019”N8ŒŽ4“úD

ěk‘˘CŹŽRˆë–çC˛“Ął‘ĺC‚‹´’źŠóCź‘şt‰ŔC“ŕ“ĄLmC‰Í–ěOC–L“c—DŽqCź‰ŞˆŔ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚Ż‚éLck‘jŠQ‚̍RüˆŰ‰ťŒř‰ĘD‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD“ż“‡D2019”N7ŒŽ15“úD

‹ß“ĄŒ’‰îCźžŠ“Ö˜YCěk‘˘C‘ĺ’ËŒ›ŽiC˛“Ął‘ĺC•Ä“c_lC”ň”~—şCŒă“Œ‹vŽkCŒŹŒ´_Cź‰ŞˆŔ•FD––˝ŒŒŒŸ¸’l‚đ—p‚˘‚˝”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚ĚŒř‰Ę—\‘ވöŽq‚ĚŒŸ“˘D‘ć58‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2019”N7ŒŽ15“úD

ˆŔ‘”ŽCěk‘˘C‹ß“Ą^‘ăC˛“Ął‘ĺC•Ä“c_lC‰Ź–ěL˜aC”ň”~—şCź”Ž”VC‘ĺ’ËŒ›ŽiCŒŹŒ´_Cź‰ŞˆŔ•F. Nivolumab“Š—^‚É‚ć‚č• …‚Ě’˜–ž‚ČŒ¸­‚đ”F‚ß‚˝ˆŤŤ‹š–Œ’†”çŽî‚Ě1—áD‘ć58‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2019”N7ŒŽ14“úD

‹ß“ĄŒ\‘ĺCěk‘˘C‹ß“Ą^‘ăC‰Ź–ěL˜aC”ň”~—şC•Ä“c_lC‘ĺ’ËŒ›ŽiC˛“Ął‘ĺCŒŹŒ´_Cź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚é‹ÇŠis”ńŹ×–E”xŠŕŠłŽŇ‚ɑ΂ˇ‚鉝Šw•úŽËü—Ă–@Œă‚ĚDurvalumab‚É‚ć‚鎥—Ă‚Ě—Ő°“IŒŸ“˘D‘ć58‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2019”N7ŒŽ14“úD

“ŕ“Ąm”üCěk‘˘C‹ß“Ą^‘ăC˛“Ął‘ĺC“ŕ“ĄLmC‰Í–ěOC–L“c—DŽqCŒáČ‰ë•FCŒŹŒ´_Cź‰ŞˆŔ•F. ŠÖßƒŠƒEƒ}ƒ`‚ĹŽĄ—Ă’†‚ɍRMDA5R‘Ě—zŤ‚đ‚݂Ƃ߁A–ł‹ŘÇŤ”畆‹Ř‰Š‚Ɛf’f‚ł‚ę‚˝ŠÔŽżŤ”x‰Š‚Ě2—á.‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD“ż“‡D2019”N7ŒŽ14“úD

•Ÿ‰Ć–ƒ”ü, –L“c—DŽq, ‰Ź–ěL˜a, ‰Í–ěO, Œă“Œ‹vŽk, ŒŹŒ´_, ŒáČ‰ë•F, ź‰ŞˆŔ•F. Stevens-JohnsonÇŒóŒQŒă‚ɍ‡•š‚ľ‚˝•ÂÇŤ×‹CŠÇŽx‰Š‚ɃXƒeƒƒCƒh‚¨‚ć‚Ńƒ^ƒNƒƒŠƒ€ƒX‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á. ‘ć6‰ń“ú–{ŒÄ‹zƒPƒAEƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ď@’†‘EŽl‘Žx•”ŠwpW‰ď. “ż“‡D2019”N6ŒŽ8“úD

ŽO‹´“ŐŽu, ”ň”~—ş, ‰Ź–ěL˜a, ‹ß“Ą^‘ă, –L“c—DŽq, Œă“Œ‹vŽk, ‹g“cŒő‹P, Źě”Ž‹v, ŒŹŒ´_, ź‰ŞˆŔ•FD”x‘˝Œ`Šŕ‚É‚¨‚Ż‚éă”çŠÔ—t“]Šˇ (EMT)‚ĚŒŸ“˘D‘ć120‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚’mD2019”N5ŒŽ12“úD

űü‹´’źŠó, “ŕ“ĄLm, ‹ß“Ą^‘ă, ‰Ź–ěL˜a, ‰Í–ěO, –L“c—DŽq, ŽO–؍_˜a, ŒáČ‰ë•F, ŒŹŒ´_, ź‰ŞˆŔ•FDŽĄ—Ă’ďRŤ‚ĚSLE‚É”ş‚¤Ô‰č‹…ᔂɃVƒNƒƒzƒXƒtƒ@ƒ~ƒhƒpƒ‹ƒX—Ă–@‚Ş’˜Œř‚ľ‚˝1—áD‘ć120‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚’mD2019”N5ŒŽ12“úD

ˆŔ‘”Ž, ’†‘şMŒł, ‘ĺ‰Y‰ë”Ž, ‘]‰ä•”ŒöŽq, Œ´“c•Žu, “ĄˆäŽu˜N, ŽO–؍_˜a, ‰ęě‹v”üŽq, ź‰ŞˆŔ•F, ˆŔ”{ł”ŽD’ˇŠú‚É‚í‚˝‚錌Ź”ÂŒ¸­‚ސćs‚ľ‚˝‰č‹…ŤŒ`Žż×–E—lŽ÷ó×–EŽîᇂĚ1—áD‘ć120‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚’mD2019”N5ŒŽ12“úD

ŹŽRˆë–çC“ŕ“ĄLmCěk‘˘C‹ß“Ą^‘ăCź‘şt‰ŔC˛“Ął‘ĺC‰Í–ěOC–L“c—DŽqCŒáČ‰ë•FCŒă“Œ‹vŽkCź‰ŞˆŔ•F. ƒ}ƒEƒX”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éV‹Kmulti-tyrosine kinase inhibitor TAS-115‚̍RüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘. ‘ć258‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡D2019”N2ŒŽ3“úD

‹ß“Ą^‘ă, Źě”Ž‹v, Žč’Ë•qŽj, â“ŒOŠî, ŒáČ‰ë•F, ź‰ŞˆŔ•FD‹CŠÇŽxšb‘§‚É‚¨‚Ż‚郊ƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_(LPA)‚Ě–đŠ„‚Ć‚ť‚Ě‘jŠQŒř‰Ę‚ɂ‚˘‚Ä‚ĚŒŸ“˘D‘ć1‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ď’†‘EŽl‘Žx•”’n•ű‰ďDL“‡D2019”N2ŒŽ2“úD
2018”N‹ĆŃ
y‰˘•ś’˜‘z
Hisatsugu Goto, Yasuhiko Nishioka. ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer? Clinical Relevance of Genetic Factors in Pulmonary Diseases, Takeshi Kaneko, Editor, pp295-315, 2018. Springer.
y‰˘•ś‘ŕ“™z
Goto H, Nishioka Y. Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression. Int J Mol Sci 19(1):98, 2018.
y‰˘•śŒ´’˜z
Kishi M, Aono Y, Sato S, Koyama K, Azuma M, Abe S, Kawano H, Kishi J, Toyoda Y, Okazaki H, Ogawa H, Uehara H, Nishioka Y. Blockade of platelet-derived growth factor receptor-ƒŔ, not receptor-ƒż ameliorates bleomycin-induced pulmonary fibrosis in mice. PLOS ONE 13(12):e0209786, 2018.

Ogawa H, Azuma M, Tsunematu T, Morimoto Y, Kondo M, Tezuka T, Nishioka Y, Tsuneyama K. Neutrophils induce smooth muscle hyperplasia via neutrophil elastase-induced FGF-2 in a mouse model of asthma with mixed inflammation. Clin Exp Allergy 48(12):1715-1725, 2018.

Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T, Toyoda Y, Azuma M, Kondo M, Kawano H, Otsuka K, Sakaguchi S, Nokihara H, Goto H, Nishioka Y. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 125:93-99, 2018.

Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M, Harada N, Nishioka Y, Sakaue H. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest 65(3,4):166-170, 2018.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Notch3-dependent ƒŔ-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat Commun 9(1):3198, 2018.

Kondo M, Ogino H, Ogawa H, Afroj T, Toyoda Y, Sakaguchi S, Tsuboi M, Bando Y, Goto H, Tsuneyama K, Nishioka Y. A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition. Respir Med Case Rep 25:119-121, 2018.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARKRtrial. BMJ Open Respir Res 5(1):e000325, 2018.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M. Macitentan reduces progression of TGF-ƒŔ1-induced pulmonary fibrosis and pulmonary hypertension. Eur Respir J 52(2): pii1701857, 2018.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 56(4):268-291, 2018.

Kishi S, Minato M, Saijo A, Murakami N, Tamaki M, Matsuura M, Murakami T, Nagai K, Abe H, Nishioka Y, Doi T. A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. Intern Med 57(9):1259-1263, 2018.

Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget 9(32):22480-22497, 2018.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Toyoda Y, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells. Sci Rep 8(1):6760, 2018.

Kozai H, Toyoda Y, Goto H, Kishi J, Tobiume M, Yamashita Y, Nishimura H, Kondo M, Kawano H, Nishioka Y. A case of interstitial pneumonia associated with anti-PL-7 antibody in a patient with rheumatoid arthritis. J Med Invest 65(1,2):147-150, 2018.

Bellaye PS, Shimbori C, Upagupta C, Sato S, Shi W, Gauldie J, Ask K, Kolb MDLysyl Oxidase-like 1 Protein Deficiency Protects Mice from AdTGF-ƒŔ1 induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58(4):461-470,2018.

Saijo A, Goto H, Nakano M, Mitsuhashi A, Aono Y, Hanibuchi M, Ogawa H, Uehara H, Kondo K, Nishioka Y. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. Cancer Lett 421:17-27, 2018.

Goto H, Okano Y, Machida H, Hatakeyama N, Ogushi F, Haku T, Kanematsu T, Urata T, Kakiuchi S, Hanibuchi M, Sone S, Nishioka Y. Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. Respir Investig 56(1):80-86, 2018.

Bellaye PS, Shimbori C, Yanagihara T, Carlson DA, Hughes P, Upagupta C, Sato S, Wheildon N, Haystead T, Ask K, Kolb M. Synergistic role of HSP90ƒż and HSP90ƒŔ to promote myofibroblast persistence in lung fibrosis. Eur Respir J 51(2):pii1700386, 2018.

Nishijima H, Kajimoto T, Matsuoka Y, Mouri Y, Morimoto J, Matsumoto M, Kawano H, Nishioka Y, Uehara H, Izumi K, Tsuneyama K, Okazaki IM, Okazaki T, Hosomichi K, Shiraki A, Shibutani M, Mitsumori K, Matsumoto M. Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). J Autoimmun 86:75-92, 2018.
y˜a•ś’˜‘z
ŹŽRˆë–ç, ź‰ŞˆŔ•FDƒeƒƒƒAL’ˇ‚Ć”xüˆŰÇDŒÄ‹zŠíŽžŠłf’fŽĄ—ĂƒAƒvƒ[ƒ`4uŠÔŽżŤ”x‰ŠE”xüˆŰÇ‚ƗމŽžŠłv ŽO“ˆ—W ‘•ŇW, ŒáČˆŔ—Ç‘ž ę–ĺ•ŇW pp20-25C2018D’†ŽR‘“XD

ź‰ŞˆŔ•FD‰ß•qŤ”x‰ŠDĄ“ú‚ĚŽĄ—ĂŽwj2018”N”Ł@•ŸˆäŽŸ–î, ‚–ؐ˝, ŹŽşˆęŹ ‘•ŇW, pp309-310, 2018. ˆăŠw‘‰@D
y˜a•śŒ´’˜z
XZrC‰Í–ěOC–L“c—DŽqCŹŽRˆë–çCź‘şt‰ŔCěk‘˘CŒă“Œ‹vŽkCź‰ŞˆŔ•FDƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éüˆŰ‰č×–E‘BˆöŽqŽó—e‘Ě‘jŠQ–ň‚̍RüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘D•ŞŽqŒÄ‹zŠí•a 22(1):96-98, 2018.
y˜a•ś‘ŕz
ŒáČ‰ë•FD‚ş‚ń‚ť‚­‚ĚŽĄ—Ă‚Ĺ‘ĺŘ‚Č‚ą‚ƁDŽl‘ˆăŠwŽGŽ 74(5,6):159-162, 2018.

ź‰ŞˆŔ•FCűü‹´ÍDŠŞ“ŞŒžDŽl‘ˆăŠwŽGŽ 74(5,6):125, 2018.

ź‰ŞˆŔ•FD”x‚Ş‚ń–Ɖu—Ă–@‚ĚĹ‹ß‚Ě˜b‘čD“ż“‡Œ§—Տ°“ŕ‰Čˆă‰ď‰ď•ń 23:40-43, 2018D

–L“c—DŽqDŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—ÁD“ż“‡Œ§—Տ°“ŕ‰Čˆă‰ď‰ď•ń 23:36-39, 2018D

ŹŽRˆë–ç, ź‰ŞˆŔ•FDƒeƒƒƒAL’ˇ‚Ć”xüˆŰÇDŒÄ‹zŠí“ŕ‰Č 34(3):300-303, 2018D

‰Ź–ěL˜a, Œă“Œ‹vŽk, ź‰ŞˆŔ•FDŠPšu‚ĚŒ´ˆö‚Ć‚ľ‚ÄŒŠ“Ś‚ľ‚Ä‚Í‚Č‚ç‚Č‚˘ŽîᇁDŒÄ‹zŠíƒWƒƒ[ƒiƒ‹ 66(3):458-465, 2018D

–L“c—DŽq, ź‰ŞˆŔ•FD–ňÜŤ”xáŠQDŒÄ‹zŠí“ŕ‰Č 34(Suppl.1):454-461, 2018.

źžŠ“Ö˜Y, ŒŹŒ´_. ALK—zŤ”x‚Ş‚ń‚ĚŽĄ—ĂƒV[ƒNƒGƒ“ƒX. Žîᇓŕ‰Č 21(5):536-543, 2018.

ź‰ŞˆŔ•FDŽż‹^‰ž“š ƒvƒ‚Š‚çƒvƒ‚ցu‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX‚É‚¨‚Ż‚é‚׃Šƒ€ƒ}ƒuiƒxƒ“ƒŠƒXƒ^Rj‚ĚŽg—p–@viŽż–âŽŇjD“ú–{ˆăŽ–V•ń 4908:55, 2018.

–L“c—DŽqCź‰ŞˆŔ•FDƒjƒ“ƒeƒ_ƒjƒu’P“Ć—Ă–@DŒÄ‹zŠíƒWƒƒ[ƒiƒ‹ 66(2):229-235, 2018D

ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—Á`Ĺ‹ß‚̐i•ŕ`D“ú–{“ŕ‰ČŠw‰ďŽGŽ 107(3):505-509, 2018.

Œă“Œ‹vŽkCźžŠ“Ö˜YCź‰ŞˆŔ•FD‚Ş‚ń‚̐i“W‚É‚¨‚Ż‚éüˆŰ×–E‚Ě‹@”\‚Ć–đŠ„`ŒŒŠÇVś‘jŠQ–ň‘ϐŤ‚Ć‚Ş‚ńŠ˛×–E—l×–E‚Ě—U“ą`D•ŞŽqŒÄ‹zŠí•a 22(1):49-51, 2018.

ź‰ŞˆŔ•FDŽż‹^‰ž“š ƒvƒ‚Š‚çƒvƒ‚ցu‹­”çÇ‚ɍ‡•š‚ľ‚˝ŠÔŽżŤ”x‰Š‚ĚŽĄ—Ă–@vi‰ń“šŽŇjD“ú–{ˆăŽ–V•ń 4898:54-55, 2018.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Toby Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ18“úD

Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Sato, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki, Yasuhiko Nishioka. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ16“úD

Hisatsugu Goto, Taito Yamago, Atsuro Saijo, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara, and Yasuhiko Nishioka. Involvement of insulin-like growth factor in RANKL-targeted therapy in mouse model of lung cancer bone metastasis.@ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ23“ú.

Kazuya Koyama, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Hirohisa Ogawa, Hisanori Uehara, Yasuhiko Nishioka. Novel Multi-tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Pulmonary Fibrosis In Mice. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ21“ú.

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating the effect of nintedanib on changes in biomarkers of ECM turnover in patients with IPF and limited FVC impairment: design of the INMARK study. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ20“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•FD”xŠŕŽĄ—Ă‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚ĚˆĘ’u‚Ă‚Ż‚ƐV“WŠJD‘ć27‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‚źD2018”N12ŒŽ15“úD

Œă“Œ‹vŽkDüˆŰ×–Eifibrocytesj‚đ•W“I‚Ć‚ľ‚˝ŒŒŠÇVś‘jŠQ–ň‘ϐŤƒƒJƒjƒYƒ€‚̉𖞂ƎĄ—Ă‚Ö‚Ě“WŠJD‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2018”N11ŒŽ30“úD

ű•Łš‹B, ˆŔ‘îM“ń, ‘ĺ‹ř•ś—˛, ŽRčÍ, —t‹v‹MŽi, ŒŹŒ´_, ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‡•š–˘ŽĄ—Ðis”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚é TS-1+CBDCA •š—p—Ă–@‚Ě‘ć II ‘Š—Տ°ŽŽŒąD‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(ƒ[ƒNƒVƒ‡ƒbƒv)D“Œ‹žD2018”N11ŒŽ30“úD

ź‰ŞˆŔ•FD•Ď‰ť‚ˇ‚é“Á”­Ť”xüˆŰÇ‚Ěƒ}ƒl[ƒWƒƒ“ƒg\ŽžŠł—‰đ‚ĆŽĄ—Ð헪\D‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D“Œ‹žD2018”N11ŒŽ29“úD

ź‰ŞˆŔ•F, ˆ˘•”^ŽĄ, ‹ŕŽq”ü‰Ř, ŽO‹´“ŐŽu, ‘ĺ’ËŒ›Ži, Œă“Œ‹vŽk, ‰Á“ĄKŹ. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éV‹KŽĄ—Ă–@ŠJ”­‚đ–ÚŽw‚ľ‚˝‘O—Տ°Œ¤‹†. ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď(ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“). ‰Ą•lD2018”N10ŒŽ20“úD

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚̐f’f‚ĆŽĄ—Á`RüˆŰ‰ť–ň‚ĚˆÓ‹``D‘ć81‰ń“ú–{ŒÄ‹zŠíŠw‰ďE“ú–{Œ‹Šj•aŠw‰ďE“ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒX^“÷‰čŽîŤŽžŠłŠw‰ď‹ăBŽx•”H‹GŠwpu‰‰‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D’ˇčD2018”N10ŒŽ6“úD

ŒáČ‰ë•FD‚ş‚ń‚ť‚­‚ĚŽĄ—Ă‚Ĺ‘ĺŘ‚Č‚ą‚ƁD‘ć257‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďŽs–ŻŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“ż“‡D2018”N8ŒŽ5“úD

ź‰ŞˆŔ•FD”x‚Ş‚ńi“W‚ÉŠÖ‚í‚éüˆŰ×–E‚Ě‹@”\‰đÍ‚Š‚玥—Ă‚Ö‚Ě“WŠJD‘ć27‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ď ŠwpW‰ďE‘‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D‰Ą•lD2018”N7ŒŽ19“úD

ź‰ŞˆŔ•FD”xŠŕŽĄ—Ă‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚ĚˆĘ’u‚Ă‚Ż‚ƐV“WŠJD‘ć108‰ń“ú–{”xŠŕŠw‰ďŠÖźŽx•”ŠwpW‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘ĺăD2018”N6ŒŽ30“úD

ź‰ŞˆŔ•FDi‰ť‚ˇ‚é”x‚Ş‚ń‚ĚŽĄ—Ă `i‚ŢƒQƒmƒ€ˆă—Ă‚ĚŒťę‚Š‚ç`D‘ć31‰ń“ú–{ŠŕŠw‰ďŽs–ŻŒöŠJuŔD“ż“‡D2018”N5ŒŽ27“úD

Œă“Œ‹vŽkDŒŒŠÇVśD‘ć22‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď(‹łˆçƒZƒ~ƒi[)D“Œ‹žD2018”N5ŒŽ17“úD

ź‰ŞˆŔ•FD”x‚Ş‚ńf—Ă‚ĚĹ‘Oü `i‚Ţ•ŞŽqf’f‚ĆŒÂ•Ę‰ťˆă—Á`D‘ć17‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŽs–ŻŒöŠJuŔD“ż“‡D2018”N4ŒŽ14“úD
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiCŽO‹´“ŐŽuC–؏hšrCź‰ŞˆŔ•FD”xŠŕEˆŤŤ‹š–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚đ—p‚˘‚˝–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚ƉťŠw—Ă–@‚Ě•š—pŒř‰Ę‚ÉŠÖ‚ˇ‚錟“˘D‘ć31‰ń“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ďŠwpW‰ď‘‰ďD“Œ‹žD2018”N12ŒŽ13“úD

•Ä“c_l, ‘ĺ’ËŒ›Ži, ‰Ź–ěL˜a, źžŠ“Ö˜Y, Œă“Œ‹vŽk, ŒŹŒ´_, ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‡•š”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚é 2 ŽŸ‰ťŠw—Ă–@‚ĚŒŸ“˘D‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD“Œ‹žD2018”N12ŒŽ1“úD

źžŠ“Ö˜Y, ź”Ž”V, ‹ß“ĄŒ’‰î, Œă“Œ‹vŽk, ‰Ź–ěL˜a, ŒŹŒ´_, –L“c—DŽq, ź‰ŞˆŔ•FD”ńŹ×–E”x‚Ş‚ń‚ɑ΂ˇ‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚̐ś‘śŠúŠÔ‚ÉŠÖ‚ˇ‚é—\Œă•s—LjöŽq‚ĚŒŸ“˘D‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD“Œ‹žD2018”N11ŒŽ30“úD

•Ä“c_lC‰Ź–ěL˜aC–L“c—DŽqC‰Í–ěOC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•F. ‚—î”xŠŕŠłŽŇ‚ĚŽá”NŽŇ‚Ć”äŠr‚ľ‚˝—Տ°“I“Á’Ľ. ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď. ‰Ą•lD2018”N10ŒŽ18“úD

XŒËŽ–í, ´…—Ç‘˝, ‚‹´ŽŽq, ‰şŕVLs, “Œ“‘ă, ‰Í–ěO, ź‰ŞˆŔ•F, •Ÿ“c’B–ç, Ź•éŒ’‘ž˜N, “c’†•Ű. ‘ć91‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď. ‹ž“sD2018”N9ŒŽ24-26“ú.

‰Ź–ěL˜aCű•Łš‹BCŠ`“ŕ‘ŽiCˆŔ‘îM“ńC‘ĺ‹ř•ś—˛C´…‰pŽĄC—t‹v‹MŽiC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‡•š–˘ŽĄ—Ðis”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚éTS-1+CBDCA•š—p—Ă–@‚Ě‘ć‡U‘Š—Տ°ŽŽŒąD‘ć16‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ďD_ŒËD2018”N7ŒŽ21“úD

ŒáČ‰ë•FC–Š‹`˛C–؉şŸOC‹ß“Ą^‘ăCź‰ŞˆŔ•FDƒNƒŠ[ƒjƒ“ƒO‹Ć‚Ě•v•w‚É”­Ç‚ľ‚˝‰ÄŒ^‰ß•qŤ”x‰Š—áD‘ć49‰ń“ú–{E‹ĆEŠÂ‹ŤƒAƒŒƒ‹ƒM[Šw‰ď‘‰ďEŠwp‘ĺ‰ďD‰Ą•lD2018”N7ŒŽ20“úD

źžŠ“Ö˜YCŒă“Œ‹vŽkCź”Ž”VC”ň”~—şC‰Ź–ěL˜aC•Ä“c_lCź‰ŞˆŔ•FD”x‚Ş‚ń‚ĚˆŤŤ‹š…‚ɑ΂ˇ‚é bevacizumab ‚Ě—LŒřŤ‚ƑϐŤ‰ť‹@˜‚̉đÍD‘ć27‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ď ŠwpW‰ďE‘‰ďD‰Ą•lD2018”N7ŒŽ19“úD

‹ß“Ą^‘ăCŽč’Ë•qŽjCŹě”Ž‹vCŒáČ‰ë•FCź‰ŞˆŔ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚đ•W“I‚É‚ľ‚˝ƒAƒŒƒ‹ƒM[Ť‹C“š‰ŠÇ§Œä‚ɂ‚˘‚Ä‚ĚŒŸ“˘D‘ć67‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ďDç—tD2018”N6ŒŽ22“úD

Źě”Ž‹vCŒáČ‰ë•FC‹ß“Ą^‘ăCź‰ŞˆŔ•F. _ŒoŹ’ˇˆöŽqiNGF)‚̓Ťšb‘§‚É‚¨‚Ż‚é‹C“š‰ß•qŤ˜´i‚ɑ΂ˇ‚é–đŠ„‚Ć‚ť‚ĚƒƒJƒjƒYƒ€. ‘ć67‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ďDç—tD2018”N6ŒŽ22“úD

–L“c—DŽqCŹŽRˆë–çCź‘şt‰ŔCěk‘˘CźžŠ“Ö˜YC”ň”~—şC‰Ź–ěL˜aC•Ä“c_lCź‰ŞˆŔ•F. “űŠŕŠłŽŇ‚Ě•úŽËüŽĄ—ĂŒă‚É”­Ç‚ľ‚˝•úŽËü”x‰Š‚É‚¨‚Ż‚é‹CŠÇŽx”x–Eôň‰t‚Ě—Ő°“IŒŸ“˘. ‘ć41‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2018”N5ŒŽ25“ú.

ěk‘˘C–L“c—DŽqCźžŠ“Ö˜YC”ň”~—şC‰Ź–ěL˜aC•Ä“c_lCŹŽRˆë–çCź‘şt‰ŔCź‰ŞˆŔ•F. EBUS-TBNAŒă‚ɏcŠu‰Š‚đ”­Ç‚ľ‚˝Ç—á‚É‚¨‚Ż‚éŠëŒŻˆöŽq‚ĚŒŸ“˘. ‘ć41‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2018”N5ŒŽ24“ú.

‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkC‰Ź–ěL˜aCźžŠ“Ö˜YCű•Łš‹BCź‰ŞˆŔ•F. ”xŠŕEˆŤŤ‹š–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚ƉťŠw—Ă–@‚Ě•š—pŒř‰Ę. ‘ć22‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďD“Œ‹žD2018”N5ŒŽ17“úD

‰Ź–ěL˜aCŒă“Œ‹vŽkC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YCű•Łš‹BCź‰ŞˆŔ•F. üˆŰ×–E‚ŞŽîᇖƉu‚É‹y‚Ú‚ˇ‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‘ć22‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďD“Œ‹žD2018”N5ŒŽ16“úD

”ň”~—şC‰Ź–ěL˜aCAfroj TaniaCŒă“Œ‹vŽkCŒŹŒ´_C‹g“cŒő‹PCěăsšőC‘ę‘ňGŒőCŹě”Ž‹vCíŽRKˆęCź‰ŞˆŔ•FDă”çŠÔ—t“]Šˇ (EMT)‚Ş”x‘˝Œ`Šŕ‚ĚˆŤŤ‰ť‚ÉŠń—^‚ˇ‚é‰Â”\Ť‚ɂ‚˘‚Ä‚ĚŒŸ“˘D‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‘ĺăD2018”N4ŒŽ28“úD

ŹŽRˆë–çC–L“c—DŽqCź‘şt‰ŔCěk‘˘CXZrC‰Í–ěOCŒă“Œ‹vŽkCź‰ŞˆŔ•FDƒ}ƒEƒX”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚émulti-tyrosine kinase inhibitor TAS-115‚̍RüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘D‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‘ĺăD2018”N4ŒŽ28“úD

ź‘şt‰ŔCXZrC–L“c—DŽqC—é]—ÁŽqCŹŽRˆë–çCěk‘˘C“ŕ“ĄLmC‰Í–ěOCŒă“Œ‹vŽkCź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚é“Á”­Ť”xüˆŰÇ‚ɑ΂ˇ‚éNintedanib‚ĚŽĄ—ĂÇ—á‚ĚŒŸ“˘D‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‘ĺăD2018”N4ŒŽ27“úD

“ŕ“ĄLmC‰Í–ěOCŽR‰ş—Y–çC‹ß“Ą^‘ăC‰Ź–ěL˜aC–L“c—DŽqCŠÝCŒă“Œ‹vŽkCź‰ŞˆŔ•FDƒAƒUƒ`ƒIƒvƒŠƒ“•š—p—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ŠÔŽżŤ”x‰Š‡•šRMDA5R‘Ě—zŤ”畆‹Ř‰Š‚Ě3—áD‘ć62‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ďD“Œ‹žD2018”N4ŒŽ26“úD

–L“c—DŽqCű•Łš‹BCŠ`“ŕ‘ŽiCˆŔ‘îM“ńC‘ĺ‹ř•ś—˛C´…‰pŽĄC—t‹v‹MŽiCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‡•š–˘ŽĄ—Ðis”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚éTS-1+CBDCA•š—p—Ă–@‚Ě‘ć‡U‘Š—Տ°ŽŽŒąD‘ć115‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ďD‹ž“sD2018”N4ŒŽ14“úD

‰Ź–ěL˜aCű•Łš‹BCźžŠ“Ö˜YC‘ĺ’ËŒ›ŽiC–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•F. “ż“‡‘ĺŠw•a‰@‚Ě”xŠŕÇ—á‚É‚¨‚˘‚č‚—îŽŇ‚ĆŽá”NŽŇ‚đ”äŠr‚ľ‚˝Œă‚ëŒü‚ŤŒ¤‹†D‘ć115‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ďD‹ž“sD2018”N4ŒŽ14“úD
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
˛“Ął‘ĺ, –L“c—DŽq, “ŕ“ĄLm, •Ä“c_l, ěk‘˘, ź‘şt‰Ŕ, ‹ß“Ą^‘ă, ŹŽRˆë–ç, ‰Í–ěO, Œă“Œ‹vŽk, ź‰ŞˆŔ•FD‹CŠÇŽx”x–Eôň‰t’†fibrocyte‚É‚¨‚Ż‚émiR-21”­Œť‚ĚŽžŠł•ĘˇˆŮ‚ÉŠÖ‚ˇ‚錟“˘D‘ć27‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ďD‚źD2018”N12ŒŽ15“úD

â“ŒOŠî, ‹ß“Ą^‘ă, ‹{é—ş, ‰Ź–ěL˜a, ”ň”~—ş, ”ö–Žu, Źě”Ž‹v, ‰Í–ěO, –L“c—DŽq, ŒŹŒ´_, ŒáČ‰ë•F, Œă“Œ‹vŽk, ź—Ǎ_, ź‰ŞˆŔ•FDƒGƒC‚ĚŽh‘nŒă‚É”­Ç‚ľ‚˝”畆Mycobacterium massilienseÇ‚Ěˆę—áD‘ć69‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ďD‚źD2018”N12ŒŽ15“úD

Œ´“cŽŃŠó, ‹ß“Ą^‘ă, ź‘şt‰Ŕ, “ŕ“ĄLm, ‰Í–ěO, ‘ĺč—T—ş, â“Œ—Ç”ü, űü‹´’źŠó, ěk‘˘, ź‰ŞˆŔ•F, ‰Ź–ěL˜a, ”ň”~—ş, źžŠ“Ö˜Y, ŒŹŒ´_, –L“c—DŽq, ŒáČ‰ë•F, Œă“Œ‹vŽk, ăŒ´‹v“T, Š—´™ZD–TŽîᇐŤ_ŒoÇŒóŒQ‚đ‡•š‚ľ‚˝Ź×–E”xŠŕ‚Ěˆę—áD‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‚źD2018”N12ŒŽ15“úD

â“Œ‹IŽq, ‹ß“Ą^‘ă, ‰Í–ěO, “Ą–ě‘׋P, ‰Ş‹v–Ť–ç, –L“c—DŽq, ŒŹŒ´_, ŒáČ‰ë•F, Œă“Œ‹vŽk, ‚ŽR“NŽĄ, ź‰ŞˆŔ•FD’×ᇐŤ‘ĺ’°‰Š‰Á—Ă’†‚É”­Ç‚ľCŽĄ—Ă‚É“ďa‚ľ‚˝ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ěˆę—áD‘ć60‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‚źD2018”N12ŒŽ15“úD

‹{–{Œ›ĆC‹ß“Ą^‘ăC“ŕ“ĄLmCŽRč”Ž‹PC–L“c—DŽqC‰Ź–ěL˜aC‰Í–ěOCŒă“Œ‹vŽkCŠ—´™ZCź‰ŞˆŔ•FD–Ɖu‰îÝŤ‰óŽ€Ťƒ~ƒIƒpƒ`[‚Ě1—áD‘ć119‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďDźŽRD2018”N12ŒŽ2“úD

‹ŕŽq—y—SC‹ß“Ą^‘ăCűü‹´’źŠóC”ň”~—şC‰Ź–ěL˜aC˛“Ął‘ĺCŽO–؍_˜aCŒă“Œ‹vŽkCˆŔ”{ł”ŽCź‰ŞˆŔ•FD‘˝”­ŹŒ‹ß‰e‚đ”F‚ß‚˝HIV—zŤƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ě1—áD‘ć119‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďDźŽRD2018”N12ŒŽ2“úD

ŽR‰ş—Y–çC‰Í–ěOCĄ‘qŒ’C“ŕ“ĄLmC‹ß“Ą^‘ăC‰Ź–ěL˜aC˛“Ął‘ĺC–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•FDTAFROÇŒóŒQ‚Ě1—áD‘ć29‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD‚źD2018”N12ŒŽ1“úD

“ŕ“ĄLmC‰Í–ěOC‹ß“Ą^‘ăC‰Ź–ěL˜aC˛“Ął‘ĺC–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•FDEBƒEƒCƒ‹ƒXÄŠˆŤ‰ť‚đ”˝•œ‚ľ‚˝‚ŽžŠłŠˆ“ŽŤŠÖßƒŠƒEƒ}ƒ`‚ɑ΂ľ‚ăAƒoƒ^ƒZƒvƒg‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—áD‘ć29‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD‚źD2018”N11ŒŽ30“úD

‹ß“Ą^‘ăCâ“ŒOŠîCěk‘˘Cź‘şt‰ŔCŹŽRˆë–çC˛“Ął‘ĺC–L“c—DŽqCŒáČ‰ë•FCŹě”Ž‹vCŒă“Œ‹vŽkCź‰ŞˆŔ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚đ•W“I‚É‚ľ‚˝ƒAƒŒƒ‹ƒM[Ť‹C“š‰ŠÇ§Œä‚ɂ‚˘‚Ä‚ĚŒŸ“˘D‘ć257‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2018”N8ŒŽ5“úD

űü‹´’źŠóC‰Ź–ěL˜aCű•Łš‹BCźžŠ“Ö˜YC”ň”~—şCź”Ž”VC•Ä“c_lC•Ÿ‰Ć–ƒ”üCŽO‹´“ŐŽuC‹{–{Œ›ĆCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚鍂—îŽŇ”xŠŕ‚Ě—Ő°“IŒŸ“˘D‘ć257‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2018”N8ŒŽ5“úD

X‚ ‚¸‚łC“ŕ“ĄLmCŽRúą”Ž‹PC—Ń—ŒbCâ“Œ‹IŽqCŒ´“cšŠóC‰Í–ěOC–L“c—DŽqCŒă“Œ‹vŽkCŠ—´™ZC‹v•Ű‹X–žCź‰ŞˆŔ•FD–Ɖu‰îÝŤ‰óŽ€Ťƒ~ƒIƒpƒ`[‚Ě1—á. ‘ć257‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2018”N8ŒŽ5“úD

ŽO‹´“ŐŽuCěk‘˘C•Ä“c_lCźžŠ“Ö˜YC”ň”~—şC‰Ź–ěL˜aC‹ß“Ą^‘ăCűü‹´’źŠóCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚É‚ć‚é–ňÜŤŠÔŽżŤ”xŽžŠł‚ĚŒŸ“˘B‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď^‘ć57‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď ŽáŽčŒü‚Ż‚Ě‹łˆçƒZƒ~ƒi[. o‰_D2018”N7ŒŽ15“úD
@
X•śC•Ä“c_lC‹ß“Ą^‘ăC‰Ź–ěL˜aC”ň”~—şCźžŠ“Ö˜YC•Ÿ‰Ć–ƒ”üCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FD•ĄŽ‹‚đ”­Ç‚ľAŽÎ‘ä•”ŽîᇂđŒ_‹@‚ɐf’f‚ł‚ę‚˝”ńŹ×–E”xŠŕ‚Ě1—áD‘ć57‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDo‰_D2018”N7ŒŽ14“úD

š d“š‘ĺC•Ä“c_lC‰Í–ěOCźžŠ“Ö˜YC”ň”~—şC‹ß“Ą^‘ăCâ“ŒOŠîCŹě”Ž‹vCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FD’°Œ^”x‘BŠŕ‚Ě1—áD‘ć57‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDo‰_D2018”N7ŒŽ14“úD

â“Œ‹IŽqC–L“c—DŽqC‰Í–ěOC˛“Ął‘ĺCŹŽRˆë–çCź‘şt‰ŔCěk‘˘C“ŕ“ĄLmCŒáČ‰ë•FCź‰ŞˆŔ•FD“–‰Č‚ĹŒoŒą‚ľ‚˝RMDA5R‘Ě—zŤ”畆‹Ř‰Š‡•šŠÔŽżŤ”x‰Š‚Ě—Ő°‘œ‚ĚŒŸ“˘D‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDo‰_D2018”N7ŒŽ14“úD

‘˝”Ś—L仔TC‰Ź–ěL˜aCźžŠ“Ö˜YCź”Ž”VC‹ß“Ą^‘ăCâ“Œ—Ç”üCź–{‘厑CŒă“Œ‹vŽkC‘ę‘ňGŒőCź‰ŞˆŔ•FDˆŤŤ‹š…‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝•úŽËü—U”­ŒŒŠÇ“÷Žî‚Ě1—áD‘ć59‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDo‰_D2018”N7ŒŽ14“úD

“ŕ“ĄLmCX“c—DCěk‘˘C‹ß“Ą^‘ăCź‘şt‰ŔC‰Í–ěOC–L“c—DŽqCŠÝCŒă“Œ‹vŽkCź‰ŞˆŔ•FDTocilizumab ‚Ş—LŒř‚Ĺ‚ ‚Á‚˝dÇŹl”­ÇƒXƒeƒBƒ‹•a‚Ě1—áD‘ć118‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD“ż“‡D2018”N6ŒŽ3“úD

•Ä“c_lC‰Ź–ěL˜aCź”Ž”VC‘ĺ’ËŒ›ŽiC”ň”~—şCźžŠ“Ö˜YC–L“c—DŽqCŒă“Œ‹vŽkCŒŹŒ´_Cź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚é Pembrolizumab ‚ĚŽg—pŒoŒąD‘ć118‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD“ż“‡D2018”N6ŒŽ3“úD

”ü”nłlC‰Ź–ěL˜aC‹ß“Ą^‘ăCź”Ž”VC‘ĺ’ËŒ›ŽiC”ň”~—şC˛“Ął‘ĺC–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•FD“Á”­Ť”xœ‰ťÇ‚Ě2—áD‘ć118‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD“ż“‡D2018”N6ŒŽ3“úD

‹{–{ˆťCź”Ž”VC‰Ź–ěL˜aC‹ß“Ą^‘ăC‘ĺ’ËŒ›ŽiCŹŽRˆë–çC–L“c—DŽqCŒáČ‰ë•FCź‰ŞˆŔ•FD”xM.chelonae Ç‚ĚŒo‰ß’†‚ɐf’f‚ł‚ę‚˝”xM.massiliense Ç‚Ě1—á. ‘ć118‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD“ż“‡D2018”N6ŒŽ3“úD

“ŕ“ĄLmCX“c—DC‘ĺ’ËŒ›ŽiC‰Í–ěOC–L“c—DŽqCŠÝCŒă“Œ‹vŽkCź‰ŞˆŔ•FDTocilizumab‚Ş—LŒř‚Ĺ‚ ‚Á‚˝dÇŹl”­ÇƒXƒeƒBƒ‹•a‚Ě1—áD‘ć256‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2018”N2ŒŽ11“ú.
2017”N‹ĆŃ
y‰˘•ś‘ŕ“™z
Sato S, Kolb MR. Personalised medicine for IPF: getting closer, but not there yet. Lancet Respir Med 5(11):836-837, 2017.
y‰˘•śŒ´’˜z
Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18(1):172, 2017.

Nagai K, Kishi J, Morizumi S, Minakuchi J, Bando Y, Nishioka Y, Doi T. Henoch-Schonlein purpura nephritis occurring postpartum in a patient with anti-PL-7 anti-synthetase syndrome. Mod Rheumatol 27(5):910-913, 2017.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas. Monoclon Antib Immunodiagn Immunother 36(4):157-162, 2017.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine Catabolism as a Metabolic Strategy for Cancer Survival. Cell Rep 19(7):1313-1321, 2017.

Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(3):104-112, 2017.

Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med 6(4):768-777, 2017.

Saijo A, Hanibuchi M, Goto H, Toyoda Y, Tezuka T, Nishioka Y. An analysis of the clinical features of lung cancer in patients with connective tissue diseases. Respir Investig 55(2):153-160, 2017.

Kakiuchi S, Hanibuchi M, Tezuka T, Saijo A, Otsuka K, Sakaguchi S, Toyoda Y, Goto H, Kawano H, Azuma M, Ogushi F, Nishioka Y. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145-152, 2017.

Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(1):20-24, 2017.

Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain. Monoclon Antib Immunodiagn Immunother 36(1):25-29, 2017.

Oyama Y, Enomoto N, Suzuki Y, Kono M, Fujisawa T, Inui N, Nakamura Y, Kuroishi S, Yokomura K, Toyoshima M, Imokawa S, Oishi K, Watanabe S, Kasahara K, Baba T, Ogura T, Ishii H, Watanabe K, Nishioka Y, Suda T. Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). Respir Med 123:63-70, 2017.

Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med 6(2):382-396, 2017.
y˜a•ś’˜‘z
–L“c—DŽq, ź‰ŞˆŔ•FDƒ‰ƒ“ƒQƒ‹ƒnƒ“ƒX×–E‘gD‹…ÇD‹CŠÇŽx”x–EôňuBALv–@‚ĚŽčˆř‚Ť ‰ü’ů‘ć3”ŁC“ú–{ŒÄ‹zŠíŠw‰ď‚Ń‚Ü‚ńŤ”xŽžŠłŠwp•”‰ď, Œúś˜J“­Č“ŤŽžŠłŽ•žŒ¤‹†Ž–‹Ć‚Ń‚Ü‚ńŤ”xŽžŠł’˛¸Œ¤‹†”Ç •Ň, 2017. pp128-131DŽ˝“°o”ŁD

ű•Łš‹BCź‰ŞˆŔ•FD•ŞŽqś•¨Šw“I‚É‚Ý‚˝ŠÔŽżŤ”x‰Š‚¨‚ć‚Ń”xŠŕDŠÔŽżŤ”x‰Š‡•šÇ”xŠŕ‚ÉŠÖ‚ˇ‚éƒXƒe[ƒgƒƒ“ƒgC“ú–{ŒÄ‹zŠíŠw‰ď Žîᇊwp•”‰ďE‚Ń‚Ü‚ńŤ”xŽžŠłŠwp•”‰ď •ŇW, 2017Dpp13-18. “ě]“°D

Œă“Œ‹vŽk, ź‰ŞˆŔ•FD”x–E”÷ÎÇD“Ť‚Ń‚Ü‚ńŤ”xŽžŠłf—Ă‚ĚŽčˆř‚ŤC“ú–{ŒÄ‹zŠíŠw‰ď ŠÄC, Œúś˜J“­Č‰ČŠwŒ¤‹†”ď•â•‹ŕ“ŤŽžŠł­ôŒ¤‹†Ž–‹Ću‚Ń‚Ü‚ńŤ”xŽžŠł‚ÉŠÖ‚ˇ‚é’˛¸Œ¤‹†v”Ç “Ť‚Ń‚Ü‚ńŤ”xŽžŠłf—Ă‚ĚŽčˆř‚ŤěŹˆĎˆő‰ď* •ŇW, 2017. pp2-15D“ě]“°D

ű•Łš‹BCź‰ŞˆŔ•FD‚ś‚ń”xÇiŒ]”xCƒAƒXƒxƒXƒg”xjDŽ„‚ĚŽĄ—Ă 2017-18”N“x”Ĺ, ‰Ž“c‹’jE–k‘ş‘yˆę˜YŠÄC, 2017. pp242-243. “ú–{ˆăŽ–V•ńŽĐD

ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‚Ě‹}Ť‘ˆŤDĄ“ú‚ĚŽĄ—ĂŽwj2017”N”Ĺ •ŸˆäŽŸ–î, ‚–ؐ˝, ŹŽşˆęŹ •Ň, 2017Dpp308-309. ˆăŠw‘‰@D
y˜a•śŒ´’˜z
‘ë‘q‹PŽŔ, ű•Łš‹B, –L“c—DŽq, ‹ß“Ą^‘ă, ź”Ž”V, •Ÿ‰Ć–ƒ”ü, ź‰ŞˆŔ•FD‹š…’†‚É‘˝”‚ĚLanghansŒ^‹×–E‚đ”F‚ß‚˝‹š…IL-6”Z“x‚ލ‚’l‚Ĺ‚ ‚Á‚˝Mycobacterium aviumÇ‚É”ş‚¤‹š–Œ‰Š‚Ěˆę—áDŒ‹Šj 92(9):559-566, 2017D
y˜a•ś‘ŕz
‰Ź–ěL˜a, ź‰ŞˆŔ•FD‚Ş‚ń“]ˆÚ‚Ě—Ő°Œ¤‹†‚Ě—đŽj‚Ć“W–]D“ú–{—Őଠ75(‘8):15-20, 2017.

ŠÝDäPŒ´•a‚Ě‘ŸŠíÇó‚Ćƒ}ƒlƒWƒƒ“ƒg‚̐i•ŕ@ŠÔŽżŤ”x‰ŠE”xüˆŰÇDƒAƒŒƒ‹ƒM[ 66(9):1161-1164, 2017D

–L“c—DŽq, ź‰ŞˆŔ•F. Precision MedicineGƒRƒ“ƒpƒjƒIƒ“f’f‚Ć“Á”­Ť”xüˆŰÇ. ŒÄ‹zŠí“ŕ‰Č 32(3):292-299, 2017.

ź‰ŞˆŔ•F, ˆ˘•”^ŽĄDƒ|ƒhƒvƒ‰ƒjƒ“‚đ•W“I‚Ć‚ľ‚˝ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éV‹KR‘Ěˆă–ňŠJ”­Dś‰ťŠw 89(4):564-567, 2017.

‘ĺ’ËŒ›ŽiCź‰ŞˆŔ•FD”xŠŕ‚É‚¨‚Ż‚é•W€ŽĄ—Ă‚Ć‚ľ‚Ă̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ňDŠŕ‚ƉťŠw—Ă–@ 44(8):655-660, 2017.

ŠÝ, –L“c—DŽqDƒ‹[ƒvƒXt‰Š‚É‚¨‚Ż‚é’ˇŠú—\Œă—\‘ށDƒŠƒEƒ}ƒ`‰Č58(1):102-108, 2017D

‰Ź–ěL˜a, ŒŹŒ´_D–Ɖu—Ă–@‚ĚŒťó‚ƍĄŒă‚Ě“W–]D“ú–{—Őଠ75(7):1115-1120, 2017.

Œă“Œ‹vŽkCź‰ŞˆŔ•FDŒŒŠÇVś‘jŠQ–ň‘ϐŤ‚ĚƒƒJƒjƒYƒ€D“ú–{—Őଠ75(7):1039-1043C2017.

“Œ“‘ăD•W€—\–hôE´Œ‰‘€ě(ƒKƒEƒ“ƒeƒNƒjƒbƒN‚Č‚Ç)D‹~‹}EW’†ŽĄ—Ă 29(—Ő‘):e1-e13, 2017D

Œă“Œ‹vŽkCź‰ŞˆŔ•FDüˆŰ×–E‚É‚ć‚é”x‚Ş‚ń‚ɑ΂ˇ‚錌ŠÇVś‘jŠQ–ň‚̑ϐŤƒƒJƒjƒYƒ€DĹVˆăŠw 72(4):132-137C2017.

Œă“Œ‹vŽkCŽO‹´“ŐŽuCź‰ŞˆŔ•FDŒŒŠÇVś‘jŠQ–ň‘ϐŤ‚ĆfibrocyteD•ŞŽqŒÄ‹zŠí•a 21(1):4-7C2017D
yŠw‰ď”­•\-‘ŰŠw‰ďz
H. Goto. A. Mitsuhashi, Y. Nishioka. Mechanism of acquired resistance to anti-angiogenic therapy mediated by fibrocytes. The 22nd Congress of Asian Pacific Society of Respirology. Sydney, AustraliaD2017”N11ŒŽ24“úD

H. Ogino, H. Goto, Y. Okano, H. Machida, N. Hatakeyama, F. Ogushi, T. Haku, T. Kanematsu, T. Urata, S. Kakiuchi, M. Hanibuchi, S. Sone, Y. Nishioka. Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer. ERS International Congress 2017. Milan,Italy. 2017”N9ŒŽ10“ú.

A. Saijo, H. Goto, M. Nakano, A.Mitsuhashi, H. Ogino, M. Tobiume, K. Otsuka, H. Yoneda, M.Hanibuchi, Y. Nishioka.Bone Marrow-Derived Fibrocytes Promote Stem Cell-Like Properties of Lung Cancer Cells. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ24“ú.

Y. Toyoda, S. Morizumi, S. Sato, H. Okazaki, Y. Chen, H.Goto, H. Ogawa, H. Nishimura, K. Koyama, H. Kawano, Y. Aono, H. Uehara, Y. Nishioka.Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ23“ú.

H. Goto, A.Mitsuhashi, A. Saijo, H. Ogino, K. Otsuka, M. Tobiume, H. Yoneda, M. Hanibuchi, Y. Nishioka. Fibrocytes as a Possible Cellular Biomarker for Anti-Angiogenic Therapy in Lung Cancer. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ21“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—Á`Ĺ‹ß‚̐i•ŕ`D•˝Ź29”N“x“ú–{“ŕ‰ČŠw‰ďśŠU‹łˆçu‰‰‰ďBƒZƒbƒVƒ‡ƒ“(‘ć2‰ń)D•ÄŽqD2017”N10ŒŽ29“úD

ź‰ŞˆŔ•F. ‚Ş‚ń–Ɖu—Ă–@‚ĚŠî‘b‚Ć—Ő°`Ĺ‹ß‚Ě˜b‘č`@‘ć56‰ń“ú–{–ňŠw‰ďE“ú–{–ňÜŽt‰ďE“ú–{•a‰@–ňÜŽt‰ď@’†‘Žl‘Žx•”Šwp‘ĺ‰ďƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D“ż“‡D2017”N10ŒŽ22“úD

ź‰ŞˆŔ•FDIIPs‚Ě•a‘ԁEŽĄ—Ă‚Š‚çPM/DM‚É”ş‚¤ŠÔŽżŤ”x‰Š‚đl‚Ś‚é. ‘ć9‰ń‹Ř‰Šƒ[ƒNƒVƒ‡ƒbƒv(‹łˆçu‰‰)D“Œ‹žD2017”N10ŒŽ21“úD

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚ĚŽĄ—Ð헪-RüˆŰ‰ťŽĄ—Ă‚đ‚˘‚ÂA’N‚É“ą“ü‚ˇ‚é‚Ě‚ŠH-@‘ć58‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D‰Ą•lD2017”N10ŒŽ15“úD

Œă“Œ‹vŽkCź‰ŞˆŔ•FDˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRŒŒŠÇVś—Ă–@‚̉”\Ť‚ƑϐŤ‹@˜D‘ć24‰ńÎ–ȁE’†”çŽîŒ¤‹†‰ďD‘ĺăD2017”N10ŒŽ7“úD

ˆ˘•”^ŽĄC‰Á“ĄKŹCź‰ŞˆŔ•FDˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éƒ|ƒhƒvƒ‰ƒjƒ“‚đ•W“I‚Ć‚ľ‚˝R‘Ě—Ă–@‚ĚŠJ”­D‘ć24‰ńÎ–ȁE’†”çŽîŒ¤‹†‰ďD‘ĺăD2017”N10ŒŽ7“úD

Œă“Œ‹vŽkCŽO‹´“ŐŽuCźžŠ“Ö˜YCű•Łš‹BCź‰ŞˆŔ•FDüˆŰ×–E(fibrocyte)‚đ•W“I‚Ć‚ľ‚˝‚Ş‚ń“]ˆÚEi“WƒƒJƒjƒYƒ€‚Ě‰đ–ž‚ĆŒŒŠÇVś‘jŠQ–ň‘ϐŤŽ•ž‚ĚŽŽ‚݁D‘ć26‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D‘ĺă. 2017”N7ŒŽ27“úD

ź‰ŞˆŔ•F. ”xüˆŰÇ‚Ě×–E•ŞŽq•a‘Ô‚ĆŠÖ˜Aˆâ“`Žq. ‘ć38‰ń“ú–{‰ŠÇEÄśˆăŠw‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ‘ĺă. 2017”N7ŒŽ19“úD

ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—Á`Ĺ‹ß‚̐i•ŕ`D•˝Ź29”N“x“ú–{“ŕ‰ČŠw‰ďśŠU‹łˆçu‰‰‰ďBƒZƒbƒVƒ‡ƒ“(‘ć1‰ń)D“Œ‹žD2017”N6ŒŽ11“úD

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇF‹´“n‚ľŒ¤‹†‚ĚˆÓ‹`‚Ć“W–]D‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•Ęu‰‰)D“Œ‹žD2017”N4ŒŽ22“úD

ź‰ŞˆŔ•FDBlockade of growth factor signals in fibrogenesis of the lungFtherapeutic efficacy and mechanism of actionD‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(International Symposium)D“Œ‹žD2017”N4ŒŽ21“úD
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
źžŠ“Ö˜YCű•Łš‹BC‰Ź–ěL˜aCŒŹŒ´_C–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•FDÄ”­Ź×–E”xŠŕ‚ɑ΂ˇ‚épaclitaxel—Ă–@‚ĚŒŸ“˘D‘ć58‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD‰Ą•lD2017”N10ŒŽ15“úD

źžŠ“Ö˜YCŒă“Œ‹vŽkC‰Ź–ěL˜aCŒŹŒ´_Cź‰ŞˆŔ•FDœ‘—R—ˆüˆŰ×–E(fibrocyte)‚Í”xŠŕ‚Ě‚Ş‚ńŠ˛×–E—l“ÁŤ‚𑣐i‚ˇ‚éD‘ć76‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ďD‰Ą•lD2017”N9ŒŽ28“úD

ŒáČ‰ë•FC’ˇ@‰ë”üCŠâ“c‹MCě“Y˜a‹`CÎŕVŒ[‰îC’|’J–LCź‰ŞˆŔ•FCÔ’r‰ëŽjD“ż“‡‘ĺŠw‚É‚¨‚Ż‚é’S“–ŠłŽŇ‚đ—p‚˘‚˝‘˝EŽí˜AŒg‹łˆç‚ĚŽć‚č‘g‚݁D‘ć49‰ń“ú–{ˆăŠw‹łˆçŠw‰ď‘ĺ‰ďDŽD–yD2017”N8ŒŽ19“úD

źžŠ“Ö˜YC‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiCŽč’Ë•qŽjCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FDClinical efficacy of bevacizumab for non-squamous non-small cell lung cancer patients with malignant pleural effusion. ‘ć15‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ďD_ŒËD2017”N7ŒŽ29“úD

‰Ź–ěL˜aCű•Łš‹BCźžŠ“Ö˜YCŽč’Ë•qŽjCŒă“Œ‹vŽkCź‰ŞˆŔ•FD“ż“‡‘ĺŠw•a‰@‚É‚¨‚Ż‚鍂—îŽŇ”xŠŕ‚ĆŽá”NŽŇ”xŠŕ‚Ě—Ő°“I“Á’Ľ‚ÉŠÖ‚ˇ‚é”äŠrŒŸ“˘. ‘ć15‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ďD_ŒËD2017”N7ŒŽ29“úD

Œă“Œ‹vŽkCźžŠ“Ö˜YC’†–ě–œ—L—˘C”ň”~—şC‘ĺ’ËŒ›ŽiC•Ä“c_lCű•Łš‹BCź‰ŞˆŔ•FD‚Ş‚ńŠ˛×–E‰ť‚Ě—U“ą‚đ‰î‚ľ‚˝fibrocyte‚Ě”x‚Ş‚ńi“WE“]ˆÚ‘ŁiƒƒJƒjƒYƒ€D‘ć26‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ďD‘ĺă. 2017”N7ŒŽ27“úD

Źě”Ž‹vCŒáČ‰ë•FC‹ß“Ą^‘ăCŽč’Ë•qŽjCź‰ŞˆŔ•FDIL-17/D’†‹…‚Í‹C“š”S–ŒÚ’…•ŞŽq‚đáŠQ‚ľFGF-2ŽYś‚đ‰î‚ľ‚˝‹C“š•˝ŠŠ‹Ř”ěŒú‚đ—U“ą‚ˇ‚éD‘ć66‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ďD“Œ‹žD2017”N6ŒŽ17“úD

‹ß“Ą^‘ăCŽč’Ë•qŽjCŹě”Ž‹vCŒáČ‰ë•FCź‰ŞˆŔ•FDƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚̓AƒŒƒ‹ƒM[Ť‹C“š‰ŠÇ‚Ě—U“ą‚ÉŠÖ—^‚ľ‚Ä‚˘‚éD‘ć66‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ďD“Œ‹žD2017”N6ŒŽ16“úD

˜aňrqCˆ˘•”^ŽĄC‰Ź–ěL˜aCŒă“Œ‹vŽkCű•Łš‹BC‰Á“ĄKŹCź‰ŞˆŔ•FDˆŤŤ‹š–Œ’†”çŽî“ŻŠˆÚAƒ}ƒEƒXƒ‚ƒfƒ‹‚ɑ΂ˇ‚éV‹Kƒ}ƒEƒXRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚLpMab-21‚É‚ć‚éRŽîᇌř‰Ę‚ĚŒŸ“˘D‘ć21‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2017”N6ŒŽ15“úD

ŽRŽq‘דlCŒă“Œ‹vŽkCźžŠ“Ö˜YCű•Łš‹BCź‰Ş ˆŔ•FD”x‚Ş‚ńœ“]ˆÚ‚É‚¨‚Ż‚éRANKL•W“IŽĄ—Ă‚ĚŒŔŠE‚Ɖ”\ŤD‘ć21‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2017”N6ŒŽ15“úD

‘ĺ’ËŒ›ŽiCű•Łš‹BCŒă“Œ‹vŽkCź‰ŞˆŔ•FD”xŠŕEˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRPD-1R‘́ARPD-L1R‘̂ƉťŠw—Ă–@‚Ě•š—pŒř‰Ę‚ĚŠî‘b“IŒŸ“˘D‘ć21‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2017”N6ŒŽ15“úD

Hirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa, Yasuhiko Nishioka. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. ‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹ž‘ŰƒtƒH[ƒ‰ƒ€D2017”N4ŒŽ23“úD

ű•Łš‹BC’†ŁŸ‘ĽC–Lč“ZC–؉şŹŽOC“‡“c‹v•vC’ß”ö”ü•äCŒ´“c˜a‘ăC…ˆäŒ¤ŽĄC—t‹v‹MŽiCź‰ŞˆŔ•FD“ż“‡Žs‚É‚¨‚Ż‚éCOPD‘Šú”­ŒŠ‚đ–Ú“I‚Ć‚ľ‚˝ŒŸfƒVƒXƒeƒ€D‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2017”N4ŒŽ23“úD

Žč’Ë•qŽjCŹě”Ž‹vC‹ß“Ą^‘ăC–L“c—DŽqC˛“Ął‘ĺCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDƒ_ƒjRŒ´—U“ąŤ‚ĚƒAƒŒƒ‹ƒM[Ť‹C“š‰ŠÇ‚¨‚ć‚Ń‹C“šƒŠƒ‚ƒfƒŠƒ“ƒO‚ÍPAR-2 antagonist‚Ě“Š—^‚É‚ć‚č—}§‚ł‚ę‚éD‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2017”N4ŒŽ23“ú.

–L“c—DŽqCŠÝC‰Í–ěOCXZrCŹŽRˆë–çCź‘şt‰ŔCěk‘˘CŽč’Ë•qŽjCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚é‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX‡•šŠÔŽżŤ”x‰Š‚Ě—Ő°“IŒŸ“˘D‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2017”N4ŒŽ22“úD

Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Atsushi Mitsuhashi, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroto Yoneda, Masaki Hanibuchi, Yasuhiko Nishioka. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. ‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2017”N4ŒŽ22“úD

Shun Morizumi, Seidai Sato, Hiroyasu Okazaki, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano, Yasuhiko Nishioka.Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice. ‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2017”N4ŒŽ21“ú.

‘ĺŽR‹gKC‰|–{‹I”VC—é–Ř—EŽOC‰Í–ě‰ëlC’†‘ş—S‘ž˜YC“ĄŕV•üKCŠŁ’ź‹PC•ÎdéC‰Ą‘şŒőŽiC–L“ˆŠ˛śC–…ěŽj˜NC‘ĺÎŒiŽmC“n•Ó’mŽuCŠ}Œ´Žő˜YC”nę’qŽCŹ‘q‚ŽuCÎˆäŠ°C“n•ÓŒ›‘ž˜NCź‰ŞˆŔ•FC{“c—˛•ś. Pleuroparenchymal fibroelastosis‚É‚¨‚Ż‚é”A’†ƒfƒXƒ‚ƒVƒ“‚Ě—L—pŤ‚ĚŒŸ“˘. ‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD“Œ‹žD2017”N4ŒŽ21“ú.

‰Í–ěOC–L“c—DŽqCŠÝCXZrC‹ß“Ą^‘ăCŽR‰ş—Y–çCŽč’Ë•qŽjCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒXÇ—á‚Ě—Ő°“IŒŸ“˘D‘ć61‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ďD•Ÿ‰ŞD2017”N4ŒŽ20“úD

ű•Łš‹BC‰Á”[—şC‘q–{‘ěĆCŒă“Œ‹vŽkCź‰ŞˆŔ•FCŠŕŠłŽŇŒŒŸ÷’†—V—ŁDNA‚đ—p‚˘‚˝ˆâ“`Žq•ĎˆŮŒŸ¸‹Zp‚Ě”äŠrD‘ć114‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ďD“Œ‹žD2017”N4ŒŽ14“úD
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
•Ä“c_lC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YC”ň”~—şC‰Ź–ěL˜aCź”Ž”VC–L“c—DŽqCŒă“Œ‹vŽkCŒŹŒ´_Cź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚énivolumab‚Ě—LŠQŽ–Ű‚ĚŒŸ“˘D‘ć117‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚źD2017”N12ŒŽ3“úD

’Ň–{‰ę”üC“ŕ“ĄLmC‹ß“Ą^‘ăCź”Ž”VC‰Í–ěOC‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCź‰ŞˆŔ•FD‘˝”­’P_Œo‰Š‚đ‡•š‚ľ‚˝DŽ_‹…Ť‘˝”­ŒŒŠÇ‰ŠŤ“÷‰čŽîÇiEGPAj‚É‚¨‚˘‚ĖƉuƒOƒƒuƒŠƒ“‘ĺ—Ę—Ă–@iIVIGj‚Ş—LŒř‚Ĺ‚ ‚Á‚˝3—áD‘ć117‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚źD2017”N12ŒŽ3“úD

‰Í–ěOCź–{–žCź‰ŞˆŔ•FD‚Ů‚Ú‚ˇ‚ׂĂ̋š‘B‘Žżă”ç×–E‚ސŹn‰ß’ö‚ĹAire‚đ”­Œť‚ˇ‚é‹@”\‚đ”ő‚Ś‚Ä‚˘‚éD‘ć28‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2017”N11ŒŽ25“úD

‰Ź–ěL˜aC–L“c—DŽqC‰Í–ěOCŠÝC‹ß“Ą^‘ăCXZrCŽR‰ş—Y–çCŒă“Œ‹vŽkCŒáČ‰ë•FCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚é”x•a•Ď‡•š‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒXÇ—á‚Ě—Ő°“IŒŸ“˘D‘ć28‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2017”N11ŒŽ25“úD

Ą‘qŒ’C“ŕ“ĄLmCŽR‰ş—Y–çC‰Ź–ěL˜aCŠÝC‰Í–ěOC‹ß“Ą^‘ăCXZrC–L“c—DŽqCŒă“Œ‹vŽkCŒáČ‰ë•FCź‰ŞˆŔ•FDƒ‹[ƒvƒXS‹Ř‰Š‚Ě2—áD‘ć28‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2017”N11ŒŽ25“úD

ŽR‰ş—Y–çC‰Í–ěOCŠÝC“ŕ“ĄLmC‰Ź–ěL˜aC‹ß“Ą^‘ăCXZrC–L“c—DŽqCŒă“Œ‹vŽkCŒáČ‰ë•FCź‰ŞˆŔ•FD‘SgŤ‹­”çÇ‚đ”wŒi‚Éposterior reversible encephalopathy syndrome‚đ”­Ç‚ľ‚˝ˆę—áD‘ć28‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďD“ż“‡D2017”N11ŒŽ25“úD

”ň”~—şCXZrC—é]—ÁŽqC”ę“c“N–çC‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkCăŒ´‹v“TC‹v•Ű‹X–žCź‰ŞˆŔ•FDBRAF —zŤ”xŒ´”­ˆŤŤ•FŽî‚Ě‚P—áD‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDL“‡D2017”N10ŒŽ28“úD

X“c—DC–L“c—DŽqC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YC•Ä“c_lC‹ß“Ą^‘ăCź”Ž”VCŒă“Œ‹vŽkCŒŹŒ´_Cź‰ŞˆŔ•FD•úŽËüŽĄ—Ă‚ĚƒAƒuƒXƒRƒpƒ‹Œř‰Ę‚É‚ć‚éŽîᇏkŹ‚đ”F‚ß‚˝Œă‚ɍĔ­‚ľApembrolizumab ‚Ş‘tŒ÷‚ľ‚˝”xŠŕ‚Ě‚P—áD‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDL“‡D2017”N10ŒŽ28“úD

•Ÿ“c‹Ş‘ž˜YCX“c—DC‘ĺ’ËŒ›ŽiCź‘şt‰ŔCXZrCěk‘˘CŹŽRˆë–çCĄ‘qŒ’CŒă“Œ‹vŽkCź‰ŞˆŔ•FDBAL ‚É‚ć‚čŠŕŤƒŠƒ“ƒpŠÇÇ‚Ɛf’f‚ľ‚Ś‚˝‘˝”­ƒXƒŠƒKƒ‰ƒX‰e‚đ’ć‚ľ‚˝”x‘BŠŕ‚Ě‚P—áD‘ć26‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ďDL“‡D2017”N10ŒŽ28“úD

”ü”nłlCź”Ž”VC”ň”~—şC‘ĺ’ËŒ›ŽiC“ŕ“ĄLmC–L“c—DŽqCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCź‰ŞˆŔ•FDR IFN- ƒÁR‘Ě‚Ş—zŤ‚Ĺ‚ ‚Á‚˝”dŽíŤ”ńŒ‹ŠjŤRŽ_‹ŰÇ‚Ě‚P—áD‘ć68‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ďDL“‡D2017”N10ŒŽ28“úD

—é]—ÁŽqCź‘şt‰ŔC‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiC”ň”~—şC‰Í–ěOC•Ÿ‰Ć–ƒ”üCŽR‰ş—Y–çCŒă“Œ‹vŽkCź‰ŞˆŔ•FDSƒ^ƒ“ƒ|ƒi[ƒf‚đ‚Ť‚˝‚ľ‚˝Œ‹ŠjŤS–Œ‰Š‚Ě‚P—áD‘ć68‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ďDL“‡D2017”N10ŒŽ28“úD

‘吟ˆęCXZrC”ę“c“N–çCź—§‹gOC‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiC”ň”~—şCŒă“Œ‹vŽkCăŒ´‹v“TC‹v•Ű‹X–žCź‰ŞˆŔ•FDBRAF—zŤ”xŒ´”­ˆŤŤ•FŽî‚Ě1—áD‘ć255‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2017”N8ŒŽ6“úD

ŽR‰ş‹M‰›Cź‘şt‰ŔC‰Ź–ěL˜aC‘ĺ’ËŒ›ŽiC”ň”~—şC–L“c—DŽqCŒă“Œ‹vŽkCź‰ŞˆŔ•FDSƒ^ƒ“ƒ|ƒi[ƒf‚đ‚Ť‚˝‚ľ‚˝Œ‹ŠjŤS–Œ‰Š‚Ě1—áD‘ć255‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2017”N8ŒŽ6“úD

—é]—ÁŽqCXZrC‘ĺ’ËŒ›ŽiC–L“c—DŽqC‰Í–ěOCŹŽRˆë–çCź”Ž”VCź‘şt‰ŔCŒă“Œ‹vŽkCź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚ɑ΂ˇ‚énintedanib‚ĚŽg—pŒoŒąD‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‚’mD2017”N7ŒŽ15“úD

”ü”nłlCŒáČ‰ë•FC‘ĺ’ËŒ›ŽiCŽR‰ş—Y–çCŒă“Œ‹vŽkCŠÝC‹g“cŒő‹PCăŒ´‹v“TCź‰ŞˆŔ•FDMinute Pulmonary Meningothelial-like Nodule‚Ě1—áD‘ć57‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‚’mD2017”N7ŒŽ14“úD

Ą‘qŒ’C‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YC”ň”~—şC‰Ź–ěL˜aCź”Ž”VCŒă“Œ‹vŽkCŒŹŒ´_Cź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚ĚŽg—pŒoŒąD‘ć56‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. ‚’mD2017”N7ŒŽ14“úD

Šě“c—L‰Ŕ—˘Cěk‘˘C‘ĺ’ËŒ›ŽiC‰Ź–ěL˜aC”ň”~—şCźžŠ“Ö˜YCŒŹŒ´_CŒă“Œ‹vŽkCź‰ŞˆŔ•FDŹ×–E”xŠŕ‚Ö‚Ě“]‰ť‚đ”F‚ß‚˝EGFRˆâ“`Žq•ĎˆŮ—zŤ”x‘BŠŕ‚Ě1—áD‘ć56‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. ‚’mD2017”N7ŒŽ14“úD

X“c—DC–L“c—DŽqCXZrC‘ĺ’ËŒ›ŽiC‹ß“Ą^‘ăCŹŽRˆë–çCź‘şt‰ŔCŒă“Œ‹vŽkCź‰ŞˆŔ•FD•úŽËüŽĄ—Ă‚ĚƒAƒuƒXƒRƒpƒ‹Œř‰Ę‚É‚ć‚é‚ƍl‚Ś‚ç‚ę‚éŽîᇏkŹ‚đ”F‚ß‚˝”xŠŕ‚Ě1—áD‘ć56‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. ‚’mD2017”N7ŒŽ14“úD

‹ß“Ą^‘ăCŽč’Ë•qŽjC‰Í–ěOCŒă“Œ‹vŽkCŠÝCű•Łš‹BCŒáČ‰ë•FC“yŽtł‘ž˜YCŠ—´™ZCź‰ŞˆŔ•FDŹ”]•‚Žî‚¨‚ć‚ѐ…“ޏǂđ”F‚ߊJ“ŞŒ¸ˆłp‚đ—v‚ľ‚˝NPSLE‚Ě1—áD‘ć116‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚’mD2017”N5ŒŽ21“úD

ź‘şt‰ŔCŽč’Ë•qŽjCźžŠ“Ö˜YC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒŹŒ´_Cű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FD”xG•˝ă”çŠŕŽĄ—ĂŒă‚Ě‹ó“´•a•Ď‚É”F‚ß‚˝”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ě1—áD‘ć116‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďD‚’mD2017”N5ŒŽ21“úD
2016”N‹ĆŃ
y‰˘•ś’˜‘z
Yasuhiko Nishioka. Pathogenesis of IPF. Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease? In: Nakamura H, Aoshiba K (eds) Idiopathic Pulmonary Fibrosis, Springer, Tokyo, p43-58, 2016.
y‰˘•ś‘ŕz
Nishioka Y. Cancer immunotherapy as a promising fourth standard therapy for lung canser: Beyond 20 years for the development of immunotherapy. Respir Investig 54:297, 2016.
y‰˘•śŒ´’˜z
Toyoda Y, Ozaki R, Kishi J, Hanibuchi M, Kinoshita K, Tezuka T, Goto H, Ono H, Nagai K, Bando Y, Doi T, Nishioka Y.@An autopsy case of aortic intimal sarcoma initially diagnosed as polyarteritis nodosa. Intern Med 55(21):3191-3195, 2016.

Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, Kondo M, Takikura T, Tezuka T, Goto H, Nishioka Y. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest 63(3,4):294-299, 2016.

Ogino H, Hanibuchi M, Kakiuchi S, Saojo A, Tezuka T, Toyoda Y, Tobiume M, Otsuka K, Sakaguchi S, Goto H, Arisawa K, Nishioka Y. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. J Med Invest 63(3,4):286-293, 2016.

Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M. Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-ă2 or IL-29/IFN-ă1. Cancer Gene Ther 23(8):266-277, 2016.

Numasaki M, Tsukamoto H, Tomioka Y, Nishioka Y, Ohrui T. A Heterodimeric Cytokine, Consisting of IL-17A and IL-17F, Promotes Migration and Capillary-Like Tube Formation of Human Vascular Endothelial Cells. Tohoku J Exp Med 240(1):47-56, 2016.

Abe S, Kato KM, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci 107(9):1198-1205, 2016.

Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro-Oncology 18(4):486-496, 2016.

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Hommma S, Sugiyama Y;Japan Pirfenidone Clinical Study Group.Clinical Experience of the Long-tern Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Intern Med 55(5):443-448, 2016.

Sato S, Hanibuchi M, Takahashi M, Fukuda Y, Morizumi S, Toyoda Y, Goto H, Nishioka Y. A patient with idiopathic pleuroparenchymal fibroelastosis showing sustained pulmonary function due to treatment with pirfenidone. Intern Med 55(5):497-501C2016.

Ogino H, Hanibuchi M, Takizawa H, Sakiyama S, Sumitomo H, Iwamoto S, Ikushima H, Nakajima K, Nagahiro H, Yamago T, Toyoda Y, Bando Y, Nishioka Y. Primary pulmonary synovial sarcoma showing prolonged survival with multimodality therapy. Intern Med 55(4):381-387C2016.
y˜a•ś’˜‘z
ź‰ŞˆŔ•FD”ń“ÁˆŮŤŠÔŽżŤ”x‰Š(NSIP)D“Á”­ŤŠÔŽżŤ”x‰Š f’f‚ĆŽĄ—Ă‚ĚŽčˆř‚Ť(‰ü’č‘ć3”Ĺ), “ú–{ŒÄ‹zŠíŠw‰ď ‚Ń‚Ü‚ńŤ”xŽžŠłf’fEŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“ěŹˆĎˆő‰ď•ŇW, 2016. pp61-68. “ě]“°D

ź‰ŞˆŔ•FD“Á”­Ť”xüˆŰÇ‚ĚŠî‘bDŒÄ‹zŠíŽžŠłĹV‚ĚŽĄ—Ă2016-2018D™ŽRK”äŒĂE–ĺ“c~ˆę,EŒˇŠÔş•F•ŇD2016.pp57-60D“ě]“°

ź‰ŞˆŔ•FD“Á”­ŤŠÔŽż”x‰ŠDĄ“ú‚ĚŽĄ—ĂŽwjD•ŸˆäŽŸ–îC‚–ؐ˝CŹŽşˆęŹ‘•ŇWD2016Dpp355-356DˆăŠw‘‰@D
y˜a•ś‘ŕz
‰ŞúąO‘ׁCź‰ŞˆŔ•FD‰Á—î‚Ć”xüˆŰ‰ťDThe Lung perspectives 24(3):50-54C2016D

ŠÝ, –L“c—DŽqDRA‚É‚¨‚Ż‚é‹CŠÇŽxŠg’ŁÇ‚Í–ŤŠ´őÇ‚ĹŽŠŒČ–Ɖu‚ŞŽä‹N‚ł‚ę‚郂ƒfƒ‹‚Ĺ‚ ‚éDƒŠƒEƒ}ƒ`‰Č56(1):86-91, 2016.

ŒáČˆŔ—Ç‘žCŹ‘q‚ŽuCź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š Update Ŕ’k‰ď RüˆŰ‰ť–ňŽž‘ă‚ĚŠÔŽżŤ”x‰Šf—Ă‚đl‚Ś‚éDĹVçΊw 71(7):1235-1248C2016D

ź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š Update ˜˜_DĹVçΊw 71(7):1233-1234C2016D

‰Í–ěOCź‰ŞˆŔ•FDäPŒ´•a‚É‚¨‚Ż‚é”x•a•Ď‚Ö‚ĚƒAƒvƒ[ƒ`DƒŠƒEƒ}ƒ`‰Č 55(4):345-352C2016D

˛“Ął‘ĺ, ‘ĺ’J’źŽq, Œ´‰p“ń, ź‰ŞˆŔ•FD‚Ş‚ń—}§ˆâ“`Žq‚É‚ć‚é×–E‚ĆŒÂ‘Ě˜V‰ť‚̐§ŒäD‚Ş‚ń•ŞŽq•W“IŽĄ—Ă14(1):76-81, 2016.

Œă“Œ‹vŽkCŽO‹´“ŐŽuCź‰ŞˆŔ•FDüˆŰ×–E‚Ş‚Š‚Š‚í‚錌ŠÇVś‘jŠQ–ň‚ɑ΂ˇ‚éŠl“ž‘ϐŤƒƒJƒjƒYƒ€D•ŞŽqŒÄ‹zŠí•a 20(1):111-114C2016D

ź‰ŞˆŔ•FC˛“Ął‘ĺDƒjƒ“ƒeƒ_ƒjƒuD•ŞŽqŒÄ‹zŠí•a 20(1):100-102C2016D

Œă“Œ‹vŽkCÂ–ěƒ“TCŽO‹´“ŐŽuCź‰ŞˆŔ•FD–Ť‰ŠÇ‚ĆfibrocyteDŒÄ‹z‚ƏzŠÂ 64(2):149-155C2016D
y˜a•śŒ´’˜z
ŽRŽq‘דlCű•Łš‹BC‰Ź–ěL˜aC‘şă‰iŽCŠ—´™ZCź‰ŞˆŔ•FD‘˝Ę‚Ȑ_ŒoÇó‚đ’ć‚ľ‚˝Ź×–E”xŠŕ‚É”ş‚¤–TŽîᇐŤ_ŒoÇŒóŒQ‚Ě1—áD”xŠŕ 56(3):199-204C2016D
yŠw‰ď”­•\-‘ŰŠw‰ďz
Morizumi S, Sato S, Abe S, Okazaki H, Yanjuan C, Goto H, Hanibuchi M, Aono Y, Ogawa H, Hanibuchi M, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity. ERS2016 International Conference, London, UK. 2016”N9ŒŽ4“úD
Yasuhiko Nishioka. Introduction of Session 152 - Repair pathways: from lung development to aging of the lung -. ERS2016 Internathional Conference(Invited lecture). London, UK. 2016”N9ŒŽ4“úD
Ogino H, Goto H, Kakiuchi S, Saijo A, Sakaguchi A, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Receptor tyrosine kinase-like orphan receptor 2, ROR2, regulates the proliferation of malignant pleural mesothelioma cells. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ17“ú
Sato S, Goto H, Morizumi S, Okazaki H, Yanjuan C, Kawano H, Toyoda Y, Hanibuchi M, Azuma M, Nishioka Y. Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ16“ú
Saijo A, Goto H, Mitsuhashi A, Nakano M, Ogino H, Aono Y, Sakaguchi S, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Bone marrow-derived fibrocytes maintain stem cell-like properties of lung cancer. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú
Goto H, Mitsuhashi A, Saijo A, Kuramoto T, Tabata T, Aono Y, Uehara H, Hanibuchi M, Nishioka YDFibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab in thoracic tumors. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•FDŽîᇖƉuŠw‚ĚŠî‘b‚Ć”xŠŕ–Ɖu—Ă–@‚Ě•ŕ‚݁D‘ć57‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰Ş. 2016”N12ŒŽ21“úD
Yasuhiko Nishioka. The mechanism of immunotherapy for lung cancer. JICS/KASLC symposium. ‘ć57‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(JLCS/KASLC Joint-Symposium). •Ÿ‰Ş. 2016”N12ŒŽ19“úD
ź‰ŞˆŔ•FDŒÄ‹zŠíŽžŠł‚Ěƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ``ƒAƒJƒfƒ~ƒA”­‚Ě‘n–ň‚đ–ÚŽw‚ľ‚˝‘˝EŽí˜AŒg`D‘ć64‰ńˆă—Ă–ňŠwŒöŠJƒVƒ“ƒ|ƒWƒEƒ€D“ż“‡D2016”N11ŒŽ20“úD
Yasuhiko NishiokaDAquired resistance to anti-angiogenic therapy and new insights toward the overcomingDJASMO 2016 Annual MeetingiInternational Symposium)D_ŒËD2016”N7ŒŽ28“úD
Œă“Œ‹vŽkC‰Ź–ěL˜aCŽO‹´“ŐŽuCź‰ŞˆŔ•FDŹ×–E”xŠŕ‚É‚¨‚Ż‚éŠĚ“]ˆÚ‚ĚˆĘ’u‚Ă‚Ż‚Ć‚Ş‚ńŠ˛×–E—l×–E‚Ě–đŠ„D‘ć25‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D•ÄŽqD2016”N7ŒŽ22“úD
ź‰ŞˆŔ•FD”x‚Ş‚ń‚ɑ΂ˇ‚錌ŠÇVś‘jŠQ–ň‚̑ϐŤ‹@\‚Ć‚ť‚̍Ž•žD‘ć176‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď(ƒR[ƒq[ƒuƒŒƒCƒNƒZƒ~ƒi[)D“Œ‹žD2016”N7ŒŽ16“úD
ŠÝDŠÔŽżŤ”x‰ŠE”xüˆŰÇD‘ć65‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ď(ƒVƒ“ƒ|ƒWƒEƒ€)D“Œ‹žD2016”N6ŒŽ18“úD
ź‰ŞˆŔ•FD”xüˆŰ‰ť‚Ě×–E•ŞŽq•a‘Ô‚ĆŽĄ–üí—ށD‘ć37‰ń“ú–{‰ŠÇEÄśˆăŠw‰ďD‹ž“sD2016”N6ŒŽ16“úD
ź‰ŞˆŔ•FDŒÄ‹zŠíŠw‰ď‘ŰˆĎˆő‰ď‚ĚŠˆ“Ž‚Ć—ŻŠwŽx‰‡D‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•ĘŠé‰ć)D‹ž“sD2016”N4ŒŽ9“úD
ź‰ŞˆŔ•FDRole of fibrocytes and growth factors in lung fibrosis and cancerD‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(Inter-Assembly Symposium 2)D‹ž“sD2016”N4ŒŽ9“úD
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
ű•Łš‹BCŽč’Ë•qŽjCźžŠ“Ö˜YC‰Ź–ěL˜aCŒă“Œ‹vŽkCź‰ŞˆŔ•FD“–‰Č‚É‚¨‚Ż‚鍂—îŽŇ”xŠŕ‚ĚŽá”NŽŇ‚Ć‚Ě”äŠrŒŸ“˘D‘ć57‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2016”N12ŒŽ21“úD

źžŠ“Ö˜YCŽč’Ë•qŽjC‰Ź–ěL˜aC–L“c—DŽqCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FDˆŤŤ‹š…‚𔺂Á‚˝”ńG•˝ă”ç”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚é Bevacizumab •š—p‰ťŠw—Ă–@‚ĚŒŸ“˘D‘ć57‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2016”N12ŒŽ19“úD

‰Ź–ěL˜aCŒă“Œ‹vŽkCźžŠ“Ö˜YCŠ`“ŕ‘ŽiCű•Łš‹BCź‰ŞˆŔ•FD“ż“‡‘ĺŠw•a‰@‚É‚¨‚Ż‚éi“WŒ^Ź×–E”xŠŕŠłŽŇ‚Ě—\ŒăˆöŽq‚ÉŠÖ‚ˇ‚éŒă‚ëŒü‚ŤŒ¤‹†D‘ć57‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ďD•Ÿ‰ŞD2016”N12ŒŽ19“úD

‰Ź–ěL˜a, ű•Łš‹BC‘ĺ’ËŒ›ŽiCźžŠ“Ö˜YCâŒű‹ĹCŽč’Ë•qŽjCŠ`“ŕ‘ŽiCŒă“Œ‹vŽkCź‰ŞˆŔ•FD“ż“‡‘ĺŠw•a‰@‚É‚¨‚Ż‚éi“WŒ^Ź×–E”xŠŕŠłŽŇ‚Ě—\ŒăˆöŽq‚ɂ‚˘‚Ä‚ĚŒŸ“˘D‘ć14‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ďD_ŒËD2016”N7ŒŽ28“úD

‘ĺ’ËŒ›ŽiCű•Łš‹BC‰Ź–ěL˜aCŒă“Œ‹vŽkCź‰ŞˆŔ•FD”xŠŕCˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚Ě—LŒřŤ‚ĚŠî‘b“IŒŸ“˘D‘ć25‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ďD•ÄŽqD2016”N7ŒŽ21“úD

źžŠ“Ö˜YCŒă“Œ‹vŽkCŽO‹´“ŐŽuC’†–ě–œ—L—˘C‘ĺ’ËŒ›ŽiC‰Ź–ěL˜aCâŒű‹ĹCű•Łš‹BCź‰ŞˆŔ•FDœ‘—R—ˆüˆŰ×–E(fibrocyte)‚Í”xŠŕ‚Ě‚Ş‚ńŠ˛×–E—l“ÁŤ‚𑣐i‚ˇ‚éD‘ć25‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ďD•ÄŽqD2016”N7ŒŽ21“úD

‰Ź–ěL˜aCŒă“Œ‹vŽkCźžŠ“Ö˜YC‘ĺ’ËŒ›ŽiCű•Łš‹BCź‰ŞˆŔ•FDŽó—e‘ĚŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[ROR2‚͈ŤŤ‹š–Œ’†”çŽî×–E‚Ě‘B‚đ§Œä‚ˇ‚éD‘ć25‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ďD•ÄŽqD2016”N7ŒŽ21“úD

ˆ˘•”^ŽĄC‰Á“ĄKŹCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FDƒ|ƒhƒvƒ‰ƒjƒ“‚đ•W“I‚Ć‚ľ‚˝R‘Ě—Ă–@‚ĆƒyƒƒgƒŒƒLƒZƒh‚Ě•š—p‚É‚ć‚éˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRŽîᇌř‰Ę‚ĚŒŸ“˘D‘ć20‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďD•Ę•{D2016”N5ŒŽ31“úD

‰Í–ěOC‹ß“Ą^‘ăCźžŠ“Ö˜YC–L“c—DŽqCŠÝCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚éäPŒ´•a‚ɍ‡•š‚ľ‚˝”xŠŕ‚ĚŒŸ“˘D‘ć60‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ďD‰Ą•lD2016”N4ŒŽ23“úD

‰Ź–ěL˜aCŒă“Œ‹vŽkC‘ĺ‹ř•ś—˛C—t‹v‹MŽiCŒ“ź‹M‘ĽC‰Y“c’m”VCű•Łš‹BC‘]ŞŽO˜YCź‰ŞˆŔ•FD‚—îŽŇis”ńŹ×–E”xŠŕŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ÄPRO•]‰ż‚đŽć‚č“ü‚ę‚˝S-1—Ă–@‚Ě—Ő°‘ć‡U‘ŠŽŽŒąD‘ć113‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ďD“Œ‹žD2016”N4ŒŽ15“úD

–L“c—DŽqC˛“Ął‘ĺCŠÝC‰Í–ěOCXZrCŠÝš”üCŽč’Ë•qŽjCâŒű‹ĹCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚éäPŒ´•aŠÖ˜AŠÔŽżŤ”x‰Š‚Ě‹}Ť‘žˆŤ‚ÉŠÖ‚ˇ‚é—Տ°“IŒŸ“˘D‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‹ž“sD2016”N4ŒŽ10“úD

ű•Łš‹BC’†ŁŸ‘ĽC–Lč“ZC–؉şŹŽOC“‡“c‹v•vC’ß”ö”ü•äCŒáČ‰ë•FC—t‹v‹MŽiCź‰ŞˆŔ•FD“ż“‡Žs‚É‚¨‚Ż‚éCOPDŒ’f‚ĚŒťóD‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‹ž“sD2016”N4ŒŽ8“úD

Žč’Ë•qŽjCŹě”Ž‹vC‹ß“Ą^‘ăCŒáČ‰ë•FC–L“c—DŽqC˛“Ą ł‘ĺC‰ŞúąO‘ׁC‰Í–ěOCŠÝCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FDRAS‘jŠQÜiXRP44Xj‚đ—p‚˘‚˝šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚錟“˘D‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‹ž“sD2016”N4ŒŽ8“úD

ˆ˘•”^ŽĄC‰Á“ĄKŹC‹ŕŽq”ü‰ŘCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•FDˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éV‹KRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNE-12‚ĚŒř‰ĘD‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďD‹ž“sD2016”N4ŒŽ8“úD
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
Œ´—ϐ˘CŽč’Ë•qŽjC‹ß“Ą^‘ăC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDEB‚É‚ć‚é––˝_ŒoáŠQ‚đ’ć‚ľ‚˝Œ‹ŠjŤ‹š–Œ‰Š‚Ě1—áD‘ć67‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ďD‰ŞŽRD2016”N12ŒŽ23“úD

™•ő—DlCŽč’Ë•qŽjCěk‘˘C•Ä“c_lC‘ĺ’ËŒ›ŽiC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDEBUS-TBNAŒă‚ɏcŠu‰Š‚đ”­Ç‚ľ‚˝cŠuŒ´”­ƒZƒ~ƒm[ƒ}‚Ě1—áD‘ć25‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ďD‰ŞŽRD2016”N12ŒŽ23“úD

‹e’r‚ŽjCŽč’Ë•qŽjC‹ß“Ą^‘ăC‰Ź–ěL˜aC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDStevens-Johnson ÇŒóŒQŒă‚É”­Ç‚ľ‚˝•ÂÇŤ×‹CŠÇŽx‰Š‚ɃXƒeƒƒCƒh‚¨‚ć‚Ńƒ^ƒNƒƒŠƒ€ƒX‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—áD‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‰ŞŽRD2016”N12ŒŽ23“úD

‚“‡‘ń–çCŽč’Ë•qŽjC‹ß“Ą^‘ăC”ň”~—şC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDExon19‚Ćexon21‚Ěˆâ“`Žq•ĎˆŮ‚đ“ŻŽž‚É”F‚ß‚˝”x‘BŠŕ‚Ě1—áD‘ć56‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďD‰ŞŽRD2016”N12ŒŽ23“úD

–L“c—DŽqCŽR‰ş—Y–çCXZrC‹ß“Ą^‘ăC‰Ź–ěL˜aC‰Í–ěOCŽč’Ë•qŽjCŠÝCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚éäPŒ´•aŠÖ˜AŠÔŽżŤ”x‰Š‚Ě‹}Ť‘žˆŤ‚Ě—Ő°“IŒŸ“˘D‘ć27‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDL“‡D2016”N12ŒŽ3“úD

“c’†‚ą‚ą‚ëC‰Ź–ěL˜aC‹{“c~–çCŽR‰ş—Y–çCXZrC‹ß“Ą^‘ăC‰Í–ěOCŽč’Ë•qŽjC–L“c—DŽqCŠÝCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FD15”N‘O‚ć‚č”F‚߂閝Ťt‹@”\áŠQ‚ɑ΂ľ‚ăXƒeƒƒCƒh‰Á—Ă‚Ş‘tŒ÷‚ľ‚˝tƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě1—áD‘ć27‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDL“‡D2016”N12ŒŽ2“úD

ŽR‰ş—Y–çC–L“c—DŽqC‰Ź–ěL˜aC‰Í–ěOCŽč’Ë•qŽjCŠÝCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FD“–‰@‚É‚¨‚Ż‚郋[ƒvƒXt‰Š‚ɑ΂ˇ‚éIVCY‚ĆMMF‚ĚŽĄ—ĂŒoŒąD‘ć27‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDL“‡D2016”N12ŒŽ2“úD

‰Ź–ěL˜aCŠÝC‰Í–ěOCŽč’Ë•qŽjC–L“c—DŽqCŒă“Œ‹vŽkCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•FDŠÖßƒŠƒEƒ}ƒ`‚Ě–ň•¨—Ă–@‚É‚¨‚Ż‚é‰h—{ó‘Ԃ̕ωť‚ĚŒŸ“˘D‘ć27‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ďDL“‡D2016”N12ŒŽ2“úD

ź”Ž”VCŽč’Ë•qŽjCŽR‰ş—Y–çCźžŠ“Ö˜YC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FDGefitinib“Š—^’†‚ÉAchromobacter Xylosoxidans‚É‚ć‚é‹ŰŒŒÇ‚đ”­Ç‚ľ‚˝”x‘BŠŕ‚Ě‚P—áD‘ć115‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďDˆ¤•QD2016”N11ŒŽ27“úD

•Ä“c_lCŽč’Ë•qŽjC‰Í–ěOCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•FD‘˝”­ŤˆÝ\“ńŽw’°’×ᇂ𔺂Á‚˝MTXŠÖ˜AƒŠƒ“ƒp‘BŤŽžŠł‚Ě‚P—áD‘ć115‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ďDˆ¤•QD2016”N11ŒŽ27“úD

ŽR–{´ŹCŽč’Ë•qŽjC‰Ź–ěL˜aCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•F. ‰şŠ{Ž•“÷ŠŕŽĄ—ĂŒă‚É”­ś‚ľ‚˝•úŽËü—U”­ŒŒŠÇ“÷Žî‚Ě‚P—á. ‘ć253‰ń“ż“‡ˆăŠw‰ďŠwpW‰ďD“ż“‡D2016”N7ŒŽ24“úD

ěk‘˘CŽč’Ë•qŽjC‘ĺ’ËŒ›ŽiCXZrCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BCź‰ŞˆŔ•F. Crizotinib‚É‚ć‚éILD‚đ”­ÇŒă‚ÉAlectinib‚Ě“Š—^‚މ”\‚Ĺ‚ ‚Á‚˝ALK—Z‡ˆâ“`Žq—zŤ”x‘BŠŕ‚Ě1—á. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDL“‡D2016”N7ŒŽ9“ú.

‹ß“Ą^‘ăCŽč’Ë•qŽjC•Ä“c_lC–L“c—DŽqCŒă“Œ‹vŽkCŠÝCŒáČ‰ë•FCű•Łš‹BC‘şă‘žˆęC“yˆär•vC‰Í–k’ź–çC‘ę‘ňGŒőCź‰ŞˆŔ•F. • oƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚É‚ć‚čf’f‚ľ‰ĄŠu–Œ–D‡•Â˝p‚đs‚Á‚˝‰ĄŠu–ŒŒđ’ĘÇ‚Ě1—á. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďDL“‡D2016”N7ŒŽ9“úD

ŽR‰ş—Y–çCźžŠ“Ö˜YC˛“Ął‘ĺCŽč’Ë•qŽjCâŒű‹ĹCŒă“Œ‹vŽkCŠÝCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éäPŒ´•a‡•š”xŠŕ‚ĚŒŸ“˘. ‘ć114‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2016”N5ŒŽ22“ú.

XZrC˛“Ął‘ĺC‰Ź–ěL˜aC‰Í–ěOCâŒű‹ĹCŒă“Œ‹vŽkCŠÝCű•Łš‹BCŒáČ‰ë•FCź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éƒjƒ“ƒeƒ_ƒjƒu‚Ě“Á”­Ť”xüˆŰÇ‚ɑ΂ˇ‚éŽg—pŒoŒą. ‘ć114‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2016”N5ŒŽ22“ú.

2015”N‹ĆŃ
y‰˘•ś‘ŕz
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 10: 89-98, 2015.
y‰˘•śŒ´’˜z
Fukushima K, Nakamura S, Inoue Y, Higashiyama Y, Ohmichi M, Ishida T, Yoshimura K, Sawai T, Takayanagi N, Nakahama C, Kakugawa T, Izumikawa K, Aoki N, Nishioka Y, Kosaka O, Kohno S. Utility of a sputum antigen detection test in pneumococcal and lower respiratory infectious disease in adults. Intern Med 54(22):2843-2850, 2015.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Efficacy of perfenidone and disease severity of idiopathic pulmonary fibrosis: extended analysis of phase III trial in Japan. Respir Investig 53(6):279-287, 2015.

Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomisa H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 6:8792, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Ishizawa K. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids. Biol Pharm Bull 38(11):1752-1756, 2015.

Kawano H, Nishijima H, Morimoto J, Hirota F, Morita R, Mouri Y, Nishioka Y, Matsumoto M. Aire expression is inherent to most medullary thymic epithelial cells during their differentiation program. J Immunol 195(11):5149-5158, 2015.

Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 6(34):36003-36018, 2015.

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. Mod Rheumatol. 25(4):609-614, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49(4):398-404, 2015.

Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, Ohtani N, Hara E. Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun 6:7035, 2015.

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group. Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. J Rheumatol 42(4):614-622, 2015.

Tezuka T, Ogawa H, Azuma M, Goto H, Uehara H, Aono Y, Hanibuchi M, Yamaguchi Y, Fujikawa T, Itai A, Nishioka Y. IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators. PLoS One 10(3):e0121615, 2015.

Kawano H, Hanibuchi M, Yoshijima T, Toyoda Y, Kishi J, Tezuka T, Nishioka Y. A case of atypical Takayasu arteritis initially presenting with peripheral artery disease. Case Reports in Clinical Pathology 2(2):34-40, 2015.

Sato S, Hanibuchi M, Tobiume M, Kishi J, Toyoda Y, Kawano H, Takahashi M, Fukuda Y, Nishioka Y. A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof. Case Reports in Clinical Pathology 2(1):6-11, 2015.
y˜a•ś’˜‘z
ź‰ŞˆŔ•F. DŽ_‹…Ť”x‰Š. Ą“ú‚ĚŽĄ—ĂŽwj. •ŸˆäŽŸ–î, ‚–ؐ˝, ŹŽşˆęŹ‘•ŇW. 2015. p330. ˆăŠw‘‰@.

˛“Ął‘ĺ, ź‰ŞˆŔ•F. ×–Eś•¨ŠwA•ŞŽq•a‘Ô. ĹVˆăŠw•Ęű “Á”­Ť”xüˆŰÇ‚Ć‚ť‚ĚŽü•ÓŽžŠł. ŒáČˆŔ—Ç‘ž•ŇW. 2015. pp42-47. ĹVˆăŠwŽĐ.

Œă“Œ‹vŽkD”x‚Ş‚ńD“ż“‡‘ĺŠw•a‰@‚̍ŐVŽĄ—Ă‚Ş‚í‚Š‚é–{C“ż“‡‘ĺŠw•a‰@•Ň’˜D2015Dpp30-31DƒoƒŠƒ…[ƒƒfƒBƒJƒ‹D

ź‰ŞˆŔ•FD‡–°Žž–łŒÄ‹zÇŒóŒQD“ż“‡‘ĺŠw•a‰@‚̍ŐVŽĄ—Ă‚Ş‚í‚Š‚é–{C“ż“‡‘ĺŠw•a‰@•Ň’˜D2015Dpp32-33DƒoƒŠƒ…[ƒƒfƒBƒJƒ‹D

Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “ż“‡‘ĺŠw•a‰@ŒÄ‹zŠíEäPŒ´•a“ŕ‰Č. ŒÄ‹zŠíŽžŠłf—Ă‚ĚĹć’[. ™ŽRK”äŒĂ, ‹ß“Ą‹u, ’†ź—mˆę, ‰œ‘ş–ž”Vi, ‚‹´O‹B, ˆęƒmŁł˜a, ‹g–ěˆę˜Y, –{ŠÔ‰h, ŒˇŠÔş•F, ’r“c“ż•F, {“c—˛•ś, ˆÉ’B—mŽŠ, ‰iˆŔ•, Ž›“cOŽi•ŇW. 2015. pp432-434. ć’[ˆă—Ă‹ZpŒ¤‹†Š.

ź‰ŞˆŔ•F. ”xŠŕ. Ą“ú‚̐f—Ă‚Ě‚˝‚ß‚É ƒKƒCƒhƒ‰ƒCƒ“ŠO—ˆf—Ă2015. ňF‰p•ŇW. 2015. pp570-572. “úŒoƒƒfƒBƒJƒ‹ŠJ”­.
y˜a•ś‘ŕz
–L“c—DŽqC‰Í–ěOCź‰ŞˆŔ•FDŠÔŽżŤ”x‰Š‚̖Ɖu—Ă–@‚Í—L—p‚ŠHDŒÄ‹zŠí“ŕ‰Č 28(6):451-455C2015.

ź‰ŞˆŔ•F. IPF‚Ě•aˆö˜_. THE LUNG perspective 23(3): 66-69, 2015.

ŽRŒű•Žj, ”“Œ_, V’J•ŰŽŔ, —k‰ÍGÍ, źˆäŽŽq, d´r—Y, “c粕‘, ‚‰Ş§, ”ŃŠÔ“w, ‘ĺ‰Y‰ë”Ž, Šě‘˝Gm, ŒËŞšD, –ě“c˜aŽ, XZrDˆÓŽŻáŠQŠłŽŇ‚̊ӕʐf’f‚É‚¨‚Ż‚éÚ×‚Č•a—đŠm”F‚̏d—vŤD“ú–{“ŕ‰ČŠw‰ďŽGŽ 104(7):1495-1503, 2015.

ű•Łš‹B, ź‰ŞˆŔ•F. Current topics from major journals-‰p•ś´“lj‚ç ALK—zŤ”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚é1ŽŸŽĄ—Ă‚Ĺ‚ĚƒNƒŠƒ]ƒ`ƒjƒu‚ƉťŠw—Ă–@‚Ě”äŠrŽŽŒą. “ú–{‹š•”—Տ° 74(6):717, 2015.

ź‰ŞˆŔ•F. –ň•¨ŽĄ—Ă‚É‚¨‚Ż‚éƒXƒeƒƒCƒh‚ĚˆĘ’u‚Ă‚Ż‚Ƃ́H. Modern Physician 6 35(6):766-768, 2015.

ź‰ŞˆŔ•F. ”xüˆŰÇ. ŒÄ‹z‚ƏzŠÂ 63(4): 315-322, 2015.

ź‰ŞˆŔ•F, ˆ˘•”Gˆę, ˛“Ął‘ĺ, Œă“Œ‹vŽk. Fibrocyte. Respiratory Medical Research 3(2):60-63, 2015.

ź‰ŞˆŔ•F. ‚Ş‚ń–Ɖu—Ă–@‚̉ߋŽ‚Ć–˘—ˆFƒGƒrƒfƒ“ƒX‚ŞŽŚ‚ľ‚˝V‚˝‚ȉ”\ŤD“ú–{Œűo‰ČŠw‰ďŽGŽ 64(1):1-11, 2015.

“ż“‡‘ĺŠw‘ĺŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”@ŒÄ‹zŠíEäPŒ´•a“ŕ‰ČŠw•Ş–ě. ŒÄ‹zŠí´“ljď. ŒÄ‹z 34(2):233, 2015.

ű•Łš‹B, ź‰ŞˆŔ•F. R‚Ş‚ńÜ‚Ě•›ě—p‚Ě—\–h“IŽĄ—Ă. “ú–{—Őଠ73(‘2):93-97, 2015.

ź‰ŞˆŔ•F. ŒÄ‹zŠíŠ´őÇ|Ĺ‹ß‚Ě˜b‘č|. Źź“‡ˆăŽt‰ď‰ď•ń 49:26-27, 2015.

Œă“Œ‹vŽk, ź‰ŞˆŔ•F. ŒŒŠÇVś‘jŠQÜ‚ɑ΂ˇ‚é‘ϐŤƒƒJƒjƒYƒ€. ˆăŠw‚Ě‚ ‚ä‚Ý 252(7):814-818C2015.

ű•Łš‹B. COPD|•a‘Ô‚Ě—‰đ‚Ćƒ}ƒlƒWƒƒ“ƒg‚ĚŽŔŰ|. Źź“‡ˆăŽt‰ď‰ď•ń 49:31-33, 2015.
y˜a•śŒ´’˜z
’†–ě–œ—L—˘, ‹g“cŹ“ń, ’†ŽRł, ‘ĺ‹ř•ś—˛, ű•Łš‹B, ź‰ŞˆŔ•F. ƒCƒ“ƒtƒ‹ƒGƒ“ƒUiH1N1j2009‚É”ş‚¤ARDS‚ÉPMX-DHP—Ă–@‚Ş‘tŒř‚ľ‚˝1—á. Š´őÇŠwŽGŽ 89(3):416-421, 2015.

ű•Łš‹B, ‘ĺ’ËŒ›Ži, ’Ëúą—C‹M, â‰ş’źŽŔ, Œ÷“‚ľ‚Ě‚Ô, •Ÿ“c—I, ź‰ŞˆŔ•F. Acute fibrinous and organizing pneumoniaƒpƒ^[ƒ“‚Ě“Á”­ŤŠÔŽżŤ”x‰Š‚ŞŽŚ´‚ł‚ę‚˝1—á. THE LUNG perspectives 23(2):2-5, 2015.

˛“Ął‘ĺ, Œă“Œ‹vŽk, ˆ˘•”Gˆę, ’|úą˛•v, ‰Í–ěO, Â–ěƒ“T, ź‰ŞˆŔ•F. ƒqƒgfibrocyte•Ş‰ť‚É‚¨‚Ż‚éˆâ“`Žq”­Œť‰đÍ‚Ć•ŞŽq•W“IŽĄ—Ă–ň‚É‚ć‚é•Ş‰ť§Œä‚ĚŒŸ“˘. •ŞŽqŒÄ‹zŠí•a 19(1):135-139, 2015.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Yasuhiko Nishioka. Novel mechanisms in acquired resistance to anti-angiogenic therapy against lung cancer and mesothelioma. The 2nd Gene & Immunotherapy Conference Vietnam (Invited lecture). HCM City, Vietnam. 2015”N9ŒŽ25“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Yoshinori Aono, Hirokazu Ogino, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. International Conference of Cancer Immunotherapy and Macrophages 2015. “Œ‹ž. 2015”N7ŒŽ9“ú.

Hirokazu Ogino, Atsushi Mitsuhashi, Hisatsugu Goto, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Characterization of Sphere-Forming Stem-Like Population of Lung Cancer Cell Line in Multi-Organ Metastasis Model. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ19“ú.

Yasuhiko Nishioka. What is a Role of Fibrocytes in Lung Fibrosis and Cancer? ATS 2015 International Conference (Invited lecture). Denver, CO. 2015”N5ŒŽ19“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Terumi Yoshijima, Hiroyasu Okazaki, Akio Takezaki, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Kinase Inhibitors for Growth Factor Receptors on the Differentiation of Human Fibrocytes. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The Role of Fibrocytes in the Acquired Resistance to Anti-Angiogenic Therapy with Bevacizumab in Malignant Pleural Mesothelioma. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•F.@‚Ş‚ń–Ɖu‚đl‚Ś‚é`i•ŕ‚ˇ‚éŠî‘bŒ¤‹†‚đ—Տ°‚Ö‚Ç‚¤Šˆ‚Š‚ˇ‚ŠH`.@‘ć24‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[).@ź]. 2015”N12ŒŽ20“ú.

ź‰ŞˆŔ•F.@“Á”­Ť”xüˆŰÇ‚Ě×–E•ŞŽq•a‘ÔŒ¤‹†‚ĆŽĄ—Â̐i•ŕ.@ ‘ć30‰ń’ˇčDDSEÄśˆă—ĂŒ¤‹†‰ď(“Á•Ęu‰‰). ’ˇč.@2015”N12ŒŽ4“ú.

ź‰ŞˆŔ•F.@‚Ş‚ń–Ɖu‚ĚABCF”x‚Ş‚ń‚ɑ΂ˇ‚é–Ɖu—Ă–@‚Ě—‰đ‚ÉŒü‚Ż‚Ä.@‘ć56‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€).@‰Ą•l.@2015”N11ŒŽ28“ú.

ź‰ŞˆŔ•F. “úíf—Ă‚É‚¨‚Ż‚éäPŒ´•a”x‚ĚŠÓ•Ę–@. “ú–{ŒÄ‹zŠíŠw‰ď‘ć36‰ńśŠU‹łˆçu‰‰‰ď(‹łˆçu‰‰). –źŒĂ‰Ž. 2015”N11ŒŽ1“ú.

Yasuhiko Nishioka, Hisatsugu Goto. Mechanisms of acquired resistance to anti-angiogenic therapy and new insights toward the overcoming. ‘ć74‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (Core Symposia 2). –źŒĂ‰Ž. 2015”N10ŒŽ8“ú.

‘ĺ–؍OŽĄ, ź‰ŞˆŔ•F, ‰Á“ĄKŹ. V‹KRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚLpMab-7‚̍RŽîᇌř‰Ę‚ĚŒŸ“˘. ‘ć19‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď(ƒ[ƒNƒVƒ‡ƒbƒv). źŽR. 2015”N6ŒŽ11“ú.

“Œ“‘ă. ‹ŰŒŒÇˆČŠO‚ĚESBL Š´őÇ‚ŕƒJƒ‹ƒoƒyƒlƒ€‚ĚŽg—p‚đ„§‚ˇ‚é. ‘ć63‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď(ƒ[ƒNƒVƒ‡ƒbƒv). “Œ‹ž. 2015”N6ŒŽ5“ú.

Œă“Œ‹vŽk. Life in DUKE -DUKE‘ĺŠw—ŻŠw‘ĚŒą-. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•ĘŠé‰ć). “Œ‹ž. 2015”N4ŒŽ19“ú.

ź‰ŞˆŔ•F. V‹K•ŞŽq•W“I–ň‚Ć‚ť‚Ěƒ^[ƒQƒbƒg. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(‹łˆçu‰‰). “Œ‹ž. 2015”N4ŒŽ17“ú.

ź‰ŞˆŔ•F. “úíf—Ă‚É‚¨‚Ż‚éäPŒ´•a”x‚ĚŠÓ•Ę–@. “ú–{ŒÄ‹zŠíŠw‰ď‘ć36‰ńśŠU‹łˆçu‰‰‰ď(‹łˆçu‰‰). “Œ‹ž. 2015”N4ŒŽ16“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
ű•Łš‹BC‰Á”[—şC‘q–{‘ěĆCŒă“Œ‹vŽkCâŒű‹ĹC–L“c—DŽqCŽč’Ë•qŽjCźžŠ“Ö˜YCź‰ŞˆŔ•F.@ŠŕŠłŽŇŒŒŸ÷’†—V—ŁDNA‚đ—p‚˘‚˝ˆâ“`Žq•ĎˆŮŒŸ¸‹Zp‚Ě”äŠr.@‘ć56‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď.@‰Ą•l.@2015”N11ŒŽ27“ú.

źžŠ“Ö˜YCâŒű‹ĹAŽč’Ë•qŽjCŠ`“ŕ‘ŽiC–L“c—DŽqCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•F.@“–‰@‚É‚¨‚Ż‚éäPŒ´•a‚ɍ‡•š‚ľ‚˝”xŠŕ‚ĚŒŸ“˘.@‘ć56‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď.@‰Ą•l.@2015”N11ŒŽ26“ú.

‰Ź–ěL˜a, ŽO‹´“ŐŽu, Œă“Œ‹vŽk, źžŠ“Ö˜Y, ˛“Ął‘ĺ, âŒű‹Ĺ, Žč’Ë•qŽj, ‘q–{‘ěĆ, “c”¨Ë, ăŒ´‹v“T, ű•Łš‹B, ź‰ŞˆŔ•F. Sphere Œ`ŹŠŕŠ˛×–E—l•Ş‰ć‚Ěƒqƒg”xŠŕ‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚é–đŠ„‚É‚Â‚˘‚ẲđÍ. ‘ć74‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. –źŒĂ‰Ž. 2015”N10ŒŽ10“ú.

ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, ‘ĺ’ËŒ›Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. V‹KƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě NZ-12 ‚ĚˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRŽîᇌř‰Ę. ‘ć74‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. –źŒĂ‰Ž. 2015”N10ŒŽ9“ú.

‰Ź–ěL˜a, Œă“Œ‹vŽk, ŽO‹´“ŐŽu, źžŠ“Ö˜Y, ˛“Ął‘ĺ, Š`“ŕ‘Ži, ű•Łš‹B, ăŒ´‹v“T, ź‰ŞˆŔ•F. Sphere Œ`ŹŠŕŠ˛×–E—l•Ş‰ć‚Ě”xŠŕ‘˝‘ŸŠí“]ˆÚ‚É‚¨‚Ż‚é–đŠ„‚É‚Â‚˘‚ẲđÍ. ‘ć24‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ‘ĺă. 2015”N7ŒŽ23“ú.

źžŠ“Ö˜Y, Œă“Œ‹vŽk, ŽO‹´“ŐŽu, ’†–ě–œ—L—˘, ŽRŽq‘דl, âŒű‹Ĺ, Š`“ŕ‘Ži, ű•Łš‹B, ź‰ŞˆŔ•F. Fibrocyte ‚Í‚Ş‚ńŠ˛×–EŤˆŰŽ‚É‚ć‚č”xŠŕi“W‚𑣐i‚ˇ‚é. ‘ć24‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ‘ĺă. 2015”N7ŒŽ23“ú.

âŒű‹Ĺ, –L“c—DŽq, Žč’Ë•qŽj, ’|úą˛•v, ’†–ě–œ—L—˘, ‘ë‘q‹P”ü, ˛“Ął‘ĺ, ‰ŞúąO‘×, ‘ĺ’ËŒ›Ži, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ŠÝ, ű•Łš‹B, ź‰ŞˆŔ•F. ”x–EoŒŒ‚đ‚Ť‚˝‚ľ‚˝ 11 Ç—á‚ĚŒŸ“˘. ‘ć38‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2015”N6ŒŽ11“ú.

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, źžŠ“Ö˜Y, ű•Łš‹B, ź‰ŞˆŔ•F. üˆŰ×–Eifibrocytesj‚ŞŠÖ‚í‚錌ŠÇVś‘jŠQÜ‚ɑ΂ˇ‚éŠl“ž‘ϐŤƒƒJƒjƒYƒ€. ‘ć19‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. źŽR. 2015”N6ŒŽ11“ú.

‘ĺ’ËŒ›Ži, ű•Łš‹B, Œă“Œ‹vŽk, ź‰ŞˆŔ•F. ”xŠŕ‚ɑ΂ˇ‚éRPD-L1R‘ĚŽĄ—Ă‚ĚŠî‘b“IŒŸ“˘. ‘ć19‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. źŽR. 2015”N6ŒŽ11“ú.

Źě”Ž‹v, Žč’Ë•qŽj, ź‰ŞˆŔ•F. ƒ_ƒjRŒ´Œo•@Š´ě‚ÍIL-17‚đ‘‰Á‚ł‚š•˝ŠŠ‹Ř”ěŒú‚𔺂¤‹C“šƒŠƒ‚ƒfƒŠƒ“ƒO‚đ—U“ą‚ˇ‚é. ‘ć64‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ď. “Œ‹ž. 2015”N5ŒŽ27“ú.

’}Œă“Žq, ŠÝ, –L“c—DŽq, ‰Í–ěO, ź‰ŞˆŔ•F. ŠÖßƒŠƒEƒ}ƒ`ŠłŽŇ‚É‚¨‚Ż‚é‰h—{•]‰ż–@‚ĚŒŸ“˘. ‘ć59‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď. –źŒĂ‰Ž. 2015”N4ŒŽ24“ú.

–L“c—DŽq, ‘ë‘q‹PŽŔ, ‹ß“Ą^‘ă, ˛“Ął‘ĺ, ”öč—Ě•F, ŠÝ, Žč’Ë•qŽj, ‰Í–ěO, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. äPŒ´•a‚ɍ‡•š‚ľ‚˝ŒŒ‹…ćÐHŤƒŠƒ“ƒp‘gD‹…Ç‚Ě4Ç—á. ‘ć59‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď. –źŒĂ‰Ž. 2015”N4ŒŽ24“ú.

˛“Ął‘ĺ, Œă“Œ‹vŽk, XZr, ˆ˘•”Gˆę, ‹g“ˆ‹PŽŔ, ‰ŞúąO‘×, ű•Łš‹B, ź‰ŞˆŔ•F. ”xüˆŰ‰č×–E‚ɑ΂ˇ‚éfibrocyte‚̍ě—p‚Ćnintedanib‚Ě—}§Œř‰Ę. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2015”N4ŒŽ19“ú.

ű•Łš‹B, ’†ŁŸ‘Ľ, –Lé“Z, –؉şŹŽO, “‡“c‹v•v, ’ß”ö”ü•ä, ŒáČ‰ë•F, —t‹v‹MŽi, ź‰ŞˆŔ•F. “ż“‡Žs‚É‚¨‚Ż‚éCOPDŒŸfƒVƒXƒeƒ€‚̍\’z. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2015”N4ŒŽ19“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Fibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2015”N4ŒŽ18“ú.

’†‘şMŒł, “Œ“‘ă, ‰F‚Œ›Œá, ŽO–؍_˜a, ‰ęě‹v”üŽq, ź‰ŞˆŔ•F, ”nŒ´•ś•F, “Ą“c”ŽŒČ. “–‰@‚ĹŒoŒą‚ľ‚˝dÇ”MŤŒŒŹ”ÂŒ¸­ÇŒóŒQ‚Ě3—á. ‘ć89‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď. ‹ž“s. 2015”N4ŒŽ17“ú.

Žč’Ë•qŽj, Źě”Ž‹v, –L“c—DŽq, ’|úą˛•v, ˛“Ął‘ĺ, ‰ŞúąO‘×, ‹g“ˆ‹PŽŔ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Plasminogen Activator Inhibitor-1 ‘jŠQÜ(IMD-4690)‚Ě–Ťšb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚錟“˘. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2015”N4ŒŽ17“ú.

Š`“ŕ‘Ži, ‰Ź–ěL˜a, ‘ĺ’ËŒ›Ži, âŒű‹Ĺ, źžŠ“Ö˜Y, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ă‚ĚŒťó. ‘ć55‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2015”N4ŒŽ17“ú.

“Œ “‘ă, ź‰ŞˆŔ•F. ‘ϐŤ—Δ^‹ŰŽ‘ąŠ´ő‚É‚¨‚Ż‚é‘n•”‚Ö‚Ěƒ|ƒŠƒ~ƒLƒVƒ“ B —°Ž_‰–ŽU•z‚ĚŒŸ“˘. ‘ć89‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď. ‹ž“s. 2015”N4ŒŽ17“ú.

’†–ě–œ—L—˘, ‹g“ˆ‹PŽŔ, ű•Łš‹B, ’†‘şMŒł, ŽO–؍_˜a, ‰ęě‹v”üŽq, ź‰ŞˆŔ•F. Pneumocystis jiroveci‚ɑ΂ľST‡Ü‚Ě’EŠ´ě—Ă–@‚đs‚Á‚˝4Ç—á‚ĚŒŸ“˘. ‘ć89‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď. ‹ž“s. 2015”N4ŒŽ16“ú.

Šââ–ƒˆßŽq, ˛“Ął‘ĺ, âŒű‹Ĺ, –L“c—DŽq, Źě”Ž‹v, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Šƒ}[ƒJ[‚ĚŒŸ“˘. ‘ć112‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ď. ‹ž“s. 2015”N4ŒŽ11“ú.

‰Ź–ěL˜a, –L“c—DŽq, ’†–ě–œ—L—˘, “Œ“‘ă, ű•Łš‹B, ź‰ŞˆŔ•F. ”畆‹Ř‰Š‚ɑ΂ľ‚ăXƒeƒƒCƒh‚¨‚ć‚іƉu—}§Ü‚É‚ć‚é‰Á—Ă’†‚É”­Ç‚ľ‚˝”dŽíŤMycobacterium aviumÇ‚Ě1—á. ‘ć90‰ń“ú–{Œ‹Šj•aŠw‰ď‘‰ď. ’ˇč. 2015”N3ŒŽ27“ú.

“Œ“‘ă, ’†‘]ˆŸ˛”ü, “ĄŒ´”ÍŽq, ”¨”ü’qŽq, ‰Á“Ą^‰î, ź‰ŞˆŔ•F. uHYDRO AGv‚đ—p‚˘‚˝ƒ^ƒbƒ`ƒpƒlƒ‹‰tť•ŰŒěƒtƒBƒ‹ƒ€‚Ěˆă—ĂŒťę‚É‚¨‚Ż‚é—L—pŤ‚ĚŒŸ“˘. ‘ć30‰ń“ú–{ŠÂ‹ŤŠ´őŠw‰ď‘‰ďEŠwpW‰ď. _ŒË. 2015”N2ŒŽ20“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
Žl‹{—R‹MC˛“Ął‘ĺC’|úą˛•vC‹ß“Ą^‘ăC‘ë‘q‹PŽŔCâŒű‹ĹA–L“c—DŽqCŒă“Œ‹vŽkCŠÝCű•Łš‹BCź‰ŞˆŔ•F.@ƒTƒ‹ƒRƒCƒh[ƒVƒXŒo‰ßŠĎŽ@’†‚É”­Ç‚ľ‚˝Œ‹ŠjŤ‹š–Œ‰Š‚Ě‚P—á.@‘ć24‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď.@ź]. 2015”N12ŒŽ20“ú.

•Ä“c_lC˛“Ął‘ĺCěk‘˘C‰Ź–ěL˜aC’|úą˛•vCâŒű‹ĹC–L“c—DŽqC“Œ“‘ăCŒă“Œ‹vŽkCŠÝCű•Łš‹BCź‰ŞˆŔ•F.@œ‘ˆŮŒ`ŹÇŒóŒQ‚É”dŽíŤŒ‹ŠjÇ‚đ‡•š‚ľŽĄ—Ă‚É“ďa‚ľ‚˝ˆę—á.@‘ć66‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ď. ź]. 2015”N12ŒŽ19“ú.

’–Žq–˘ŠóC‰Ź–ěL˜aC’†–ě–œ—L—˘C‰ŞúąO‘ׁC‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkCŠÝCű•Łš‹BCâ“Œ—Ç”üCíŽRKˆęCź‰ŞˆŔ•F.@”]AŒűŠW‚AA“Ş‚¨‚ć‚яŹ’°‚ւ̉“Šu“]ˆÚ‚đŒ`Ź‚ˇ‚é‹H‚Č—Ő°Œo‰ß‚đ‚˝‚Ç‚Á‚˝‰Eă—tŒ´”­‘˝Œ`Šŕ‚Ěˆę–UŒŸ—á.@ ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď.@ź]. 2015”N12ŒŽ19“ú.

‘]‰ä•”—m•˝C˛“Ął‘ĺCźžŠ“Ö˜YC’†–ě–œ—L—˘C‰Í–ěOCâŒű‹ĹC–L“c—DŽqCŒă“Œ‹vŽkCŠÝCű•Łš‹BCź‰ŞˆŔ•F.@ŠŕŤ‘–Œ‰Š‚ɑ΂ľƒAƒtƒ@ƒ`ƒjƒu‚Ş‘tŒř‚ľ‚˝2—á.@‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď.@ź]. 2015”N12ŒŽ19“ú.

‹ß“Ą^‘ăC˛“Ął‘ĺCŽč’Ë•qŽjC–L“c—DŽqC”ň”~—şCŒă“Œ‹vŽkCŠÝCű•Łš‹BCź‰ŞˆŔ•F.@‹š–Œ‰ŠESŠO–Œ‰Š‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝ŹlStill•a‚Ě2—á.@ ‘ć113‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚ź.@2015”N12ŒŽ6“ú.

XZrC˛“Ął‘ĺC‰Ź–ěL˜aC‹ß“Ą^‘ăCŽč’Ë•qŽjC–L“c—DŽqCŒă“Œ‹vŽkCŠÝCű•Łš‹BCź‰ŞˆŔ•F.@“–‰Č‚ĹŽ{s‚ł‚ę‚˝‹š–Œ–ü’…p‚É‚¨‚Ż‚éƒ^ƒ‹ƒNťÜ‚ĆOK-432‚ĚŽg—pŹŃ‚Ě”äŠr.@‘ć113‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚ź. 2015”N12ŒŽ6“ú.

ŽR‰ş—Y–çC‰Ź–ěL˜aCŠÝC–L“c—DŽqCXZrC‹ß“Ą^‘ăC‘ë‘q‹PŽŔC˛“Ął‘ĺC‰Í–ěOCŽč’Ë•qŽjCŒă“Œ‹vŽkCű•Łš‹BAź‰ŞˆŔ•F.@‹š–Œ‰ŠAƒlƒtƒ[ƒ[ÇŒóŒQ‚¨‚ć‚яdÇ‘m–X•Ů•Â˝•s‘SÇ‚đ’ć‚ľ‚˝‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX‚Ěˆę—á.@‘ć26‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď.@‰ŞŽR. 2015”N12ŒŽ5“ú.

Š“cŒh‰î, ˛“Ął‘ĺ, –L“c—DŽq, âŒű‹Ĺ, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. PS•s—ÇALK—Z‡ˆâ“`Žq—zŤ‚ĚŽá”N”x‘BŠŕ‚ɑ΂ľƒNƒŠƒ]ƒ`ƒjƒu‚Ş‘tŒř‚ľ‚˝ˆę—á. ‘ć251‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡. 2015”N8ŒŽ2“ú.

ěk‘˘, âŒű‹Ĺ, ’Ëúą—C‹M, ˛“Ął‘ĺ, ”ň”~—ş, •Ä“c_l, ’|úą˛•v, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. ŠŕŤ‘–Œ‰Š‚Éafatinib‚Ş‘tŒř‚ľ‚˝EGFR exon18 G719A•ĎˆŮ‚đ‚ŕ‚”x‘BŠŕ‚Ěˆę—á. ‘ć54‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. źŽR. 2015”N7ŒŽ3“ú.

’–Žq–˘Šó, ‰Ź–ěL˜a, âŒű‹Ĺ, ŠÝš”ü, –L“c—DŽq, ‹ß“Ą^‘ă, ’†–ě–œ—L—˘, ŠÝ, ű•Łš‹B, ź‰ŞˆŔ•F. Nocardia wallaceiŠ´őÇ‚Ě1—á. ‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. źŽR. 2015”N7ŒŽ3“ú.

•ˆä”ü‹MŽqC‹ß“Ą^‘ăC˛“Ął‘ĺC‰Í–ěOC–L“c—DŽqCű•Łš‹BCź‰ŞˆŔ•F. DŽ_‹…Ť’_ŠÇ‰Š‚đ‡•š‚ľ‚˝‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX‚Ě‚P—á. ‘ć112‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2015”N6ŒŽ7“ú.

‘ë‘q‹PŽŔCâŒű‹ĹCXZrC‘ĺ’ËŒ›ŽiCŠÝš”üCŽč’Ë•qŽjCźžŠ“Ö˜YCŠ`“ŕ‘ŽiCű•Łš‹BCź‰ŞˆŔ•F. N-acetylcysteine‹z“ü‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ƒsƒ‹ƒtƒFƒjƒhƒ“’ďRŤ“Á”­Ť”xüˆŰÇ‚Ě1—á. ‘ć112‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2015”N6ŒŽ7“ú.

”öč—Ě•F, âŒű‹Ĺ, Žč’Ë•qŽj, ‘ĺ’ËŒ›Ži, XZr, ŠÝ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. ‹š–Œ’ź‰ş‚É‘Ńó‚É•Ş•z‚ˇ‚邡‚čƒKƒ‰ƒX‰A‰e‚Ĺ”­Ç‚ľ‚˝AŽŠŒČ–ƉuŤ”x–E’`”’Ç‚Ěˆę—á. ‘ć23‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. ‚’m. 2015”N2ŒŽ28“ú.

’†–ě–œ—L—˘, “Œ“‘ă, ‘ë‘q‹PŽŔ, âŒű‹Ĺ, –L“c—DŽq, ă‰ńŽŃ‘ă, ˆŔ•”GÄ, ű•Łš‹B, “yˆär•v, ź‰ŞˆŔ•F. ’ˇŠúŠÔƒXƒeƒƒCƒh“Š—^‚Ş”­Ç‚ĚŒ_‹@‚Ć‚Č‚Á‚˝AMycobacterium intracellulare‚É‚ć‚éŠÖß‰Š‚ƍœ‘‰Š‚Ě2Ç—á. ‘ć65‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ď. ‚’m. 2015”N2ŒŽ28“ú.

–ě“c˜aŽ, “Œ“‘ă, ź”—Š°—˛, •š’JGŽĄ, ˛“Ą‰ë”ü, ”¨”ü’qŽq, ÎŕVŒ[‰î, ź‰ŞˆŔ•F. ^‹ŰŠ´őBUNDLE‚Ě“ż“‡‘ĺŠw•a‰@‚Ĺ‚ĚŠˆ—p‚ɂ‚˘‚Ä. ‘ć250‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡. 2015”N2ŒŽ1“ú.

ˆîŠ_‘ž‘˘, ‰Ź–ěL˜a, âŒű‹Ĺ, –L“c—DŽq, ’†–ě–œ—L—˘, XZr, ˛“Ął‘ĺ, Źě”Ž‹v, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Šƒ}[ƒJ[‚ĚŒŸ“˘. ‘ć250‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡. 2015”N2ŒŽ1“ú.

ŠŰ‹´•üŽq, ’†‘şMŒł, ‘]‰ä•”ŒöŽq, ”Ş–Ř‚Đ‚Š‚é, ‚‹´^”üŽq, ‰F‚Œ›Œá, “ĄˆäŽu˜N, ŽO–؍_˜a, ‰ęě‹v”üŽq, ˆŔ”{ł”Ž, źžŠ“Ö˜Y, ’†–ě–œ—L—˘, “Œ“‘ă, ź‰ŞˆŔ•F, ‹ß“ĄŒ›•Ű, ˆä“ŕV, “Ą“c”ŽŒČ, ”nŒ´•ś•F. “–‰@‚ĹŒoŒą‚ľ‚˝dÇ”MŤŒŒŹ”ÂŒ¸­ÇŒóŒQ‚Ě‚R—á. ‘ć250‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡. 2015”N2ŒŽ1“ú.
2014”N‹ĆŃ
y‰˘•ś‘ŕ“™z
Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Invest 61(3,4):241-253, 2014.

Nishioka Y. Physician scientists in respiratory medicine. Respir Investig 52(5):279, 2014.

Nishioka Y. New wave of immunotherapy against lung cancer rolls in to clinic. Transl Lung Cancer Res 3(1):1, 2014.

Goto H, Mitsuhashi A, Nishioka Y. Role of surfactant protein A in non-infectious lung diseases. J Med Invest 61(1,2):1-6, 2014.
y‰˘•śŒ´’˜z
Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS ONE 9(11):e113606, 2014.

Ogawa H, Ledford JG, Mukherjee S, Aono Y, Nishioka Y, Lee JJ, Izumi K, Hollingsworth JW. Surfactant protein D attenuates sub-epithelial fibrosis in allergic airways disease through TGF-beta. Respir Res 15(1):143, 2014.

Sato S, Hanibuchi M, Fukuya A, Yabuki Y, Bando H, Yoshijima T, Goto H, Ogawa H, Nishioka Y. Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6. Lung 192(5):711-717, 2014.

Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y. Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 51(6):793-801, 2014.

Yokoi K, Tanei T, Godin B, van de Ven AL, Hanibuchi M, Matsunoki A, Alexander J, Ferrari M. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Letters 345(1):48-55, 2014.

Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saijo A, Kawano H, Goto H, Aono Y, Hanibuchi M, Horikawa H, Nakajima T, Furukawa T, Sone S, Akiyama S, Nishioka Y. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 66(3):560-568, 2014.
y˜a•ś’˜‘z
ŠÝ, ‰Í–ěO, ź‰ŞˆŔ•F. ‹­”çÇ. ĹVˆăŠwE•Ęű V‚ľ‚˘f’f‚ĆŽĄ—Ă‚ĚABC 85, ™ŽRK”äŒĂ•ŇW. 2014. pp34-41. ĹVˆăŠwŽĐ.

ű•Łš‹B. Œ‹Šj. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. p175. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

–L“c—DŽq. ƒVƒF[ƒOƒŒƒ“ÇŒóŒQEƒx[ƒ`ƒFƒbƒg•a. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp134-135. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ŠÝ. ‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒXE‘˝”­Ť‹Ř‰Š/”畆‹Ř‰ŠE‘SgŤ‹­”çÇ. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp132-133. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ŠÝ. äPŒ´•aE–ƉuŽžŠłEƒAƒŒƒ‹ƒM[ŽžŠł‚Ć‚Í. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp128-129. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

Š`“ŕ‘Ži. ”x‚Ş‚ńE‹Ö‰ŒŽw“ąE‹Ö‰ŒŽx‰‡. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp65-67. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

–L“c—DŽq. ‰ßŠˇ‹CÇŒóŒQ. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp63-64. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

Š`“ŕ‘Ži. ‡–°Žž–łŒÄ‹zÇŒóŒQ. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp61-62. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

Œă“Œ‹vŽk. ”x‰Š. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp59-60. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

Œă“Œ‹vŽk. –Ť•ÂÇŤ”xŽžŠłEŠÔŽżŤ”x‰Š. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp57-58. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ű•Łš‹B. ŠPšuEá‚. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. p29. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ű•Łš‹B. ”­”M. Ž•ŠE“W–] •ĘűEŽ•‰ČˆăŽt‚Ě‚˝‚ß‚ĚˆăŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{Ÿ•F, Ô’r‰ëŽj, ‰ŐŒ´–Ť, Žsě“N—Y•ŇW. 2014. pp11-12. ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ź‰ŞˆŔ•F. ×–EE•ŞŽqś•¨. ŒÄ‹zŠíŽžŠł•śŒŁƒŒƒrƒ…[2014`2015. ‹´–{CŠÄC. 2014. pp12-25. Š”ŽŽ‰ďŽĐŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ.
y˜a•ś‘ŕz
ź‰ŞˆŔ•F. COPDf—Ă‚ĚŒťó‚Ć“ż“‡Œ§‚Ĺ‚ĚŽć‚č‘g‚Ý. ˆ˘“ěˆă•ń 175:20-21, 2014.

ź‰ŞˆŔ•F. ”xüˆŰÇ‚Ć‘BˆöŽqƒVƒOƒiƒ‹. ŒÄ‹z‚ƏzŠÂ 62(9):873-878, 2014.

Œă“Œ‹vŽk, ź‰ŞˆŔ•F. V–ň‚ĚĹ‹ß‚Ě˜b‘čuƒfƒmƒXƒ}ƒuv. •ŞŽqŒÄ‹zŠí•a 18(1):109-111, 2014.

ź‰ŞˆŔ•F. V–ňŽĄ—Ă–ň‚ĚŠJ”­ó‹ľ‚ƏŤ—ˆ“W–]. “ú–{ˆăŽt‰ďŽGŽ143(5):1011, 2014.
y˜a•śŒ´’˜z
–؉şŸO, Â–ěƒ“T, ’|úą˛•v, ‰ŞúąO‘×, ‹g“ˆ‹PŽŔ, ŠÝš”ü, “Œ“‘ă, ŠÝ, ňŒ[‰î, ź‰ŞˆŔ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éFAKƒVƒOƒiƒ‹‘jŠQ–ň‚̍RüˆŰ‰ťŒř‰Ę. •ŞŽqŒÄ‹zŠí•a 18(1):154-157, 2014.

’r’źŽq, Š ’JƒAƒL, ŕ_Œű^—, HX—eŽq, ź”Ž”V, ’†–ě–œ—L—˘, ’Ź“c‹v“T, ”ŠŽR’¨ś, ‰Ş–ě‹`•v,ŽÂŒ´•×, ‘ĺ‹ř•ś—˛. ”xŠŕ‰ťŠw—Ă–@ŠłŽŇ‚ĚQOL/PRO•]‰ż‚É‹y‚Ú‚ˇŒ‡‘Ş‚Ě‰e‹ż. ‚’mŒ§ˆăŽt‰ďˆăŠwŽGŽ 19(1):112-121, 2014.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Yasuhiko Nishioka, Shuichi Abe, Seidai Sato, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki, Masaki Hanibuchi. Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production. The 18th International Colloquium on Lung and Airway Fibrosis (ICLAF). Mont-Tremblant, Quebec Canada. 2014”N9ŒŽ23“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Seiji Yano, Keisuke Izumi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. ATS 2014 International Conference (Mini-symposium). San Diego, CA. 2014”N5ŒŽ21“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma,Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation. ATS 2014 International Conference. San Diego, CA. 2014”N5ŒŽ18“ú.

Hisatsugu Goto, Yasuhiko Nishioka.The role of surfactant protein A in the host defense of the lung. The 117th Conference of KATRD (Invited lecture). Buan, Korea. 2014”N4ŒŽ11“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
Œă“Œ‹vŽkCź‰ŞˆŔ•F. ‹}ŤEˆŸ‹}ŤŒo‰ß‚đŽŚ‚ˇŠÔŽżŤ”x‰Š‚Ě—Ő°. ‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď(‹łˆçu‰‰j. ‚ź. 2014”N12ŒŽ13“ú.

ź‰ŞˆŔ•F. ‚Ş‚ń–Ɖu—Ă–@‚̉ߋŽ‚Ć–˘—ˆFƒGƒrƒfƒ“ƒX‚ŞŽŚ‚ľ‚˝V‚˝‚ȉ”\ŤD‘ć62‰ń“ú–{ŒűoŠw‰ď ’†‘EŽl‘’n•ű•”‰ď(“Á•Ęu‰‰). “ż“‡. 2014”N10ŒŽ25“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽu, źžŠ“Ö˜Y, ‘q–{‘ěĆ, “c”¨Ë, ű•Łš‹B, Š`“ŕ‘Ži, Â–ěƒ“T, ăŒ´‹v“T, ź‰ŞˆŔ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂ˇ‚éŠl“ž‘ϐŤƒƒJƒjƒYƒ€‚Ć‚ľ‚Ă̐üˆŰ×–Eifibrocytesj‚Ě–đŠ„. ‘ć18‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ĺ‘ä. 2014”N6ŒŽ27“ú.

ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Š/”xüˆŰÇ. ‘ć61‰ń“ú–{–ƒŒ‰ČŠw‰ďŠwpW‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ‰Ą•l. 2014”N5ŒŽ16“ú.

ź‰ŞˆŔ•F. ‰pŒę˜_•ś‚̏‘‚Ť•ű‚ĆŽw“ąƒ|ƒCƒ“ƒg`“–‰Č‚É‚¨‚Ż‚éŒoŒą‚Š‚ç`. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(“Á•ĘŠé‰ć). ‘ĺă. 2014”N4ŒŽ27“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽu, ˆ˘•”Gˆę, Â–ěƒ“T, ź‰ŞˆŔ•F. ŒÄ‹zŠíŽžŠł‚É‚¨‚Ż‚閝Ť‰ŠÇ‚Ć fibrocyte. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ‘ĺă. 2014”N4ŒŽ27“ú.

ź‰ŞˆŔ•F. ”x‚Ş‚ńE’†”çŽî‚É‚¨‚Ż‚錌ŠÇVś‘jŠQ–ň‘ϐŤ. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒVƒ“ƒ|ƒWƒEƒ€). ‘ĺă. 2014”N4ŒŽ26“ú.

ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ð헪. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[). ‘ĺă. 2014”N4ŒŽ25“ú.

ź‰ŞˆŔ•F. ‚Ş‚ń•ŞŽq•W“IŽĄ—Ă‚ĚŠî‘b‚Ć—Ő°.•˝Ź25”N“x“ż“‡—Տ°×–EŠw‰ď‘‰ď‚¨‚ć‚ŃŠwpW‰ď(“Á•Ęu‰‰). “ż“‡. 2014”N3ŒŽ6“ú.

ź‰ŞˆŔ•F. ‚—îŽŇ”x‰Šf—Ă‚Ěl‚Ś•ű. ‘ć25‰ń“ú–{˜V”NˆăŠw‰ďŽl‘’n•ű‰ď(‹łˆçu‰‰). “ż“‡. 2014”N2ŒŽ23“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
Hitoshi Nishijima, Junko Morimoto, Yasuhiro Mouri, Hiroshi Kawano, Koichi Ikuta, Mitsuru Matsumoto. Approaches to identify Aire-regulated non-tissue-restricted antigen genes by the ectopic expression of Aire in thymic cortex. ‘ć43‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď. ‹ž“s. 2014”N12ŒŽ10“ú.

Hiroshi Kawano, Junko Morimoto, Yasuhiro Mouri, Hitoshi Nishijima, Yasuhiko Nishioka, Mitsuru Matsumoto. Unexpected disturbance of the development of medullary thymic epithelial cells at immature stages by the long-term ablation of mature Aire-expressing cells. ‘ć43‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď. ‹ž“s. 2014”N12ŒŽ10“ú.

Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, ˛“Ął‘ĺ, źžŠ“Ö˜Y, âŒű‹Ĺ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ă‚ĚŒťó. ‘ć55‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď. ‹ž“s. 2014”N11ŒŽ16“ú.

ŸN“cŒ÷, Š`“ŕ‘Ži, “c“‡‘sˆę˜Y, Ž›‰Ş˜a•F, ’†‘ş•qŒČ, ě“Y˜a‹`, ź‰ŞˆŔ•F, —k‰ÍGÍ, …Œű˜a•v. ”xŠŕ–ň•¨—Ă–@‚É‚¨‚Ż‚é–ňÜŤŠÔŽżŤ”x‰Š‚Ě”­Ç‚Ć‚ť‚ĚƒŠƒXƒNˆöŽq‚̉đÍ. ‘ć55‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď. ‹ž“s. 2014”N11ŒŽ15“ú.

‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, ŹŠ}Œ´—@, ź‰ŞˆŔ•F. ‚Ş‚ń“ÁˆŮ“IRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚ĚŽ÷—§. ‘ć73‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ‰Ą•l. 2014”N9ŒŽ27“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽu, źžŠ“Ö˜Y, Š`“ŕ‘Ži, ű•Łš‹B, ăŒ´‹v“T, –î–쐚“ń, ź‰ŞˆŔ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂ˇ‚éŠl“ž‘ϐŤƒƒJƒjƒYƒ€‚Ć‚ľ‚Ă̐üˆŰ×–Eifibrocytesj‚Ě–đŠ„. ‘ć73‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ‰Ą•l. 2014”N9ŒŽ27“ú.

âŒű‹Ĺ, Œă“Œ‹vŽk, ‘ĺ‹ř•ś—˛, —t‹v‹MŽi, Œ“ź‹M‘Ľ, ‰Y“c’m”V, Š`“ŕ‘Ži, ű•Łš‹B, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ‚—îŽŇisNSCLCŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ÄPRO•]‰ż‚đŽć‚č“ü‚ę‚˝TS-1—Ă–@‚Ě—Ő°‘ć‡U‘ŠŽŽŒą. ‘ć52‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď. ‰Ą•l. 2014”N8ŒŽ28“ú.

‘ĺ’ËŒ›ŽiCŒă“Œ‹vŽkC—t‹v‹MŽi, Œ“ź‹M‘Ľ, ‰Y“c’m”V, Š`“ŕ‘ŽiCű•Łš‹BC‘ĺ‹ř•ś—˛, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ‚—îŽŇis”ńŹ×–E”xŠŕŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ÄPRO•]‰ż‚đŽć‚č“ü‚ę‚˝TS-1—Ă–@‚Ě—Ő°‘ć‡U‘ŠŽŽŒą. ‘ć12‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď. •Ÿ‰Ş. 2014”N7ŒŽ18“ú.

‰Á“ĄKŹ, ź‰ŞˆŔ•F. ŒŒŹ”Â‹ĂWˆöŽqPodoplanin‚ɑ΂ˇ‚é‚Ş‚ń“ÁˆŮ“IR‘Ě‚ĚŠJ”­. ‘ć23‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ‹ŕ‘ň. 2014”N7ŒŽ11“ú.

ŽRŽq‘דl, Œă“Œ‹vŽk, ŽO‹´“ŐŽu, ‘q–{‘ěĆ, “c”¨Ë, źžŠ“Ö˜Y, Š`“ŕ‘Ži, ű•Łš‹B, Źě”Ž‹v, ăŒ´‹v“T, ź‰ŞˆŔ•F. ƒqƒgŹ×–E”xŠŕœ“]ˆÚ‚ɑ΂ˇ‚éRANKL•W“IŽĄ—Ă‚É‚¨‚Ż‚éIGF-1‚ĚŠÖ—^. ‘ć23‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ‹ŕ‘ň. 2014”N7ŒŽ10“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽu, ‘q–{‘ěĆ, “c”¨Ë, źžŠ“Ö˜Y, Š`“ŕ‘Ži, ű•Łš‹B, ăŒ´‹v“T, ź‰ŞˆŔ•F. ”xŠŕ‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚Ż‚ésphereŒ`ŹŠŕŠ˛×–E—l•Ş‰ć‚Ě–đŠ„. ‘ć23‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ‹ŕ‘ň. 2014”N7ŒŽ10“ú.

‘ĺ’ËŒ›Ži, ˆ˘•”^ŽĄ, ű•Łš‹B, –؏hšr, ě“Y˜a‹`, ‰Á“ĄKŹ, ź‰ŞˆŔ•F. ‹š–Œ’†”çŽî“ŻŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚Ż‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚ĚRŽîᇌř‰Ę. ‘ć18‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ĺ‘ä. 2014”N6ŒŽ26“ú.

“Œ“‘ă, ź‰ŞˆŔ•F. —Δ^‹ŰŠ´őŠłŽŇ‚É‚¨‚Ż‚éTolerance ‚ĆƒoƒCƒIƒtƒBƒ‹ƒ€Œ`Ź”\‚ĚŒŸ“˘. ‘ć88‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď. •Ÿ‰Ş. 2014”N6ŒŽ20“ú.

’†–ě–œ—L—˘, űü‹´’źŠó, ‹g“ˆ‹PŽŔ, źžŠ“Ö˜Y, Žč’Ë•qŽj, “Œ“‘ă, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚ĹŒoŒą‚ľ‚˝dÇ”MŤŒŒŹ”ÂŒ¸­ÇŒóŒQ(severe fever with thrombocytopenia syndrome: SFTS)‚Ě1—á. ‘ć88‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď. •Ÿ‰Ş. 2014”N6ŒŽ19“ú.

˛“Ął‘ĺ, ŠÝš”ü, –؉şŸO, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. ŒŒ´ SP-D ă¸‚đ”F‚ß‚˝ Idiopathic pleuroparenchymal fibroelastosis (IPPFE) Ç—á‚ĚŒŸ“˘. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. ‘ĺă. 2014”N4ŒŽ27“ú.

ŠÝš”ü, Â–ěƒ“T, “Œ“‘ă, –؉şŸO, ˛“Ął‘ĺ, ‹g“ˆ‹PŽŔ, ’|úą˛•v, ź‰ŞˆŔ•F. PDGFƒŒƒZƒvƒ^[-ƒż, ƒŔ‘jŠQR‘Ě‚ĚƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆŰÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚éRüˆŰ‰ťŒř‰Ę. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. ‘ĺă. 2014”N4ŒŽ26“ú.

Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, ˛“Ął‘ĺ, źžŠ“Ö˜Y, âŒű‹Ĺ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ă‚ĚŒťó. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. ‘ĺă. 2014”N4ŒŽ26“ú.

–L“c—DŽq, ŠÝ, ‰Í–ěO, Œă“Œ‹vŽk, ű•Łš‹B, ’†“‡—˜”Ž, ź‰ŞˆŔ•F. ŠÖßƒŠƒEƒ}ƒ`ŠłŽŇ—R—ˆ‚̐üˆŰ‰č×–E—lŠŠ–Œ×–E‚É‚¨‚˘‚Ä thymidine phosphorylase‚ÍCXCL10 ‚đ§Œä‚ˇ‚é. ‘ć58‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďŠwpW‰ď. “Œ‹ž. 2014”N4ŒŽ26“ú.

ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, “Œ–ž”ü, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî“ŻŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚Ż‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚ĚRŽîᇌř‰Ę. ‘ć54‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. ‘ĺă. 2014”N4ŒŽ25“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
”“Œ’qŽqC‰Ź–ěL˜aCâŒű‹ĹCŽč’Ë•qŽjCXZrC‹g“ˆ‹PŽŔCŠÝCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•F. ’š“ÁˆŮ“IR‘Ě‚Ş‚’l‚đ’ć‚ľ‚˝’šŠÖ˜A‰ß•qŤ”x‰Š‚Ěˆę—á. ‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‚ź. 2014”N12ŒŽ13“ú.

Šâ˛‚ ‚ä‚݁C˛“Ął‘ĺCâŒű‹ĹC–L“c—DŽqC“c“‡‘sˆę˜YCŸN“cICŒă“Œ‹vŽkCŠ`“ŕ‘ŽiCű•Łš‹BCź‰ŞˆŔ•F. UGT1A1ˆâ“`Žq‚ĚƒwƒeƒÚ‡‘́i–6‚Ü‚˝‚́–28j‚đŽ‚ÂŠłŽŇ‚É‚¨‚Ż‚鉖Ž_ƒCƒŠƒmƒeƒJƒ““Š—^‚ÉŠÖ‚ˇ‚錟“˘. ‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‚ź. 2014”N12ŒŽ13“ú.

‹ß“Ą^‘ă, ˛“Ął‘ĺ, –L“c—DŽq, ŠÝ, Žč’Ë•qŽj, ‹g“ˆ‹PŽŔ, ŠÝš”ü, ‰Í–ěO, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. ŒŒŹ”ÂŒ¸­‚đŒ_‹@‚Ć‚ľ‚Đf’f‚ł‚ę‚˝‚—îŽŇ‚ĚSLE‚Ě2—á. ‘ć25‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. ‚’m. 2014”N12ŒŽ6“ú.

XZrC˛“Ął‘ĺCâŒű‹ĹC–L“c—DŽqCŠÝš”üCŹě”Ž‹v, Š`“ŕ‘ŽiCŒă“Œ‹vŽkCű•Łš‹BCź‰ŞˆŔ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Šƒ}[ƒJ[‚ĚŒŸ“˘. ‘ć111‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. źŽR. 2014”N11ŒŽ30“ú.

ŒIŒ´Œ’Žm, ‹g“ˆ‹PŽŔ, âŒű‹Ĺ, –L“c—DŽq, ’†–ě–œ—L—˘, ŠÝ, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Œo‰ß’†‚ÉŒŒ‹…ćÐHÇŒóŒQ‚đ”­Ç‚ľAƒVƒNƒƒzƒXƒtƒ@ƒ~ƒhŠÔŸ[‘ĺ—ʐҍ—Ă–@‚Ş‘tŒř‚ľ‚˝dÇSLE‚Ě1—á. ‘ć111‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. źŽR. 2014”N11ŒŽ30“ú.

ŽR‰ş—Y–ç, ‰Ź–ěL˜a, ˆ˘‰ÍO˜a, ŠÝš”ü, âŒű‹Ĺ, ‹g“ˆ‹PŽŔ, ˛“Ął‘ĺ, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ŠÝ, ű•Łš‹B, ź‰ŞˆŔ•F. ’š“ÁˆŮ“IR‘Ě‚Ş‚’l‚đ’ć‚ľ‚˝’šŠÖ˜A‰ß•qŤ”x‰Š‚Ěˆę—á. ‘ć249‰ń“ż“‡ˆăŠw‰ďŠwpW‰ď. “ż“‡. 2014”N7ŒŽ27“ú.

ˆ˘‰ÍO˜a, ˛“Ął‘ĺ, ‹ß“Ą^‘ă, ’Ëúą—C‹M, Žč’Ë•qŽj, –L“c—DŽq, âŒű‹Ĺ, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰Č‚É‚¨‚Ż‚éˆŤŤ‹š…’™—Ż—á‚ɑ΂ˇ‚éƒ^ƒ‹ƒNťÜ‚ĚŽg—pŒoŒą. ‘ć53‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. •ÄŽq. 2014”N7ŒŽ12“ú.

ź–{N•˝, ”öč—Ě•F, –L“c—DŽq, ’†–ě–œ—L—˘, XZr, ‰Í–ěO, ŠÝ, Š`“ŕ‘Ži, ű•Łš‹B, ź‰ŞˆŔ•F. ‚CaŒŒÇ‚É‚Ä”­Ç‚ľ‚˝‘˝‘ŸŠíƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě1—á. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. •ÄŽq. 2014”N7ŒŽ12“ú.

’Ëúą—C‹M, ‘ĺ’ËŒ›Ži, ŠÝš”ü, ‹ß“Ą^‘ă, ‹g“ˆ‹PŽŔ, ˛“Ął‘ĺ, ‰ŞúąO‘×, ’|úą˛•v, “Œ“‘ă, ű•Łš‹B, â‰ş’źŽŔ, •Ÿ“c—I, ź‰ŞˆŔ•F. Acute Fibrinous and Organizing PneumoniaiAFOPj‚Ěˆę–UŒŸ—á. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. •ÄŽq. 2014”N7ŒŽ12“ú.

‰Ź–ěL˜a, źžŠ“Ö˜Y, ‘ĺ’ËŒ›Ži, âŒű‹Ĺ, Žč’Ë•qŽj, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Lambert-Eaton‹Ř–ł—͏njóŒQ‚đŒ_‹@‚É”­ŒŠ‚ł‚ę‚˝Ź×–E”xŠŕ‚Ěˆę—á. ‘ć53‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. •ÄŽq. 2014”N7ŒŽ11“ú.

”öč—Ě•F, –L“c—DŽq, ŠÝ, –؉şŸO, Žč’Ë•qŽj, ŠÝš”ü, ˛“Ął‘ĺ, Š`“ŕ‘Ži, ű•Łš‹B, ź‰ŞˆŔ•F. śt“Ž–Ź•ÂÇ“™‚É‚ć‚čŒ‹ßŤ‘˝”­“Ž–Ź‰Š‚Ş‹^‚í‚ę‚˝ŒŒŠÇ“ŕ–Œ“÷Žî‚Ě1–UŒŸ—á. ‘ć110‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2014”N6ŒŽ8“ú.

‹ß“Ą^‘ă, XZr, âŒű‹Ĺ, źžŠ“Ö˜Y, ‹g“ˆ‹PŽŔ, ’†–ě–œ—L—˘, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Pemetrexed‚ĆBevacizumab‚Ě•š—p—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝‚—îŽŇ”ńŹ×–E”xŠŕ‚Ě1—á. ‘ć110‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2014”N6ŒŽ8“ú.

âV“Ą—FŽq, ˆÉ¨F”V, ᢒm~Žq, ŽRŒű_Ži, ŠâŁr, ŽR“c”Žˆű, “Y–Ř•, Žá’ΓNŽO, Œă“Œ‹vŽk, ˛“c­—˛. śŽşŽűk•s‘S‚ĆŠÔŽżŤ”x‰Š‚É”ş‚¤”x‚ŒŒˆłÇ‚đ‡•š‚ľ‚˝”畆‹Ř‰Š‚Ě1—á. ‘ć110‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2014”N6ŒŽ8“ú.

ŽR–{šŽq, ű•Łš‹B, XZr, ŠÝš”ü, –؉şŸO, ‰Í–ěO, ’|úą˛•v, –L“c—DŽq, “Œ“‘ă, Œă“Œ‹vŽk, ŠÝ, ź‰ŞˆŔ•F. śă—t–ł‹C”x‚đ’ć‚ľ‚˝ƒAƒŒƒ‹ƒM[Ť‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ěˆę—á. ‘ć248‰ń“ż“‡ˆăŠw‰ď. “ż“‡. 2014”N2ŒŽ16“ú.

’Ă•Ű—F, ű•Łš‹B, ‘ę‘ňGŒő, ‹g“cŒő‹P, ‹g“ˆ‹PŽŔ, ‘ĺ’ËŒ›Ži, ˛“Ął‘ĺ, źžŠ“Ö˜Y, –L“c—DŽq, Žč’Ë•qŽj, Š`“ŕ‘Ži, Œă“Œ‹vŽk, â“Œ—Ç”ü, ćŽRł“ń, ź‰ŞˆŔ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚Ěˆę—á. ‘ć248‰ń“ż“‡ˆăŠw‰ď. “ż“‡. 2014”N2ŒŽ16“ú.

”öč—Ě•F, űü‹´’źŠó, Œă“Œ‹vŽk, –L“c—DŽq, Žč’Ë•qŽj, ‘ĺ’ËŒ›Ži, źžŠ“Ö˜Y, âŒű‹Ĺ, –؉şŸO, Š`“ŕ‘Ži, Źě”Ž‹v, ěăsšő, ű•Łš‹B, ‹ß“Ą˜a–ç, ćŽRł“ń, ňŒ[‰î, ź‰ŞˆŔ•F. ‹CŠÇŽx‹ž’źŽ‹‰şśŒŸ‚ɂĐf’f‚ÉŽŠ‚Á‚˝oncocytic carcinoid‚Ěˆę—á. ‘ć22‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. ‰ŞŽR. 2014”N2ŒŽ15“ú.

Ľź–ƒ”ü, “ŕ“ĄLm, ŠÝš”ü, ’†–ě–œ—L—˘, ‹g“cŒő‹P, ěăsšő, –؉şŸO, “Œ“‘ă, ‹g“ˆ‹PŽŔ, ˛“Ął‘ĺ, ŠÝ, X‰Í—R—˘Žq, źŽR—F—Žq, ĺ”ü‰Ŕ, â“Œ—Ç”ü, “n糏r‰î, ăŒ´‹v“T, ňŒ[‰î, ćŽRł“ń, ű•Łš‹B, ź‰ŞˆŔ•F. ‹š…’†‚É‘˝”‚ĚLanghansŒ^‹×–E‚đ”F‚ß‚˝Mycobacterium aviumÇ‚É”ş‚¤‹š–Œ‰Š‚Ěˆę—á. ‘ć64‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ď. ‰ŞŽR. 2014”N2ŒŽ15“ú.
2013”N‹ĆŃ
y‰˘•ś‘ŕz
Nishioka Y, Azuma M, Kishi M, Aono Y. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis. J Med Invest 60(3,4):175-183, 2013.

y‰˘•śŒ´’˜z
Honjo A, Ogawa H, Azuma M, Tezuka T, Sone S, Biragyn A, Nishioka Y. Targeted reduction of CCR4+ cells is sufficient to suppress allergic inflammation. Respir Investig 51(4):241-249, 2013.

Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of focal adhesion klinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 49(4):536-543, 2013.

Okamoto T, Miyazaki Y, Ogura T, Chida K, Kohno N, Kohno S, Taniguchi H, Akagawa S, Mochizuki Y, Yamauchi K, Takahashi H, Johkoh T, Homma S, Kishi K, Ikushima S, Konno S, Mishima M, Ohta K, Nishioka Y, Yoshimura N, Munakata M, Watanabe K, Miyashita Y, Inase N. A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51(3):191-199, 2013.

Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S. Akt kinase@-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene 32(37):4427-4435, 2013.

Huang J, Tabata S, Kakiuchi S, The Van T, Goto H, Hanibuchi M, Nishioka Y. Identification of pregnancy -associated plasma protein A as a migration-promoting gene in malignant pleural@mesothelioma cells: a potential therapeutic target. Oncotarget 4(8):1172-1184, 2013.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J. Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama SI, Sone S. Minakuchi K, Kato Y, Nishioka Y. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 190(12):6239-6249, 2013.

Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol 182(5):1843-1853, 2013.

Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M, Iguratimod-Clinical Study Group (Kishi J). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430-439, 2013.

Matsui S, Hebisawa A, Sakai F, Yamamoto H, Terasaki Y, Kurihara Y, Waseda Y, Kawamura T, Miyashita T, Inoue H, Hata N, Masubuchi H, Sugino K, Kishi J, Kobayashi H, Usui Y, Komazaki Y, Kawabata Y, Ogura T. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology 18(3):480-487, 2013.

Sato S, Hanibuchi M, Kuramoto T, Yamamori N, Goto H, Ogawa H, Mitsuhashi A, Van TT, Kakiuchi S, Akiyama SI, Nishioka Y, Sone S. Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clin Exp Metastasis 30(3):333-344, 2013.

Makino H, Aono Y, Azuma M, Kishi M, Yokota Y, Kinoshita K, Takezaki A, Kishi J, Kawano H, Ogawa H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of CXCR4 antagonist in bleomycin -induced pulmonary fibrosis in mice. J Med Invest 60(1-2):127-137, 2013.

Yuasa S, Yamaguchi H, Nakanishi Y, Kawaminami S, Tabata R, Shimizu N, Kohno M, Shimizu T, Miyata J, Nakayama M, Kishi J, Toyoda Y, Nishioka Y, Tani K. Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J Med Invest 60(1-2):77-90, 2013.
y˜a•ś’˜‘z
ź‰ŞˆŔ•F, Â–ěƒ“T. ˆŔ’čŠú‚Ć‘ˆŤŠú‚̑Ήž. “Á”­ŤŠÔŽżŤ”x‰Š‚ĚŽĄ—Ă‚ĆŠÇ—, ™ŽRK”äŒĂ•ŇW. 2013. pp 177-184. Ž˝“°o”ĹŠ”ŽŽ‰ďŽĐ.

ź‰ŞˆŔ•F. “Á”­ŤŠíŽż‰ť”x‰Š. “ŕ‰ČŠw ‘ć10”Ĺ, –îúą‹`—Y‘•ŇW. 2013. pp 806-808. ’Š‘q‘“X.

ź‰ŞˆŔ•F. Fibrocyte‚ĆŒÄ‹zŠíŽžŠł. •ĘűEˆăŠw‚Ě‚ ‚ä‚Ý ŒÄ‹zŠíŽžŠł-state of arts Ver.6, –k‘ş—@, ’F_ˆę˜Y, Îˆä–FŽ÷•ŇW. 2013. pp 23-25, ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ.

ź‰ŞˆŔ•F. Çó‚Ć•a‘Ԑś—. —Տ°•a‘ÔŠw1ŠŞ(‘ć2”Ĺ), –k‘şš‘•ŇW. 2013. pp 231-233. ƒk[ƒ”ƒFƒ‹ƒqƒƒJƒ.

ź‰ŞˆŔ•F. •›t”玿ƒXƒeƒƒCƒh–ň. ŒÄ‹zŠíŽžŠłĹV‚ĚŽĄ—Ă2013-2015, ŠŃ˜a•q”Ž, ™ŽRK”äŒĂ, –ĺ“c~ˆę•ŇW. 2013. pp 97-101. “ě]“°.

ź‰ŞˆŔ•F. ”xüˆŰ‰ť‚É‚¨‚Ż‚éfibrocyte‚Ě–đŠ„. Annual Review 2013 ŒÄ‹zŠí. ‰iˆäŒúŽu, ’F_ˆę˜Y, ŒK–ě˜a‘P, ‚‹´˜a‹v•ŇW. 2013. pp28-33. ’†ŠOˆăŠwŽĐ.
y˜a•ś‘ŕz
ź‰ŞˆŔ•F, Œă“Œ‹vŽk. ”x–Eă”çáŠQ‚ƏC•œ. ŒÄ‹z‚ƏzŠÂ 61(12):1146-1151, 2013.

Œă“Œ‹vŽk, ź‰ŞˆŔ•F. •úŽËü”x‘Ÿ‰Š. “ú–{—Őଠ71(‘6):526-529, 2013.

ź‰ŞˆŔ•F, Â–ěƒ“T. Fibrocyte‚Ě–đŠ„. “ú–{‹š•”—Տ° 72(‘):S186-189, 2013.

ź‰ŞˆŔ•F. “ż“‡‘ĺŠw‘ĺŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”ŒÄ‹zŠíEäPŒ´•a“ŕ‰ČŠw•Ş–ě‚Ě‚˛Đ‰î. “ż“‡Œ§ˆăŽt‰ď•ń 508:32-33, 2013.

ź‰ŞˆŔ•F. •ŞŽq•W“IŽĄ—ÂƖƉu—Ă–@. Šŕ‚ƉťŠw—Ă–@ 40(8):1004-1008, 2013.

˛“Ął‘ĺ, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ƒqƒg”xŠŕ‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚Ćmacrophage stimulatuing protein. THE LUNG perspectives 21(3):72-77, 2013.

ź‰ŞˆŔ•F. IPF‚Ě—Ő°ŽŽŒą‚đl‚Ś‚é(ŠŞ“ŞŒž). ŒÄ‹z‚ƏzŠÂ 61(7):603, 2013.

Œă“Œ‹vŽk, Š`“ŕ‘Ži, ź‰ŞˆŔ•F. ”x‚Ş‚ń×–E‚̍œ“]ˆÚ‚ÉŠÖ—^‚ˇ‚éˆâ“`Žq‚Ě’Tő. ś‘̂̉Ȋw 64(3):279-282, 2013.

ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—Ă:Ĺ‹ß‚̐i•ŕ. “ú–{—Տ°“ŕ‰Čˆă‰ď‰ďŽ 28(1):46-50, 2013.

ź‰ŞˆŔ•F,Â–ěƒ“T. ŠÔŽżŤ”x‰Š‚Ć‘BˆöŽq. ƒAƒŒƒ‹ƒM[‚Ě—Ő° 443(33):421-424, 2013.

ź‰ŞˆŔ•F. “ŤŒÄ‹zŠíŽžŠł‚Ě•ŞŽq•a‘ԉ𖞂ƐV‹KŽĄ—Ă–@‚ĚŠJ”­. Žl‘ˆăŠwŽGŽ 69(1,2):52-56, 2013.

Š`“ŕ‘Ži, ź‰ŞˆŔ•F. mTOR‘jŠQ–ň‚É‚ć‚é”xáŠQ‚Ć‚ť‚̑Ήž. •ŞŽqŒÄ‹zŠí•a 17(1):42-45, 2013.

ŠÝ, ‰Í–ěO, ź‰ŞˆŔ•F. ŠÖßƒŠƒEƒ}ƒ`‚ĆŠÔŽżŤ”x•a•Ď.ƒŠƒEƒ}ƒ`‰Č 49(2):161-165, 2013.

ź‰ŞˆŔ•F, Â–ěƒ“T, ˆ˘•”Gˆę.@”xüˆŰÇ‚É‚¨‚Ż‚éüˆŰ‰č×–E‚Ě—R—ˆ.@ŒÄ‹zŠí“ŕ‰Č 23(1):20-24, 2013.
y˜a•śŒ´’˜z
“Œ“‘ă, ’†‘]ˆŸ˛”ü, ź–ě‚ł‚¨‚č, ‚ŠJ“o–ÎŽq, ćŽRł“ń, ‰Á“Ą^‰î, ź‰ŞˆŔ•F. ˆă—Ï]Ž–ŽŇ‚É‚¨‚Ż‚é–AóƒAƒ‹ƒR[ƒ‹ŤŽčŽwÁ“ĹÜ‚ĚŽE‹ŰŒř‰Ę, “h•z–ʐϋy‚ŃŽg—pŠ´‚ÉŠÖ‚ˇ‚錟“˘. “ú–{ŠÂ‹ŤŠ´őŠw‰ďŽ 28(6):342-347, 2013.

Â–ěƒ“T, ŠÝš”ü, ‰ŞúąO‘×, ’|úą˛•v, ź‰ŞˆŔ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éPDGFƒŒƒZƒvƒ^[ƒżCƒŔ‘jŠQR‘Ě‚ĚRüˆŰ‰ťŒř‰Ę. •ŞŽqŒÄ‹zŠí•a 17(1):136-139, 2013.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Yoshinori Aono, Shuichi Abe, Katsuhiro Kinoshita, Masami Kishi, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast acivation via producing growth factors.@18th Congress of the Asian Pacific Society of Respirology. ‰Ą•l. 2013”N11ŒŽ13“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. 18th Congress of the Asian Pacific Society of Respirology. ‰Ą•l. 2013”N11ŒŽ13“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Yasuhiko Nishioka, Isaiah J. Fidler. Therapeutic efficacy of endothelin receptor blockade on experimental brain metastases of human non-small cell lung cancer.@18th Congress of the Asian Pacific Society of Respirology. ‰Ą•l. 2013”N11ŒŽ13“ú.

Hisatsugu Goto, Fumitaka Ogushi, Takashi Haku, Tomoyuki Urata, Takanori Kanematsu, Soji Kakiuchi, Masaki Hanibuchi, Saburo Sone, Yasuhiko Nishioka. Phase ‡U study of S-1 with patient-reported outcome evaluation in elderly patients with advanced non-small cell lung cancer.@18th Congress of the Asian Pacific Society of Respirology. ‰Ą•l. 2013”N11ŒŽ13“ú.

Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Akio Takezaki, Terumi Yoshijima, Masami Kishi, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Shuichi Abe, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi, Yasuhiko Nishioka. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. 18th Congress of the Asian Pacific Society of Respirology. ‰Ą•l. 2013”N11ŒŽ12“ú.

Momoyo Azuma, Keiji Murakami, Katuhiko Hirota, Tsuneko Ono, Yoichiro, Miyake, Yasuhiko Nishioka. The relationship between antibiotic tolerance and severity of clinical isolated Pseudomonas aeruginosa in respiratory disease patients. The28th International Congress of Chemotherapy and Infection and the 14th Asia-pacific Society of Clinical Microbiology and Infection. ‰Ą•l. 2013”N6ŒŽ7“ú.

Yasuhiko Nishioka, Shuichi Abe, Yoshinori Aono, Katsuhiro Kinoshita, Hideki Makino, Masami Kishi, Masaki Hanibuchi. Fibrocytes regulate function of lung fibroblasts by producing profibrotic growth factors.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ22“ú.

Hirohisa Ogawa, J.G. Ledford, S. Mukherjee, Yoshinori Aono, Yasuhiko Nishioka, Keisuke Izumi, J.W. Hollingsworth. Surfactant protein D attenuates sub-epithelial fibrosis in a model of allergic airways disease trough regulation of TGF-ƒŔ.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, and Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.@AACR Annual Meeting 2013. Washington, DC. 2013”N4ŒŽ7“ú.

Yasuhiko Nishioka. Application of dendritic cells and antibodies in cancer treatment. The first Gene & Immunotherapy Conference (Invited lecture). HCM City, Vietnam. 2013”N3ŒŽ21“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Trung The Van, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Saburo Sone, Yasuhiko Nishioka. Acquired resistance to anti-VEGF therapy via angiogenic switch in orthotopically implanted human malignant pleural mesothelioma in SCID mice.@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.

Sawaka Yukishige, Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijyo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•F. “Á”­ŤŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—Ă-Ĺ‹ß‚Ě˜b‘č-. ‘ć49‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘Žx•”śŠU‹łˆçu‰‰‰ďi‹łˆçu‰‰j. ‚ź. 2013”N12ŒŽ1“ú.

ź‰ŞˆŔ•F. ”xŠŕ‚É‚¨‚Ż‚éƒxƒoƒVƒYƒ}ƒu‚đ—p‚˘‚˝RŒŒŠÇVś—Ă–@‚ɑ΂ˇ‚éŠl“ž‘ϐŤƒƒJƒjƒYƒ€.@‘ć72‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ďiInternational Sessionj. ‰Ą•l. 2013”N10ŒŽ3“ú.

ź‰ŞˆŔ•F. Translational Research.@‘ć11‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ďi‹łˆçu‰‰j. ĺ‘ä. 2013”N8ŒŽ30“ú.

ź‰ŞˆŔ•F. ‚Ş‚ń•ŞŽq•W“IŽĄ—Ă‚ĚŠî‘b‚Ć—Ő°.@“ú–{•úŽËüŽîᇊw‰ď@‘ć15‰ń•úŽËüŽîᇊw‰Ä‹GƒZƒ~ƒi[(‹łˆçu‰‰). “ż“‡. 2013”N8ŒŽ3“ú.

ˆ˘•”Gˆę, Â–ěƒ“T, ‰ŞúąO‘×, ŠÝš”ü, ’|úą˛•v, –؉şŸO, “Œ“‘ă, ŠÝ, ź‰ŞˆŔ•F. ”xüˆŰÇ‚É‚¨‚Ż‚鑝BˆöŽqŽYś‚đ‰î‚ľ‚˝fibrocyte‚Ě–đŠ„‚ĆŒŸ“˘.@‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

Â–ěƒ“T. ˆ˘•”Gˆę, ’|úą˛•v, ‰ŞúąO‘×, ŠÝš”ü, ź‰ŞˆŔ•F. DNAƒ}ƒCƒNƒƒAƒŒƒC–@‚đ—p‚˘‚˝Fibrocyte‚Ć’P‹…‚Ěˆâ“`Žq”­Œť‰đÍ‚ĚŒŸ“˘.@‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

Źě”Ž‹vCÂ–ěƒ“TCŽč’Ë•qŽjCŒă“Œ‹vŽkCź‰ŞˆŔ•F. Surfactant Protein D‚̓_ƒjRŒ´–Ť–\˜I‚É‚ć‚é‹C“šüˆŰ‰ť‚đ—}§‚ˇ‚éD‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ20“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽuCÂ–ěƒ“TCź‰ŞˆŔ•F. ”xŠŕi“W‚É‚¨‚Ż‚éSP-A‚ĆŽîᇊ֘Aƒ}ƒNƒƒtƒ@[ƒW.@‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2013”N4ŒŽ19“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
Žč’Ë•qŽj, Źě”Ž‹v, –؉şŸO, ű•Łš‹B, ź‰ŞˆŔ•F. Calpain inhibitoriCalpeptinj‚Ěšb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚錟“˘. ‘ć63‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďH‹GŠwp‘ĺ‰ď. “Œ‹ž. 2013”N11ŒŽ30“ú.

‰Ş–ě‹`•v, Œă“Œ‹vŽk, —t‹v‹MŽi, Œ“ź‹M‘Ľ, ‰Y“c’m”V, Š`“ŕ‘Ži, ű•Łš‹B, ‘ĺ‹ř•ś—˛, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ‚—îŽŇis”ńŹ×–E”xŠŕŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ÄPRO•]‰ż‚đŽć‚č“ü‚ę‚˝TS-1—Ă–@‚Ě—Ő°‘ć‡U‘ŠŽŽŒą. ‘ć54‰ń“ú–{”xŠŕŠw‰ď‘‰ď. “Œ‹ž. 2013”N11ŒŽ21“ú.

Žč’Ë•qŽj, –L“c—DŽq, Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, źžŠ“Ö˜Y, –؉şŸO, Œă“Œ‹vŽk, ŸN“cI, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰Č‚Ě”xŠŕ‰ťŠw—Ă–@‚É‚¨‚Ż‚éshort-hydration Cisplatin‚Ě”E—eŤ‚ÉŠÖ‚ˇ‚錟“˘. ‘ć51‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď. ‹ž“s. 2013”N10ŒŽ25“ú.

źžŠ“Ö˜Y, Š`“ŕ‘Ži, Žč’Ë•qŽj, Œă“Œ‹vŽk, ŽRŽq‘דl, ‘ĺ’ËŒ›Ži, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éBevacizumab’ˇŠúˆŰŽ“Š—^Ç—á‚ĚŒŸ“˘. ‘ć51‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď. ‹ž“s. 2013”N10ŒŽ25“ú.

Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, źžŠ“Ö˜Y, Žč’Ë•qŽj, –L“c—DŽq, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ă‚ĚŒťó. ‘ć11‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď. ĺ‘ä. 2013”N8ŒŽ31“ú.

źžŠ“Ö˜Y, Œă“Œ‹vŽk, “c”¨Ë, ŽO‹´“ŐŽu, –L“c—DŽq, ű•Łš‹B, Š`“ŕ‘Ži, HŽRLˆę, ź‰ŞˆŔ•F. ‚Ş‚ń×–E‚Ě—V‘–‚É‚¨‚Ż‚éthymidine phosphorylase‚ĆCXCL11‚Ě–đŠ„. ‘ć22‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ź–{. 2013”N7ŒŽ11“ú.

Œă“Œ‹vŽk, ŽO‹´“ŐŽu, ‘q–{‘ěĆ, “c”¨Ë, źžŠ“Ö˜Y, ű•Łš‹B, Š`“ŕ‘Ži, Â–ěƒ“T, ăŒ´‹v“T, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ”xsurfactant protein A (SP-A) ‚Ě”xŠŕi“W‚É‚¨‚Ż‚é‹@”\‰đÍ. ‘ć22‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. ź–{. 2013”N7ŒŽ11“ú.

‹ß“Ąˆç”ü, ‘剺’Žj, Œł–Ř—R”ü, ű•Łš‹B, •‹v—mŽO. –ŤŠú•a‰@‚Ĺ‚Ěˆă—ĂƒNƒ‰[ƒN‚Ě–đŠ„‚É‚Â‚˘‚Ä.‘ć63‰ń“ú–{•a‰@Šw‰ď. VŠƒ. 2013”N6ŒŽ28“ú.

‘吟O—S, ‘厭•Ű, ˆ˘•”“ú“o”ü, Œł–Ř—R”ü, ű•Łš‹B, •‹v—mŽO. –ŤŠú•a“‚Ĺ‚Ěš\ႋzˆřƒJƒe[ƒeƒ‹ŠÇ—•ű–@‚ɂ‚˘‚Ä. ‘ć63‰ń“ú–{•a‰@Šw‰ď. VŠƒ. 2013”N6ŒŽ28“ú.

Œł–Ř—R”ü, ‘厭•Ű, ˆ˘•”“ú“o”ü, ’ˇ”ö—DŽq, ű•Łš‹B, •‹v—mŽO. ˆÝᑉh—{ŠłŽŇ‚É‚¨‚Ż‚é“œŽż§ŒŔH‚Ě—LŒřŤ‚ɂ‚˘‚Ä. ‘ć63‰ń“ú–{•a‰@Šw‰ď. VŠƒ. 2013”N6ŒŽ27“ú.

ű•Łš‹B, ‘ĺ’ËŒ›Ži, Œă“Œ‹vŽk, ‘q–{‘ěĆ, ŽO‹´“ŐŽu, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, ƒtƒBƒhƒ‰[ ƒCƒUƒCƒA[ J. EndothelinŽó—e‘̝hRÜ‚É‚ć‚é”xŠŕ”]“]ˆÚ—}§Œř‰Ę‚ĚŒŸ“˘. ‘ć17‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‹ž“s. 2013”N6ŒŽ13“ú.

‰Šr, “c”¨Ë, ű•Łš‹B, ź‰ŞˆŔ•F. ˆŤŤ’†”çŽî‚É‚¨‚Ż‚éPAPPA‚Ě‹@”\‰đÍ‚Ć•ŞŽq•W“IŽĄ—Ă–@ŠJ”­‚ĚŒŸ“˘. ‘ć17‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‹ž“s. 2013”N6ŒŽ13“ú.

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, źžŠ“Ö˜Y, ‘q–{‘ěĆ, “c”¨Ë, ű•Łš‹B, –î–쐚“ń, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî“ŻŠˆÚAƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚Ż‚éRVEGFŽĄ—ÑϐŤ‰ťƒƒJƒjƒYƒ€‚ĚŒŸ“˘. ‘ć17‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. ‹ž“s. 2013”N6ŒŽ13“ú.

ŠÝ, ’†ě–ƒ–ë, ‰Í–ěO, ź”öi, •˝“c—L‹IŘ, ŽR“c”Žˆű, ˛“c­—˛, ź‰ŞˆŔ•F. äPŒ´•a‚̊֐߉Š‚É‚¨‚Ż‚éăüâ|ƒŠƒ“ƒpß‚Ě’´‰š”gŤó‚ÉŠÖ‚ˇ‚錟“˘. ‘ć86‰ń“ú–{’´‰š”gˆăŠw‰ďŠwpW‰ď. ‘ĺă. 2013”N5ŒŽ25“ú.

ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, –؏hšr, ě“Y˜a‹`, “Œ–ž”ü, ű•Łš‹B, …Œű˜aś, ź‰ŞˆŔ•F. ƒqƒgNK×–E‚đ‰î‚ľ‚˝Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-8‚ĚˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRŽîᇌř‰Ę. ‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2013”N4ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice. ‘ć53‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2013”N4ŒŽ21“ú.

‹g“ˆ‹PŽŔ, ‰Í–ěO, Žč’Ë•qŽj, –L“c—DŽq, ŠÝ, ź‰ŞˆŔ•F. Œ´ˆö•s–ž‚Ě––˝•ÂÇŤ“Ž–ŹŽžŠł‰Á—Ă’†‚ÉŠĽ“Ž–ŹáŽ‚Ş”­Šo‚ľ‚ˆŔ“Ž–Ź‰Š‚Ɛf’f‚ľ‚˝1—á. ‘ć57‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď. ‹ž“s. 2013”N4ŒŽ20“ú.

ű•Łš‹B, Œă“Œ‹vŽk, ‹ß“Ą^‘ă, ŽRŽq‘דl, ‰ŞúąO‘×, Žč’Ë•qŽj, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éIdiopathic pleuroparenchymal fibroelastosis(IPPFE)Ç—á‚ĚŒŸ“˘-IgG4ŠÖ˜AŽžŠł‚Ć‚ĚŠÖ˜AŤ-. ‘ć110‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ď. “Œ‹ž. 2013”N4ŒŽ13“ú.

Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, ŽRŽq‘דl, źžŠ“Ö˜Y, Žč’Ë•qŽj, Œă“Œ‹vŽk, Â–ěƒ“T, ű•Łš‹B, ź‰ŞˆŔ•F.“–‰@‚É‚¨‚Ż‚éŠÔŽżŤ”x‰Š‡•š”xŠŕ‚ĚŽĄ—Ă‚ĚŒťó. ‘ć110‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ď. “Œ‹ž. 2013”N4ŒŽ12“ú.

Œă“Œ‹vŽk. Ź—t’†SŤŹ—ąó‰A‰e‚Ć‹­‚˘•ÂÇŤŠˇ‹CáŠQ‚đ’ć‚ľ‚˝–Ť‰ß•qŤ”x‰Š‚Ěˆę—á. ‘ć5‰ńŒÄ‹z‹@”\ƒCƒ[ƒWƒ“ƒOŒ¤‹†‰ďŠwpW‰ď. “ż“‡. 2013”N1ŒŽ13“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
“ŕ“ĄLm, ‰Í–ěO, ‘ĺ’ËŒ›Ži, –L“c—DŽq, ŠÝ, Žč’Ë•qŽj, –؉şŸO, ‹g“ˆ‹PŽŔ, ŠÝš”ü, ű•Łš‹B, ź‰ŞˆŔ•F. • •”‘ĺ“Ž–ŹŽüˆÍ‰Š‚𔺂Á‚˝‘˝”­ŒŒŠÇ‰ŠŤ“÷‰čŽîÇ‚Ě2—á. ‘ć24‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. •ÄŽq. 2013”N12ŒŽ7“ú.

ŽR–{šŽq, ű•Łš‹B, XZr, ŠÝš”ü, –؉şŸO, ‰Í–ěO, ’|úą˛•v, –L“c—DŽq, “Œ“‘ă, Œă“Œ‹vŽk, ŠÝ, ź‰ŞˆŔ•F. śă—t–ł‹C”x‚đ’ć‚ľ‚˝ƒAƒŒƒ‹ƒM[Ť‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ěˆę—á. ‘ć50‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. L“‡. 2013”N12ŒŽ7“ú.

’Ă•Ű—F, ű•Łš‹B, ‘ę‘ňGŒő, ‹g“cŒő‹P, ‹g“ˆ‹PŽŔ, ‘ĺ’ËŒ›Ži, ˛“Ął‘ĺ, źžŠ“Ö˜Y, –L“c—DŽq, Žč’Ë•qŽj, Š`“ŕ‘Ži, Œă“Œ‹vŽk, â“Œ—Ç”ü, ćŽRł“ń, ź‰ŞˆŔ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚Ěˆę—á. ‘ć50‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. L“‡. 2013”N12ŒŽ7“ú.

–—m•˝, źžŠ“Ö˜Y, –؉şŸO, ŠÝš”ü, ‘ĺ’ËŒ›Ži, ű•Łš‹B, ź‰ŞˆŔ•F, ˆä“ŕV, Â–ěƒ“T. “ż“‡Œ§‚Ĺ”­ś‚ľ‚˝dÇ”MŤŒŒŹ”ÂŒ¸­ÇŒóŒQisevere fever with thrombocytopenia syndrome: SFTSj‚Ě1—á. ‘ć109‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚ź. 2013”N12ŒŽ1“ú .

â“ŒOŠî, ű•Łš‹B, –L“c—DŽq, Žč’Ë•qŽj, ‹g“ˆ‹PŽŔ, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ŠÝ, ź‰ŞˆŔ•F, â–{K—T. ‹CŠÇŽxŠg’ŁÇ‚đ’ć‚ľ‚˝Œ´”­Ťü–щ^“Ž•s‘SÇ‚Ě1—á. ‘ć109‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď.‚ź. 2013”N12ŒŽ1“ú.

’ˇŁŽŃ‹G, –L“c—DŽq, ˆ˘•”Gˆę, ŠÝ, ‰Í–ěO, Žč’Ë•qŽj, ‹g“ˆ‹PŽŔ, ű•Łš‹B, ’r“c^—R”ü, ćŽRł“ń, ź‰ŞˆŔ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ĚŒo‰ßŠĎŽ@’†‚É”x‘BŠŕ‚đ‡•š‚ľ‚˝1—á. ‘ć49‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‚ź. 2013”N7ŒŽ20“ú.

Ľź–ƒ”ü, ŠÝš”ü, Â–ěƒ“T, ’|úą˛•v, “Œ“‘ă, –؉şŸO, ˆ˘•”Gˆę, ű•Łš‹B, ‹g“cŒő‹P, ćŽRł“ń, •Ÿ“c—I, ź‰ŞˆŔ•F. “ż“‡‘ĺŠw•a‰@‚É‚¨‚Ż‚é‹šo‹žiVATSj‰ş”xśŒŸÇ—á‚ĚŒŸ“˘. ‘ć49‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‚ź. 2013”N7ŒŽ19“ú.

”öč—Ě•F, Š`“ŕ‘Ži, Žč’Ë•qŽj, źžŠ“Ö˜Y, ‘ĺ’ËŒ›Ži, ŽRŽq‘דl, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. “ż“‡‘ĺŠw•a‰@‚É‚¨‚Ż‚éBevacizumab ’ˇŠúˆŰŽ“Š—^—á‚ĚŒŸ“˘. ‘ć52‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. ‚ź. 2013”N7ŒŽ19“ú.

‚‹´’źŠó, ű•Łš‹B, Â–ěƒ“T, –؉şŸO, “Œ“‘ă, ŠÝš”ü, ’|úą˛•v, źžŠ“Ö˜Y, Œă“Œ‹vŽk, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éidiopathic pleuroparenchymal fibroelastosis(IPPFE)Ç—á‚ĚŒŸ“˘. ‘ć108‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2013”N6ŒŽ9“ú.

XZr, ‘ĺ’ËŒ›Ži, –L“c—DŽq, ‰Í–ěO, ŠÝ, Žč’Ë•qŽj, ‹g“ˆ‹PŽŔ, Š`“ŕ‘Ži, ű•Łš‹B, ź‰ŞˆŔ•F. ”]‰Š‚Ć• •”‘ĺ“Ž–ŹáŽ‚đ‡•š‚ľ‚˝‘˝”­ŒŒŠÇ‰ŠŤ“÷‰čŽîÇ‚Ě1—á. ‘ć108‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2013”N6ŒŽ9“ú.

•Ä“c_l, Žč’Ë•qŽj, Â–ěƒ“T, ěk‘˘, źžŠ“Ö˜Y, ŽRŽq‘דl, ‘ĺ’ËŒ›Ži, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ňŒ[‰î, ź‰ŞˆŔ•F. ‹šo‹ž‰ş‹š–ŒśŒŸ‚Őf’f‚ľ‚Ś‚˝táąŠŕ‹š–Œ“]ˆÚ‚Ě1—á. ‘ć21‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. “ż“‡. 2013”N2ŒŽ16“ú.

‹g“ˆ‹PŽŔ, ű•Łš‹B, “Œ“‘ă, –L“c—DŽq, ‰Í–ěO, ŠÝ, ’|úą˛•v, ‰ŞúąO‘×, ’ˇ”ö‘˝”üŽq, —é–Ř—íŽq, ‚ŠJ“o–ÎŽq, ćŽRł“ń, ź‰ŞˆŔ•F. “ż“‡‘ĺŠw•a‰@Eˆő‚É‚¨‚Ż‚éöÝŤŒ‹ŠjŠ´őÇ‚ĚŒťó. ‘ć63‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”‰ď. “ż“‡. 2013”N2ŒŽ16“ú.
2012”N‹ĆŃ
y‰˘•ś‘ŕz
Nishioka Y. Malignant pleural effusion: further translational research is crucial. Transl Lung Cancer Res 1(3):167-169, 2012.
y‰˘•śŒ´’˜z
Kuramoto T, Goto H, Mitsuhashi A, Tabata S, Ogawa H, Uehara H, Saijo A, Kakiuchi S, Maekawa Y, Yasutomo K, Hanibuchi M, Akiyama SI, Sone S, Nishioka Y. Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-kappa-B activity. Mol Cancer Ther 11(12):2578-2587, 2012.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 103(11):1913-1919, 2012.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181(3):1034-1043, 2012.

Tabata S, Ikeda R, Yamamoto M, Furukawa T, Kuramoto T, Takeda Y, Yamada K, Haraguchi M, Nishioka Y, Sone S, Akiyama S. Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol Rep 28(3):895-902, 2012.

Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 17(6):984-990, 2012.

Dat le T, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T. Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. Int J Oncol 40(5):1455-1469, 2012.

Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S; Japan NAC Clinical Study Group. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17(3):467-477, 2012.

Ogawa H, Azuma M, Uehara H, Takahashi T, Nishioka Y, Sone S, Izumi K. Nerve growth factor derived from bronchial epithelium after chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing hyperinnervation, and is inhibited by in vivo siRNA. Clin Exp Allergy 42(3):460-470, 2012.

Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR. SP-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185(5):525-536, 2012.

Gabr AG, Goto H, Hanibuchi M, Ogawa H, Kuramoto T, Suzuki M, Saijo A, Kakiuchi S, Trung VT, Sakaguchi S, Moriya Y, Sone S, Nishioka Y. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 29(3):207-216, 2012.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18(6):1663-1671, 2012.

Tezuka T, Azuma M, Goto H, Nishioka Y, Sone S. Psychiatric symptoms in a patient with Churg-Strauss syndrome. Intern Med 51(3):301-303, 2012.

Miyake K,, Tani K, Kakiuchi S, Suzuka C, Toyoda Y, Kishi J, Tezuka T, Yuasa S, Hanibuchi M, Aono Y, Nishioka Y, Sone S. Epidermal growth factor tyrosine kinase inhibitor (gefitinib) augments pnumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest 59(1-2):174-185, 2012.
y˜a•ś’˜‘z
ź‰ŞˆŔ•F.@–ň•¨—Ă–@. ŠÔŽżŤ”x‰Š‚đ‹†‚ß‚é, ‘ęŕVŽn•ŇW. 2012. pp86-95. Š”ŽŽ‰ďŽĐƒƒWƒJƒ‹ƒrƒ…[ŽĐ.

ŠÝ. ^‹ŰŠ´őÇ. äPŒ´•a‚Ě”x‡•šÇ f—Ăƒ}ƒjƒ…ƒAƒ‹, ‹{âM”V•Ň. 2012. pp147-153.@ˆă–ňƒWƒƒ[ƒiƒ‹ŽĐ.

ź‰ŞˆŔ•F.@äPŒ´•a‚Ě”x‡•šÇ|ŒŸ¸‚ĚŠî–{|. äPŒ´•a‚Ě”x‡•šÇ f—Ăƒ}ƒjƒ…ƒAƒ‹, ‹{âM”V•Ň. 2012. pp43-51.@ˆă–ňƒWƒƒ[ƒiƒ‹ŽĐ.
y˜a•ś‘ŕz
Œă“Œ‹vŽk. –Ú‚Ĺ‚Ý‚éƒgƒŒ[ƒjƒ“ƒO. Medicina 49(8):1434,1437, 2012.

Â–ěƒ“T, ź‰ŞˆŔ•F. ‚Ş‚ń•ŞŽq•W“I–ň‚ɍ‡•š‚ˇ‚éŠÔŽżŤ”x‰Š. Medical Science Digest 38(9):396-399, 2012.

ź‰ŞˆŔ•F. ‚Ş‚ń•ŞŽq•W“IŽĄ—Ă‚É‚¨‚Ż‚éˆę‘̉ťŠJ”­‚ĚŒťó‚Ć“W–]. ‚Ş‚ń•ŞŽq•W“IŽĄ—Ă 10(4):267-275, 2012.

ź‰ŞˆŔ•F. “ŤŒÄ‹zŠíŽžŠł‚ĚŽĄ—Ă–@‚ĚŠJ”­‚đ–ÚŽw‚ľ‚Ä. ŒÄ‹z 31(7):587-588, 2012.

ź‰ŞˆŔ•F, ‘]ŞŽO˜Y.@ŒÄ‹zŠíŽžŠł‚É‚¨‚Ż‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`:Œťó‚ƏŤ—ˆ“W–]. ŒÄ‹zŠí“ŕ‰Č 21(6):483-484, 2012.

Â–ěƒ“T, Jo Rae Wright, ź‰ŞˆŔ•F. ”xüˆŰÇ‚É‚¨‚Ż‚éSP-D‚Ě–hŒä“I–đŠ„. •ŞŽqŒÄ‹zŠí•a 16(1):147-150, 2012.

ŠÝ, ź‰ŞˆŔ•F. ƒTƒ‹ƒRƒCƒh[ƒVƒXƒ‚ƒfƒ‹‚ƐV‹KŽĄ—Ă•W“I. •ŞŽqŒÄ‹zŠí•a 16(1):56-58, 2012.

ű•Łš‹B, ź‰ŞˆŔ•F. ”x‚Ş‚ń‚ƉŠÇ. ĹVˆăŠw 67(3):479-484, 2012.

Œă“Œ‹vŽk. ”x‚̐ś‘Ě–hŒä‹@\‚É‚¨‚Ż‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’‚`‚Ě–đŠ„. ŒÄ‹z 31(1):79-89, 2012.
y˜a•śŒ´’˜z
â–{Wˆę, Š‰Ykˆę˜Y, ‘ę‘ňGŒő, ’†ě–őŽm, ’r“c^—R”ü, ŒĂě‘¸Žq, X–{‰ë”ü, ź–ě‹Žu, Œă“Ął˜a, ’†ě”üťŽq, ŽR–{—m‘ž, ŒĂ–k—Rm, •’m_˜a, ‹g“cŒő‹P, ěăsšő, “cŠ—R‹IŽq, ćŽRł“ń, ‹ß“Ą˜a–ç, â“Œ—Ç”ü, ‰ŞčO‘×, Œă“Œ‹vŽk, ź‰ŞˆŔ•F, ’O•Í. Erlotinib ‚Ĺinduction therapy ‚đs‚Á‚˝‡VAŠú”ńŹ×–E”xŠŕ‚Ě1Žčp—á. Žl‘ˆăŽ 68(5,6):251-256, 2012.

Œă“Œ‹vŽk, Â–ěƒ“T, ź‰ŞˆŔ•FD”x‚̐ś‘Ě–hŒä‹@\‚É‚¨‚Ż‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ě–đŠ„. “ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ĘˆăŠw‰ďŽGŽ 43:9-15, 2012.

–î–ě‘c, źžŠ“Ö˜Y, ‹ß“Ą^‘ă, ‰Í–ěO, –L“c—DŽq, Š`“ŕ‘Ži, ŠÝ, ű•Łš‹B, ŒĂě‹M‘ĺ, “Ą“c_Ži, ź‰ŞˆŔ•F. _ŒoŞáŠQ‚Ĺ”­Ç‚ľ‚˝_ŒoƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ěˆę—á. Žl‘ˆăŽ 68(3,4):153-158, 2012.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. Tokushima University-Seoul National University-KAIST joint meeting, Seoul, Korea. 2012”N12ŒŽ20“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Sho Tabata, Takuya Kuramoto, Hisasugu Goto, Yasuhiko Nishioka, Isaiah J Fidler. Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel. Markers in Cancer 2012 : A Joint Meeting by ASCO, EORTC and NCI. Hollywood, FL. 2012”N10ŒŽ12“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.14th International Biennial Congress of the Metastasis Research Society, Brisbane, Australia. 2012”N9ŒŽ4“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity.14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ4“ú.

Yasuhiko Nishioka, Shinji Abe, Yuki Morita, Mika Kato Kaneko, Masaki Hanibuchi, Hisatsugu Goto, Soji Kakiuchi, Yoshinori Aono, Jun Huang, Atsushi Mitsuhashi, Seidai Sato, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma.@14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ3“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Yasuhiko Nishioka, Shinji Abe, M.K. Kaneko, Yoshinori Aono, Jun Huang, Hisatsugu Goto, Masatoshi Kishuku, Masaki Hanibuchi, Saburo Sone, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma via ADCC.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Shuichi Abe, Hiroyasu Okazaki, Masami Kishi, Akio Takezaki, Katsuhiro Kinoshita, Momoyo Azuma, Jun Kishi, Yoshinori Aono, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast function. ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Yoshinori Aono, Masami Kishi, Yasuhiko Nishioka. Different functions of PDGF receptor-alpha and beta in lung fibrosis.@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Seidai Sato, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity. AACR Annual Meeting 2012. Chicago, IL. 2012”N4ŒŽ2“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Š‚̐f’f‚ĆŽĄ—ÁFĹ‹ß‚̐i•ŕ.@‘ć26‰ń“ú–{—Տ°“ŕ‰ČˆăŠw‰ď(‹łˆçu‰‰). “ż“‡. 2012”N10ŒŽ7“ú.

ź‰ŞˆŔ•F. ŠÔŽżŤ”x‰Šf—Ă‚ĚŒťó‚Ɖۑč.@‘ć47‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ďiŒÄ‹zŠíƒZƒ~ƒi[j.‰şŠÖ. 2012”N7ŒŽ21“ú.

“c”¨Ë, ’r“c—´“ń, ŽR–{‰ë’B, ŒĂě—´•F, ‘q–{‘ěĆ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, HŽRLˆę. ƒqƒgŠŕ×–E‚ĚROSŽYś‚¨‚ć‚ѐś‘ś‚É‚¨‚Ż‚éƒ`ƒ~ƒWƒ“ˆŮ‰ťě—p‚Ě–đŠ„.@‘ć16‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďiƒ[ƒNƒVƒ‡ƒbƒvj. –k‹ăB. 2012”N6ŒŽ28“ú.

Jun Huang, Shinji Abe, Yuki Morita, Shuji Ozaki, Masatoshi Kishuku, Kazuo Minakuchi, Masaki Hanibuchi, Toshio Matsumoto, Saburo Sone, Yasuhiko Nishioka. Antibody-dependent cellular cytotoxicity against mesothelioma cells mediated by anti-HM 1.24 antibodies.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiEnglish Mini-Symposiumj. _ŒË. 2012”N4ŒŽ22“ú.

Â–ěƒ“T, Jo Rae Wright, Œă“Œ‹vŽk, ź‰ŞˆŔ•F. ”x‘šEC•œ‚ĆSP-D:RüˆŰ‰ť‚ĚŽ‹“_‚Š‚ç.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒVƒ“ƒ|ƒWƒEƒ€j. _ŒË. 4ŒŽ22“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Syo Tabata, Hirohisa Ogawa, Hisanori Uehara, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. ‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď(English Mini-Symposium). _ŒË. 2012”N4ŒŽ21“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, ‰Šr, ű•Łš‹B, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě—Ă–@‚ĚŒŸ“˘.@‘ć25‰ń“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ďŠwpW‰ď‘‰ď. ‰ŞŽR. 2012”N12ŒŽ14“ú.

“c“‡‘sˆę˜Y, ŸN“cI, Š`“ŕ‘Ži, ăź‘ě, •Đ“‡‚é‚Ý, Ž›‰Ş˜a•F, ‹vŽŸ•Ä•qG, ě“Y˜a‹`, ź‰ŞˆŔ•F, —k‰ÍGÍ, …Œű˜aś. UGT1A1ˆâ“`Žq‚ĚƒwƒeƒÚ‡‘Ě(*6‚Ü‚˝‚Í*28)‚đŽ‚ÂƒCƒŠƒmƒeƒJƒ““Š—^ŠłŽŇ‚É‚¨‚Ż‚鎥—ĂˆŔ‘SŤ‚Č‚ç‚Ń‚ÉŒp‘ąŤ‚ÉŠÖ‚ˇ‚錟“˘.@‘ć33‰ń“ú–{—Տ°–ň—Šw‰ďŠwp‘‰ď . ‰Ť“ę. 2012”N11ŒŽ29“ú.

ű•Łš‹B, ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, –؏hšr, ě“Y˜a‹`, ‰Šr, ŽO‹´“ŐŽu, …Œű˜aś, ź‰ŞˆŔ•F. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-1‚ĚˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éR‘ĚˆË‘śŤ×–EáŠQŠˆŤ‚ƍRŽîᇌř‰Ę.@‘ć53‰ń“ú–{”xŠŕŠw‰ď‘‰ď. ‰ŞŽR. 2012”N11ŒŽ9“ú.

–L“c—DŽq, Š`“ŕ‘Ži, ű•Łš‹B, Žč’Ë•qŽj, Œă“Œ‹vŽk, ź‰ŞˆŔ•F. Patient-Reported-Outcome(PRO)‚É‚ć‚é”xŠŕ–ň•¨—Ă–@‚Ě—LŒřŤ‚ĚŒŸ“˘.@‘ć53‰ń“ú–{”xŠŕŠw‰ď‘‰ď. ‰ŞŽR. 2012”N11ŒŽ8“ú.

Œł–Ř—R”ü, ˆ˘•”“ú“o”ü, ’–“ŕG˜a, ű•Łš‹B, •‹v—mŽO. “–‰@‚ł̑ϐŤ‹Ű‚ɑ΂ˇ‚éŽć‚č‘g‚Ý.@‘ć20‰ń“ú–{–ŤŠúˆă—ĂŠw‰ď. •Ÿˆä. 2012”N11ŒŽ8“ú.

Œł–Ř—R”ü, ˆ˘•”“ú“o”ü, ’–“ŕG˜a, ű•Łš‹B, •‹v—mŽO. “–‰@‚ł̑ϐŤ‹Ű‚ɑ΂ˇ‚éŽć‚č‘g‚Ý.@‘ć54‰ń‘S“ú–{•a‰@Šw‰ď. ‰Ą•l. 2012”N9ŒŽ21“ú.

“c”¨Ë, ’r“c—´“ń, ŽR–{‰ë’B, ŒĂě—´•F, ‘q–{‘ěĆ, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, HŽRLˆę. ƒqƒgŠŕ×–E‚̐ś‘ś‚É‚¨‚Ż‚éƒ`ƒ~ƒWƒ“ˆŮ‰ťě—p‚Ě–đŠ„.@‘ć71‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ŽD–y. 2012”N9ŒŽ20“ú.

ź‰ŞˆŔ•F, ˆ˘•”^ŽĄ, –؏hšr, ě“Y˜a‹`, ‰Šr, ű•Łš‹B, …Œű˜aś, ‘]ŞŽO˜Y, ‰Á“ĄKŹ. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚郉ƒbƒg]ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-8‚̍RŽîᇌř‰Ę.@‘ć71‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ŽD–y. 2012”N9ŒŽ19“ú.

‰Á“ĄKŹ, ‘“cŽéŽq, ź‰ŞˆŔ•F. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚É‚ć‚é“]ˆÚ—}§Œř‰Ę‚ĚŒŸ“˘.@‘ć71‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ŽD–y. 2012”N9ŒŽ19“ú.

ƒŒ@ƒ^ƒ“ƒ_[, ź”ö‘×—C, ‹gŠŰ“N˜Y, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ‘q–{‘ěĆ, ŽO‹´“ŐŽu, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F, •Đ‹Ë–L‰ë. ”xŠŕ‚̍œ“]ˆÚ‚đ§Œä‚ˇ‚éV‹K“]ŽĘˆöŽqLBMTF‚Ě‹@”\‰đÍ.@‘ć71‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. ŽD–y. 2012”N9ŒŽ19“ú.

’Ň–{—Y‘ž, ‘“cŽéŽq, ź‰ŞˆŔ•F, ‰Á“ĄKŹ. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚É‚ć‚é“]ˆÚ—}§Œř‰Ę‚ĚŒŸ“˘.@‘ć21‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. L“‡. 2012”N7ŒŽ12“ú.

‘ĺ’ËŒ›Ži, ű•Łš‹B, Œă“Œ‹vŽk, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, Fidler Isaiah J. Endothelin Žó—e‘̝hRÜ‚É‚ć‚é”xŠŕ”]“]ˆÚ—}§Œř‰Ę‚ĚŒŸ“˘. ‘ć21‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. L“‡. 2012”N7ŒŽ12“ú.

‘q–{‘ěĆ, Œă“Œ‹vŽk, ŽO‹´“ŐŽu, “c”¨Ë, ăŒ´‹v“T, źžŠ“Ö˜Y, Š`“ŕ‘Ži, ű•Łš‹B, ‘Oě—mˆę, ˆŔ—FN“ń, HŽRLˆę, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. Ź×–E”x‚Ş‚ń“]ˆÚ‚É‚¨‚Ż‚éDll4-NotchƒVƒOƒiƒ‹‚Ě‘ŸŠí“ÁˆŮŤ‚ÉŠÖ‚ˇ‚錟“˘. ‘ć21‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. L“‡. 2012”N7ŒŽ12“ú.

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, ‘q–{‘ěĆ, “c”¨Ë, Źě”Ž‹v, ăŒ´‹v“T, HŽRLˆę, Wright Jo Rae, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ”xsurfactant protein AiSP-Aj‚Ě”xŠŕi“W‚É‚¨‚Ż‚é‹@”\‰đÍ.@‘ć21‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď. L“‡. 2012”N7ŒŽ12“ú.

ź‰ŞˆŔ•F, ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, –؏hšr, ě“Y˜a‹`, ‰Šr, ű•Łš‹B, …Œű˜aś, ‘]ŞŽO˜Y. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-8‚̍RŽîᇌř‰Ę. ‘ć16‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. –k‹ăB. 2012”N6ŒŽ28“ú.

‰Á“ĄKŹ, ˆ˘•”^ŽĄ, …Œű˜aś, ź‰ŞˆŔ•F. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚É‚ć‚é“]ˆÚ—}§‹@˜‚̉đ–ž.@‘ć16‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. –k‹ăB. 2012”N6ŒŽ28“ú.

‘q–{‘ěĆ, Œă“Œ‹vŽk, ˛“Ął‘ĺ, ŽO‹´“ŐŽu, “c”¨Ë, źžŠ“Ö˜Y, ăŒ´‹v“T, Welm Alana, ű•Łš‹B, HŽRLˆę, ‘]ŞŽO˜Y, ź‰Ş ˆŔ•F. ƒqƒg”x‚Ş‚ń‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚Ż‚éMacrophage-stimulating protein ‚Ě–đŠ„‚ÉŠÖ‚ˇ‚錟“˘.@‘ć16‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. –k‹ăB. 2012”N6ŒŽ28“ú.

–L“c—DŽq, ű•Łš‹B, Š`“ŕ‘Ži, ŸN“cI, Œă“Œ‹vŽk, Žč’Ë•qŽj, ŠÝ, Â–ěƒ“T, ź‰ŞˆŔ•F. “–‰Č‚É‚¨‚Ż‚éI––Šú‚Ě’ÁĂ‚ɂ‚˘‚Ä‚ĚŒŸ“˘.@‘ć17‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď. _ŒË. 2012”N6ŒŽ23“ú.

źžŠ“Ö˜Y, Š`“ŕ‘Ži, ź”Ž”V, ‘ĺ’ËŒ›Ži, ŽRŽq‘דl, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F. Cycleave–@‚ĆPCR-Clamp–@‚É‚ć‚éEGFRˆâ“`Žq•ĎˆŮ‘Ş’čŒ‹‰Ę‚ĆEGFRƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQÜ‚ĚŽĄ—ĂŒř‰Ę‚Ć‚Ě‘ŠŠÖ.@‘ć35‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď. “Œ‹ž. 2012”N5ŒŽ31“ú.

‰Í–ěO, ŠÝš”ü, Žč’Ë•qŽj, –L“c—DŽq, ŠÝ, ź‰ŞˆŔ•F. • •”‘ĺ“Ž–ŹŽüˆÍ‰Š‚𔺂Á‚˝granulomatosis with polyangiitis‚Ě1—á.@‘ć56‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď. “Œ‹ž. 2012”N4ŒŽ27“ú.

‘ˆî“c—DŽq, źˆäËŽq, ŽR–{—m, “Ą‘ş­Ž÷, —L“c^’mŽq, ÎˆäŠ°, ‹îč‹`—˜, ™ŽRK”äŒĂ, “n•ÓłŽ÷, ‰Pˆä—T, ‰Í‘ş“NŽĄ, Ź—щp•v, ź‰ŞˆŔ•F, –{ŠÔ‰h, Ź‘q‚Žu. IgG4ŠÖ˜AŽžŠł(IgG4RD)‚ĚŒÄ‹zŠí•a•Ď‚É‚¨‚Ż‚é—Տ°‰ć‘œ•a—Šw“IŒŸ“˘.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. _ŒË. 2012”N4ŒŽ22“ú.

ˆ˘•”Gˆę, ‰ŞúąO‘×, ŠÝš”ü, ’|úą˛•v, –؉şŸO, “Œ“‘ă, ŠÝ, Â–ěƒ“T, ź‰ŞˆŔ•F. Fibrocyte‚Ě”xüˆŰ‰č×–E‹@”\‚É‹y‚Ú‚ˇŒř‰Ę‚ĚŒŸ“˘.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. _ŒË. 2012”N4ŒŽ20“ú.

ŠÝš”ü, Â–ěƒ“T, ’|č˛•v, “Œ“‘ă, ŠÝ, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚éƒsƒ‹ƒtƒFƒjƒhƒ““Š—^Ç—á‚ĚŒŸ“˘.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. _ŒË. 2012”N4ŒŽ20“ú.

ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, –؏hšr, ě“Y˜a‹`, “Œ–ž”ü, …Œű˜aś, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-1‚̍RŽîᇌř‰Ę‚ÉŠÖ‚ˇ‚錟“˘.@‘ć52‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. _ŒË. 2012”N4ŒŽ20“ú.

Š`“ŕ‘Ži, ű•Łš‹B, “c‰Ş—˛Ź, źžŠ“Ö˜Y, Žč’Ë•qŽj, –L“c—DŽq, Œă“Œ‹vŽk, ‚‹´łK, ‹ŕŽR”Žb,ź‰ŞˆŔ•F. mTOR‘jŠQÜ“Š—^Ç—á‚É‚¨‚Ż‚éŠÔŽżŤ”xáŠQ‚Ě—Ő°“I“Á’Ľ.@‘ć109‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ď. ‹ž“s. 2012”N4ŒŽ15“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
‘şă‰iŽ, “‡’J‰ŔŒő, ŽRŽq‘דl, ‘ĺč—T—ş, ‹{éˆ¤, X“ÖŽq, –쎛—T”V, ˜aň—BM, ź‰ŞˆŔ•F, Š—´™Z. ‘˝Ę‚Ȑ_ŒoÇó‚đ’ć‚ľ‚˝Ź×–E”xŠŕ‚Ě1—á. ‘ć107‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. źŽR. 2012”N12ŒŽ8“ú.

ěk‘˘, ‰Í–ěO, “Ą“c_Ži, ‘şă‰iŽ, Žč’Ë•qŽj, ŠÝ, ű•Łš‹B, Š—´™Z, ź‰ŞˆŔ•F. MPO-ANCAŠÖ˜A”ěŒúŤd–Œ‰Š‚Ě1—á. ‘ć107‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. źŽR. 2012”N12ŒŽ2“ú.

•Ä“c_l, ‘ĺ’ËŒ›Ži, Â–ěƒ“T, –L“c—DŽq, ź–ě‹Žu, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F.“Ť‚̐tŤEŠĚŤ‹š…‚ɑ΂ľ‚Ä‹šo|• oƒVƒƒƒ“ƒg‚Ş‘tŒř‚ľ‚˝1—á. ‘ć107‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. źŽR. 2012”N12ŒŽ2“ú.

‰Í–ěO, –L“c—DŽq, ŠÝ, ű•Łš‹B, ź‰ŞˆŔ•F. RCCPR‘̍‚’l‚đ’ć‚ľAŠÖß‰Š‚𔺂킸‚É”­Ç‚ľ‚˝ƒXƒeƒƒCƒh’ďRŤŠíŽż‰ť”x‰Š‚Ě1—á. ‘ć23‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. ‰F•”. 2012”N10ŒŽ20“ú.

ű•Łš‹B, ’ˇ”ö‘˝”üŽq, —é–Ř—íŽq, ‚ŠJ“o–ÎŽq, “Œ“‘ă, ź‰ŞˆŔ•F. öÝŤŒ‹ŠjŠ´őÇ(latent tuberculosis infection: LTBI)‚ɑ΂ˇ‚鎥—Ă‚ĚŒťó‚Ć–â‘č“_. ‘ć6‰ń“ú–{Œ‹Šj•aŠw‰ď’†‘Žl‘Žx•”Œ¤‹†‰ď. ‰ŞŽR. 2012”N9ŒŽ29“ú.

’†ź‰ĂŒ›, ‰Í–ěO, ˆ˘•”Gˆę, ’|úą˛•v, Œă“Œ‹vŽk, Â–ěƒ“T, ű•Łš‹B, ćŽRł“ń, •Ÿ“c—I, ź‰ŞˆŔ•F. “Á”­Ť”xœ‰ťÇ‚Ě1—á. ‘ć47‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‰şŠÖ. 2012”N7ŒŽ21“ú.

ěk‘˘, źžŠ“Ö˜Y, Š`“ŕ‘Ži, ‘ĺ’ËŒ›Ži, ŽRŽq‘דl, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F.‘Ş’č–@‚É‚ć‚čEGFR•ĎˆŮ‚Ě‘Ş’čŒ‹‰Ę‚É‰đ—Ł‚Ş‚Ý‚ç‚ę‚˝”ńŹ×–E”xŠŕ‚Ě3—á. ‘ć51‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. ‰şŠÖ. 2012”N7ŒŽ20“ú.

•Ä“c_l, Â–ěƒ“T, ŠÝš”ü, –L“c—DŽq, ‹ß“Ą^‘ă, ‰ŞúąO‘×, ŠÝ, ű•Łš‹B, ŠÄčFˆę˜Y, •Ÿ“c—I, ź‰ŞˆŔ•F. ‚IgGŒŒÇ‚Ě’ˇŠúŠÔ‚ĚŒo‰ßŠĎŽ@’†‚É‘˝’†SŤƒLƒƒƒbƒXƒ‹ƒ}ƒ“•a‚̐f’f‚ÉŽŠ‚Á‚˝ˆę—á. ‘ć47‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‰şŠÖ. 2012”N7ŒŽ20“ú.

‘ĺ’ËŒ›Ži, –L“c—DŽq, ŠÝ, Â–ěƒ“T, ű•Łš‹B, ź‰ŞˆŔ•F, Œ´’m–ç, ŽRŒű_Ži, ˛“c­—˛. S‹Ř‰Š‚đ‡•š‚ľ‚˝Churg-StraussÇŒóŒQ‚Ě1—á. ‘ć106‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2012”N6ŒŽ17“ú.

“c‰ŞŽu•Ű, ‰Í–ěO, Žč’Ë•qŽj, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ź‰ŞˆŔ•F, ‰Ş–{kˆę, ‚ŽR“NŽĄ. FDG-PET/CT‚É‚ć‚菬’°“]ˆÚ‚đ”­ŒŠ‚ľ‚˝”xŠŕ‚Ě2Ç—á. ‘ć106‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. “ż“‡. 2012”N6ŒŽ17“ú.

‹ß“Ą^‘ă, –L“c—DŽq, ˆ˘•”Gˆę, ‰Í–ěO, ŠÝš”ü, ’|úą˛•v, “Œ“‘ă, Š`“ŕ‘Ži, Œă“Œ‹vŽk, Â–ěƒ“T, ű•Łš‹B, ź‰ŞˆŔ•F. •a¨‚ÉŠÖ˜A‚ľ‚ÄCA19-9‚Ě•Ď“Ž‚đ”F‚ß‚˝”ńŒ‹ŠjŤRŽ_‹ŰÇ‚Ě1—á. ‘ć20‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. o‰_. 2012”N3ŒŽ3“ú.

ź”Ž”V, Žč’Ë•qŽj, ‰Í–ěO, ’|úą˛•v, “Œ“‘ă, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ŠÝ, Â–ěƒ“T, ű•Łš‹B, ź‰ŞˆŔ•F. ”ńŒ‹ŠjŤRŽ_‹ŰÇ‚đ‡•š‚ľ‚˝ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě1—á. ‘ć20‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. o‰_. 2012”N3ŒŽ3“ú.

’|úą˛•v, źžŠ“Ö˜Y, ‘ĺ’ËŒ›Ži, ŠÝš”ü, Žč’Ë•qŽj, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ŠÝ, Â–ěƒ“T, ű•Łš‹B, ź‰ŞˆŔ•F. “–‰Č‚ĹŒoŒą‚ľ‚˝”x–EoŒŒ4Ç—á‚Ě—Ő°“IŒŸ“˘. ‘ć20‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. o‰_. 2012”N3ŒŽ3“ú.
2011”N‹ĆŃ
y‰˘•ś‘ŕz
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S.@Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci 16:740-748, 2011.

Nishioka Y, Aono Y, Sone S. Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy 3:107-116, 2011.
y‰˘•śŒ´’˜z
Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci 102:2157-2163, 2011.

Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T, Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12:143-153, 2011.

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine Nnetwork. Am J Pathol 179:1483-1493, 2011.

Goto H, Hanibuchi M, Sakaguchi S, Kanematsu T, Kakiuchi S, Tomimoto H, Azuma M, Tezuka T, Tada H, Miki Y, Nakamura T, Sone S, Nishioka Y. Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital. J Med Invest 58:219-226, 2011.

Batmunkh R, Nishioka Y, Aono Y, Azuma M, Kinoshita K, Kishi J, Makino H, Kishi M, Takezaki A, Sone S. CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin ƒŔ1/focal adhesion kinase pathway. J Med Invest 58:188-196, 2011.

Van TT, Hanibuchi M, Kakiuchi S, Sato S, Kuramoto T, Goto H, Mitsuhashi A, Nishioka Y, Akiyama SI, Sone S. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 68:497-504, 2011.

Kishi J, Nishioka Y, Kuwahara T, Kakiuchi S, Azuma M, Aono Y, Makino H, Kinoshita K, Kishi M, Batmunkh R, Uehara H, Izumi K, Sone S. Blockade of Th1 chemokine receptors ameriolates pulmonary granulomatosis in mice. Eur Respir J 38:415-424, 2011.

Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 10:1218-1228, 2011.

Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T. Pirfenidone Clinical Study Group in Japan. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12:93-101, 2011.

Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S. A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Lett 2:465-470, 2011.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17:2260-2269, 2011.

Yokoi K, Hawke D, Oborn CJ, Jang JY, Nishioka Y, Fan D, Kim SW, Kim SJ, Fidler IJ. Identification and validation of Src and phospho-Src family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. Transl Oncol 4:83-91, 2011.

Sakai T, Furoku S, Nakamoto M, Shuto E, Hosaka T, Nishioka Y, Sone S. Soy isoflavone equol perpetuates dextran sulfate sodium-induced acute colitis in mice. Biosci Biotechnol Biochem 75:593-595, 2011.

Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, Uehara H, Izumi K, Itai A, Sone S. IkB kinase b inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus -sensitized mouse model of chronic asthma. Clin Exp Allergy 41:104-115, 2011.
y˜a•ś’˜‘z
ź‰ŞˆŔ•F.@ƒxƒoƒVƒYƒ}ƒu@•ŞŽq•W“IŽĄ—Ă–ň|ĹV‚Ě‘I‚Ń•űEŽg‚˘•ű|.@‚Ş‚ńf—ĂƒŒƒNƒ`ƒƒ[ 2, Î‰Şç‰ÁŽj•Ň. 2011. pp262-263. ‘‡ˆăŠwŽĐ.

–؉şŸO, ź‰ŞˆŔ•F.@•śŒŁŒŸő‚ĚŽd•ű, ˆăŠw˜_•ś‚Ě“Ç‚Ý•űE‘‚Ť•ű, Šw‰ď‚Ö‚ĚŽć‚č‘g‚Ý•ű, ‘ĺŠw‰@EˆăŠw”ŽŽmE—ŻŠw‚ɂ‚˘‚Ä, ŒÄ‹zŠí‰Čˆă‚É‚Ć‚Á‚ÄŒ¤‹†‚Ƃ͉˝‚Š? ŒÄ‹zŠí Œ¤Cƒm[ƒg, ˆ°ŕV˜al, ‘ĺň‘Žj, ‰Ť‰i‘sŽĄ, •ž•”“o, ŻěN•Ň. 2011. pp82-93. f’f‚ĆŽĄ—ĂŽĐ.
y˜a•ś‘ŕz
Â–ěƒ“T, ź‰ŞˆŔ•F.@äPŒ´•a‚ĆŠÖ˜A‚ľ‚˝‚Ń‚Ü‚ńŤ”xŽžŠł.@‘‡—Տ° 60:2463-2469, 2011.

ź‰ŞˆŔ•F.@Gremlin‚Ć“Á”­ŤŠÔŽżŤ”x‰Š.@ŒÄ‹z 30:955-958, 2011.

‘]ŞŽO˜Y.@ˆăŠwŒ¤‹†‚É‚¨‚Ż‚éCOIƒ}ƒl[ƒWƒƒ“ƒg.@Š´őÇŠw‰ďŽGŽ 85:396-397, 2011.

ű•Łš‹B. QOL•]‰ż–@‚Ć‚ľ‚Ä‚Ěpatient-reported outcome(PRO)‚Ć‚Í.@CLITICAL EYES on Clinical Oncology 40:11, 2011.

ŠÝš”ü, ‘]ŞŽO˜Y. ‹š–Œ‰Š, ”^‹š.@Medical Practice 28(‘):334-338, 2011.

–؉şŸO, ź‰ŞˆŔ•F.@–ňÜŤ”xáŠQ‚̍ŐV‚Ě’mŒŠ. •ŞŽqŒÄ‹zŠí•a 15(1):66-68, 2011.

Œă“Œ‹vŽk, Julie G Ledford, Sambuddho Mukherjee, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, Jo Rae Wright. ‹}Ť”x‘š‚É‚¨‚Ż‚éSurfactant Protein A‚Ě–đŠ„. •ŞŽqŒÄ‹zŠí•a15:74-76, 2011.
y˜a•śŒ´’˜z
“Ą‰ŞŒ[‰î, źžŠ“Ö˜Y, –L“c—DŽq, Š`“ŕ‘Ži, ű•Łš‹B, ŒáČ‰ë•F, ’|“ŕ‹ąŽq, “ĄˆäŽu˜N, ’†‘şMŒł, ‰F‚Œ›Œá, ‰ęě‹v”üŽq, ˆŔ”{ł”Ž, …’J—FĆ, ź‰ŞˆŔ•F.@”畆ƒ‰ƒ“ƒ_ƒ€śŒŸ‚ސf’f‚É—LŒř‚Ĺ‚ ‚Á‚˝ŒŒŠÇ“ŕƒŠƒ“ƒpŽî‚Ěˆę—á. Žl‘ˆăŠwŽGŽ 67:257-262, 2011.

Œ“ź‹M‘Ľ, –L“c—DŽq, Œă“Œ‹vŽk, ˆ˘•”Gˆę, ‰Í–k’ź–ç, ćŽRł“ń, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y.@”x‘˝”­Œ‹ß•a•Ď‚đ’ć‚ľ‚˝Œ´”­Ť”x•˝ŠŠ‹Ř“÷Žî‚Ě1—á. “ú–{ŒÄ‹zŠíŠw‰ďŽGŽ 49:167-171, 2011.

–؉şŸO, ź‰ŞˆŔ•F, ŠÝš”ü, ’|č˛•v, Â–ěƒ“T, “Œ“‘ă, ŠÝ, ăŒ´‹v“T, ňŒ[‰î, ‘]ŞŽO˜Y. ŽžŠłŒ`Ź‚É‚¨‚Ż‚é•W“I•ŞŽq‚Ě–đŠ„ FAKƒVƒOƒiƒ‹‚Ě”xüˆŰ‰ť‚É‚¨‚Ż‚é–đŠ„ ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ‚ƒfƒ‹‚Ĺ‚ĚŒŸ“˘. •ŞŽqŒÄ‹zŠí•a 15:124-127, 2011.
yŠw‰ď”­•\-‘ŰŠw‰ďz
Masaki Hanibuchi, Shinji Abe, Masatoshi Kisyuku, Soji Kakiuchi, Kasuyoshi Kawazoe, Kazuo Minakuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka. Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC. 5th EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer'. Brussels, Belgium. 2011”N10ŒŽ27“ú.

Saburo Sone, Seiji Yano. Role of hepatocyte growth factor in resistance acquisition to EGFR-TK inhibitor (Gefitinib/Erlotinib) in EGFR mutant lung cancer patients. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Yasuhiko Nishioka. Novel targets for treatment of pulmonary fibrosis: lessons from animal study for the clinic. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Katsuhiro Kinoshita, Yasuhiko Nishioka, Masami Kishi, Momoyo Azuma, Yoshinori Aono, Hisanori Uehara, Akio Takezaki, S. Hatakeyama, E. Kawahara, Saburo Sone. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Yoshinori Aono, J.G. Ledford, Yasuhiko Nishioka, Saburo Sone, M.F. Beers, J.R. Wright. SP-D attenuates bleomycin induced lung fibrosis via regulating recruitment and activation of macrophages and fibrocytes.ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Atsushi Mitsuhasi, Hisatsugu Goto, Takuya Kuramoto, Soji Kakiuchi1, Seidai Sato, Van The Trung, Atsuro Saijo, Makoto Tobiume, Kenji Otsuka, Yasuhiko Nishioka, Jo Rae Wright, Saburo Sone. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ17“ú.

Momoyo Azuma, Yasuhiko Nishioka, Reham Mohammed El-morshedy, Jun Kishi, Masami Kishi, Katsuhiro Kinoshita, Hisanori Uehara, Keisuke Izumi, Saburo Sone. The role of sphingosine 1-phospate (SIP) signaling in pulmonary fibrosis. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ15“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďi“Á•Ęu‰‰EƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvjz
ź‰ŞˆŔ•F. •ŞŽq•W“IŽĄ—Ă‚É‚¨‚Ż‚éˆę‘̉ťŠJ”­‚Ö‚ĚŠú‘Ň. JAMTTCEJSGDT‡“ŻƒVƒ“ƒ|ƒWƒEƒ€ “Œ‹ž. 2011”N12ŒŽ9“ú.

Œă“Œ‹vŽk, Â–ěƒ“T, ź‰ŞˆŔ•F. ”x‚̐ś‘Ě–hŒä‹@\‚É‚¨‚Ż‚éƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ě–đŠ„. “ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ĘˆăŠw‰ď‘ć47‰ńŠwpŒ¤‹†‰ď(‹łˆçu‰‰). “ż“‡. 2011”N10ŒŽ29“ú.

ź‰ŞˆŔ•F, ’Ň–{—Y‘ž, ‰Á“ĄKŹ, ‘]ŞŽO˜Y. ƒqƒgƒLƒƒ‰Œ^Rƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě‚ĚŠˆŤ•]‰ż. ‘ć20‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďiƒ[ƒNƒVƒ‡ƒbƒvj. Ă‰Ş. 2011”N6ŒŽ30“ú.

‰Á“ĄKŹ, ź‰ŞˆŔ•F, ˆ˘•”^ŽĄ, …Œű˜a•v, ‘]ŞŽO˜Y. ˆŤŤƒOƒŠƒI[ƒ}‚ɑ΂ˇ‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-1‚ĚŠˆŤ•]‰ż. ‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďiƒ[ƒNƒVƒ‡ƒbƒvj. “Œ‹ž. 2011”N6ŒŽ24“ú.

‘q–{‘ěĆ, Œă“Œ‹vŽk, Š`“ŕ‘Ži, Źě”Ž‹v, ŽO‹´“ŐŽu, “c”¨Ë, ˛“Ął‘ĺ, ‘Oě—mˆę, ˆŔ—FN“ń, ź‰ŞˆŔ•F, HŽRLˆę, ‘]ŞŽO˜Y. Ź×–E”x‚Ş‚ń“]ˆÚ‚É‚¨‚Ż‚éDLL4-NotchƒVƒOƒiƒ‹‚Ě‘ŸŠí“ÁˆŮŤ‚ÉŠÖ‚ˇ‚錟“˘. ‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ďiƒ[ƒNƒVƒ‡ƒbƒvj. “Œ‹ž. 2011”N6ŒŽ24“ú.

“Œ“‘ă. —Տ°–ňÜŽt‚ĆTDM`ˆăŽt‚Ć‚ĚƒRƒ~ƒjƒ…ƒP[ƒVƒ‡ƒ“‚̏d—vŤ`. ‘ć28‰ń“ú–{TDMŠw‰ďEŠwp‘ĺ‰ďiƒVƒ“ƒ|ƒWƒEƒ€j. L“‡. 2011”N6ŒŽ18“ú.

–؉şŸO, ź‰ŞˆŔ•F, ŠÝš”ü, “Œ“‘ă, Â–ěƒ“T, ’|č˛•v, ăŒ´‹v“T, ”ŠŽRT“ń, ‰ÍŒ´‰pŽĄ, ‘]ŞŽO˜Y. ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆŰÇƒ‚ƒfƒ‹‚É‚¨‚Ż‚éFAK‘jŠQÜTAE226‚̍RüˆŰ‰ťŒř‰Ę‚ĚŒŸ“˘. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ďiƒVƒ“ƒ|ƒWƒEƒ€j. “Œ‹ž. 2011”N4ŒŽ24“ú.
yŠw‰ď”­•\-‘“ŕŠw‰ďiˆę”ʉ‰‘čjz
ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, ‹ŕŽq”ü‰Ř, ‰Šr, ű•Łš‹B, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘Ě—Ă–@‚ĚŒŸ“˘.@‘ć24‰ń“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ďŠwpW‰ď‘‰ď. ˜a‰ĚŽR. 2011”N12ŒŽ1“ú.

Žč’Ë•qŽj, Źě”Ž‹v, ŒáČ‰ë•F, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. Plasminogen Activator Inhibitor-1‘jŠQÜiIMD-4690)‚Ě–Ťšb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚Ż‚錟“˘.@‘ć61‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďH‹GŠwp‘ĺ‰ď. “Œ‹ž. 2011”N11ŒŽ10“ú.

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, ‘q–{‘ěĆ, Š`“ŕ‘Ži, ˛“Ął‘ĺ, Ttung The Van, źžŠ“Ö˜Y, “c”¨Ë, Źě”Ž‹v, ăŒ´‹v“T, HŽRLˆę, ź‰ŞˆŔ•F, Jo Rae Wright, ‘]ŞŽO˜Y. ”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A”x‚Ş‚ńi“W‚É‚¨‚Ż‚é‹@”\‰đÍ.@“ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ĘˆăŠw‰ď‘ć47‰ńŠwpŒ¤‹†‰ď. “ż“‡. 2011”N10ŒŽ29“ú.

Â–ěƒ“T, ź‰ŞˆŔ•F. ”xüˆŰÇ‚É‚¨‚Ż‚éSP-D‚Ě–hŒä“I–đŠ„.@“ú–{”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒgEŠE–ĘˆăŠw‰ď‘ć47‰ńŠwpŒ¤‹†‰ď. “ż“‡. 2011”N10ŒŽ29“ú.

ź‰ŞˆŔ•F, ‰Á“ĄKŹ, ű•Łš‹B, ‘]ŞŽO˜Y. ˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éRƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-1‚̍RŽîᇌř‰Ę.@‘ć70‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. –źŒĂ‰Ž. 2011”N10ŒŽ5“ú.

“c”¨Ë, ŽR–{‰ë’B, ’r“c—´“ń, ŒĂě—´•F, ‘q–{‘ěĆ, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, HŽRLˆę. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰[ƒ[‚É‚ć‚Á‚ă`ƒ~ƒWƒ“‚Š‚ç”hś‚ľ‚˝“œ‚Ě‰đ“œŒn‚Ö‚ĚˆÚs.@‘ć70‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď. –źŒĂ‰Ž. 2011”N10ŒŽ3“ú.

ƒŒ@ƒ^ƒ“ƒ_[, ź”ö‘×—C, ‹gŠŰ“N˜Y, ‘q–{‘ěĆ, ű•Łš‹B, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, •Đ‹Ë–L‰ë. ƒqƒg”ńŹ×–E”xŠŕ‚Ě‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚đ—p‚˘‚˝œ“]ˆÚŠÖ˜Aˆâ“`Žq‚Ě–Ô—…“I‰đÍ.@“ú–{ŠŕŠw‰ďŠwp‘‰ď. –źŒĂ‰Ž. 2011”N10ŒŽ3“ú.

˛“Ął‘ĺ, Œă“Œ‹vŽk, ‘q–{‘ěĆ, Źě”Ž‹v, ŽO‹´“ŐŽu, ƒeƒoƒ“ ƒ`ƒ…ƒ“, Š`“ŕ‘Ži, “c”¨Ë, HŽRLˆę, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ƒqƒg”x‚Ş‚ń‘˝‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚Ż‚éMacrophage Stimulationg Protein‚Ě–đŠ„‚ÉŠÖ‚ˇ‚錟“˘.@‘ć20‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ď. Ă‰Ş. 2011”N6ŒŽ30“ú.

Œă“Œ‹vŽk, ƒAƒfƒ‹ ƒKƒuƒ‹, ű•Łš‹B, ‘q–{‘ěĆ, Š`“ŕ‘Ži, ˛“Ął‘ĺ, “c”¨Ë, ƒeƒoƒ“ ƒ`ƒ…ƒ“, Źě”Ž‹v, HŽRLˆę, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ƒqƒg”xŠŕ“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚Ż‚éerlotinib‚̏hŽĺ‰îÝŤRŽîᇌř‰Ę‚ĚŒŸ“˘. ‘ć20‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ď. Ă‰Ş. 2011”N6ŒŽ30“ú.

ŽO‹´“ŐŽu, Œă“Œ‹vŽk, ‘q–{‘ěĆ, Š`“ŕ‘Ži, ˛“Ął‘ĺ, ƒeƒoƒ“ ƒ`ƒ…ƒ“, źžŠ“Ö˜Y, “c”¨Ë, HŽRLˆę, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ”xƒT[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A‚Ě”xŠŕi“W‚É‚¨‚Ż‚é‹@”\‰đÍ.@‘ć20‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ď. Ă‰Ş. 2011”N6ŒŽ30“ú.

˛“Ął‘ĺ,@ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, ‘ĺ’J’źŽq. ‚Ş‚ńƒ}ƒCƒNƒRNAƒNƒ‰ƒXƒ^[Mir17-92”­Œť‚̐ś‘Ě“ŕƒCƒ[ƒWƒ“ƒO‚Ć‚Ş‚ńŽĄ—Âւ̉ž—p.@‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. “Œ‹ž. 2011”N6ŒŽ24“ú.

ź‰ŞˆŔ•F, ˆ˘•”^ŽĄ, ‰Á“ĄKŹ, –؏hšr, ě“Y˜a‹`, ‰Šr, ű•Łš‹B, …Œű˜a•v, ‘]ŞŽO˜Y. Rƒ|ƒhƒvƒ‰ƒjƒ“R‘ĚNZ-1‚ĚˆŤŤ‹š–Œ’†”çŽî‚ɑ΂ˇ‚éR‘ĚˆË‘śŤ×–EáŠQŠˆŤ‚ƍRŽîᇌř‰Ę.@‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. “Œ‹ž. 2011”N6ŒŽ24“ú.

ƒŒ ƒ^ƒ“ ƒ_[, ź”ö‘×—C, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, •Đ‹Ë–L‰ë. ”xŠŕ‚̍œ“]ˆÚ‚đ§Œä‚ˇ‚éV‚˝‚Č“]ŽĘˆöŽq‚Ě“Ż’č‚Ć‚ť‚Ě‹@”\‰đÍ. ‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. “Œ‹ž. 2011”N6ŒŽ24“ú.

“c”¨Ë, ŽR–{‰ë’B, ’r“c—´“ń, ŒĂě—´•F, ‘q–{‘ěĆ, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y, HŽRLˆę. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰[ƒ[‚É‚ć‚Á‚ă`ƒ~ƒWƒ“‚Š‚ç”hś‚ľ‚˝“œ‚Ě‰đ“œŒn‚Ö‚ĚˆÚs. ‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. “Œ‹ž. 2011”N6ŒŽ23“ú.

ƒoƒ“ ƒe ƒ`ƒ…ƒ“, ű•Łš‹B, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ‘q–{‘ěĆ@ƒŒ ƒ^ƒ“ ƒ_[, –î–쐚“ń, HŽRLˆę, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ŒŒŠÇVś‘jŠQÜTSU-68‚ĚˆŤŤ‹š–Œ’†”çŽî“ŻŠˆÚAƒ‚ƒfƒ‹‚É‚¨‚Ż‚éRŽîᇌř‰Ę‚ĚŒŸ“˘.‘ć15‰ń“ú–{‚Ş‚ń•ŞŽq•W“IŽĄ—ĂŠw‰ďŠwpW‰ď. “Œ‹ž. 2011”N6ŒŽ23“ú.

ŒáČ‰ë•F, –{ŸÄWŽj, Žč’Ë•qŽj, Źě”Ž‹v, •Ä“c˜a•v, —t‹v‹MŽi, ™“c–ž”ü, –Š‹`˛, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. “ż“‡Œ§‚É‚¨‚Ż‚é‹CŠÇŽxšb‘§ŠłŽŇ‚ĚƒRƒ“ƒgƒ[ƒ‹‚ÉŠÖ‚ˇ‚éŽŔ‘Ô’˛¸‘ć2•ń. ‘ć23‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďt‹G—Տ°‘ĺ‰ď. ç—t. 2011”N5ŒŽ14“ú.

’|č˛•v, “Œ“‘ă, –؉şŸO, Œă“Œ‹vŽk, ‘˝“c_–ç, ŒáČ‰ë•F, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. “–‰@‚É‚¨‚Ż‚閝Ť‰óŽ€Ť”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚ɑ΂ˇ‚éƒAƒ€ƒrƒ][ƒ€‚ĚŽg—pŒoŒą. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2011”N4ŒŽ24“ú.

“Œ“‘ă, ź‰ŞˆŔ•F, Mohammed Elmorshedy Reham, ŠÝ, ŠÝš”ü, –؉şŸO, ’|č˛•v, Jun Huang, ăŒ´‹v“T, ňŒ[‰î, HŽRLˆę, ‘]ŞŽO˜Y. ”xüˆŰÇ‚É‚¨‚Ż‚éƒXƒtƒBƒ“ƒSƒVƒ“-1-ƒŠƒ“Ž_ƒVƒOƒiƒ‹‚ĚŒŸ“˘. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2011”N4ŒŽ23“ú.

Žč’Ë•qŽj, Źě”Ž‹v, ŒáČ‰ë•F, –{ňWŽj, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚̍RŒ´Š´ě‚É‚¨‚Ż‚éIKKƒŔ-NF-ƒČBŒo˜H‚̉e‹ż‚ɂ‚˘‚Ä. ‘ć51‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď. “Œ‹ž. 2011”N4ŒŽ22“ú.
yŠw‰ď”­•\-‘“ŕ’n•űŠw‰ďz
‰ŞúąO‘×, –L“c—DŽq, ŠÝ, ‰Í–ěO, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ŒáČ‰ë•F, ĺ”ü‰Ŕ, ź‰ŞˆŔ•F. ‘gDf’f‚Ş“ž‚ç‚ę‚˝ŠĚƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě2Ç—á. ‘ć22‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď’†‘EŽl‘Žx•”ŠwpW‰ď. źŽR. 2011”N12ŒŽ10“ú.

‘ĺ’ËŒ›Ži, –L“c—DŽq, Š`“ŕ‘Ži, Œă“Œ‹vŽk, ű•Łš‹B, ŒáČ‰ë•F, ź‰ŞˆŔ•F, ŠÄúąFˆę˜Y, •ŸX’mŽĄ, â“Œ—Ç”ü. ‘˝”­Œ‹ß‰e‚đ’ć‚ľ‚˝Langerhans cell histiocytosis‚Ě1—á. ‘ć105‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚ź. 2011”N11ŒŽ6“ú.

‹ß“Ą^‘ă, ‰Í–ěO, Š`“ŕ‘Ži, ŠÝ, ű•Łš‹B, ŒáČ‰ë•F, ‹ß“ĄŠG—˘, ‡“cł˜a, ÎŠŰ’źŸ, ź‰ŞˆŔ•F. IgG4ŠÖ˜A‰ş‚‘̉Š‚Ě1—á. ‘ć105‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚ź. 2011”N11ŒŽ6“ú.

‚‹´’źŠó, ”ň”~—ş, Žč’Ë•qŽj, –L“c—DŽq, “Œ“‘ă, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ŠÝ, Â–ěƒ“T, ű•Łš‹B, ŒáČ‰ë•F, ‘]ŞŽO˜Y, ź‰ŞˆŔ•F, ‚‹´”ü‹IŽq, •Ÿ“c—I. ŠÔŽżŤ”x‰Š‚̐¸¸‚É‚ć‚čf’f‚ł‚ę‚˝IgG4ŠÖ˜AŽžŠł‚Ě1—á. ‘ć46‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‘q•~. 2011”N7ŒŽ16“ú.

ź”Ž”V, –L“c—DŽq, Š`“ŕ‘Ži, ’|úą˛•v, ŠÝš”ü, ‘ĺ’ËŒ›Ži, Žč’Ë•qŽj, Œă“Œ‹vŽk, ű•Łš‹B, ŒáČ‰ë•F, ź‰ŞˆŔ•F. ‹C‹š‚đ‡•š‚ľ‚˝”xŠŕ10—á‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‘ć50‰ń“ú–{”xŠŕŠw‰ď’†‘EŽl‘Žx•”‰ď. ‘q•~. 2011”N7ŒŽ15“ú.

“c‰Ş—˛Ź, ŠÝš”ü, ’|úą˛•v, –؉şŸO, –L“c—DŽq, Š`“ŕ‘Ži, ű•Łš‹B, ˆäúą”Ž•ś, ‚‹´łK, •ŸX’mŽĄ, ‹ŕŽR”Žb, ź‰ŞˆŔ•F. “–‰@‚É‚¨‚Ż‚émTOR‘jŠQ–ň“Š—^ŠłŽŇ‚É”­Ç‚ľ‚˝ŠÔŽżŤ”x‰Š‚Ě—Ő°“IŒŸ“˘. ‘ć46‰ń“ú–{ŒÄ‹zŠíŠw‰ď’†‘EŽl‘’n•ű‰ď. ‘q•~. 2011”N7ŒŽ15“ú.

‘ž“c—ŠG, ŠâŁr, ‹v‰Ş”’—z‰Ô, ŽR“c”Žˆű, ź‰ŞˆŔ•F, ‚”öłˆę˜Y, â“Œ˛’mŽq, ”\¨”šl, “퐣ŒŤ–ç, m–Ř•q”V, •y“c‹IŽq, ă“c—R‰Ŕ, ŽRŒű_Ži, ’|’J‘P—Y, “Y–Ř•, Žá’ΓNŽO, Ô’r‰ëŽj, ‘]ŞŽO˜Y, ˛“c­—˛. SŽşŒĹ—L’˛—Ľ‚ސS•a•Ďf’f‚Ě‚Ť‚Á‚Š‚Ż‚Ć‚Č‚Á‚˝ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě1—á. ‘ć98“ú–{zŠÂŠíŠw‰ď ’†‘EŽl‘‡“Ż’n•ű‰ď. “ż“‡. 2011”N5ŒŽ13“ú.

ˆŔĎ–ƒˆß, ŠâŁr, m–Ř•q”V, Žá’ΓNŽO, ˛“c­—˛, Ô’r‰ëŽj, ‚”öłˆę˜Y, Œ´“c‰ëŽj, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. Šá, ”x, ‹Ř•a•Ď‚É‘ą‚˘‚ÄŒo‰ß’†‚ɐV•a•Ď‚ĚŒ°Ý‰ť‚đ”F‚ß‚˝ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ěˆę—á. ‘ć104‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2011”N5ŒŽ8“ú.

–؉şŸO, ˛“Ął‘ĺ, Œă“Œ‹vŽk, Š`“ŕ‘Ži, ű•Łš‹B, ŒáČ‰ë•F, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ƒxƒoƒVƒYƒ}ƒu‚Ş‘tŒ÷‚ľ‚˝”ńŹ×–E”xŠŕ‚Ě2Ç—á. ‘ć104‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2011”N5ŒŽ8“ú.

ŠÝš”ü, ź‰ŞˆŔ•F, –L“c—DŽq, ŠÝ, Œă“Œ‹vŽk, ŒáČ‰ë•F, ‘]ŞŽO˜Y. Rbó‘B–ň•ž—p’†‚ÉMPO-ANCAŠÖ˜AŒŒŠÇ‰ŠÇŒóŒQ‚đ”­Ç‚ľ‚˝2—á. ‘ć104‰ń“ú–{“ŕ‰ČŠw‰ďŽl‘’n•ű‰ď. ‚’m. 2011”N5ŒŽ8“ú.

m–؏š“ż, źžŠ“Ö˜Y, Œă“Œ‹vŽk, –{ŸÄWŽj, –؉şŸO, “Œ“‘ă, ‘˝“c_–ç, ŒáČ‰ë•F, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ClarithromycinAAmikacinAImipenem/cilastatinAMoxifloxacin‚Ě•š—p—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝”xMycobacterium abscessusŠ´őÇ‚Ě1—á. ‘ć19‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. V‹•l. 2011”N1ŒŽ22“ú.

”ň”~—ş, ˛“Ął‘ĺ, –L“c—DŽq, Œă“Œ‹vŽk, ‘˝“c_–ç, ź‰ŞˆŔ•F, ‘]ŞŽO˜Y. ˆŮ‚Č‚éEGFRˆâ“`Žq•ĎˆŮ‚đ—L‚ˇ‚é‘˝”­”x‘BŠŕ‚Ěˆę—á. ‘ć19‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ď’†‘Žl‘Žx•”‰ď. V‹•l. 2011”N1ŒŽ22“ú.
“ż“‡‘ĺŠw‘ĺŠw‰@ˆăŽ•–ňŠwŒ¤‹†•”ŒÄ‹zŠíEäPŒ´•a“ŕ‰ČŠw•Ş–ě
§770-8503“ż“‡Œ§“ż“‡Žs‘ –{’Ź‚R’š–Ú‚P‚W”Ô’n‚Ě‚P‚T
TELF088-633-7127@FAXF088-633-2134
Copyright Department of Respiratory Medicine and Rheumatology
Graduate School of Biomedical Sciences
Tokushima University